HEALTH DISCOVERY CORPORATION und die $$ SUPPORT VECTOR MACHINE §§ - 500 Beiträge pro Seite

[talis]

http://www.healthdiscoverycorp.com/

Patentschmiede, die die Support Vector Machine (SVM) im Besitz hat.

SVM ist ein mathematisches Tool, das signifikante Daten herauszufiltern in der Lage ist und bisherigen Methoden wie z.B. Neuronalen Netzen überlegen ist.

Anwendungsgebiete hauptsächlich Pharma. Es gibt 4 Lizenzpartner.
Clarient war der erste im Nov. 2005
Bruker
Epigenomics
Pfizer (Dez. 2006)
Es werden zügig Lizenzpartner gewonnen.

Es gibt ausserdem ein JV mit Atlantic Alpha Strategies, um ein „risk-to-reward investment model“ zu entwickeln.

SVM ist also vielseitig anwendbar. Möglich sind Lizenzeinnahmen sowie royalties, für den Fall ein Medikament wird mithilfe des SVM entwickelt.

MK: ca 12 Mio $
Verbindlichkeiten: 2,15 Mio $

Man kann darauf spekulieren, dass Health Discovery bald die Verlustzone verlässt.

Fazit: Health Discovery Corporation hat meiner Meinung nach die Phase der Development Stage Company bald hinter sich.

http://www.drugdiscoverynews.com/index.php?newsarticle=1255" target="_blank" rel="nofollow ugc noopener">http://www.drugdiscoverynews.com/index.php?newsarticle=1255

[talis]

Bei Health Discovery sehe ich Parallelen zu Biophan, insofern dass man am Erfolg der Produkte keinen Zweifel hat, man sich aber fragen muss, ob die Aktionäre nicht vor dem Erreichen des breakeven in der dilution ertinken, weil das Unternehmen ständig Finanzierungsbedarf hat.

Die Unbekannte bei Health Discovery ist, wieviel Einnahmen das Unternehmen aus der Lizenzvereinbarung mit Pfizer und den anderen kürzlich abgeschlossenen Verträgen hat. Ich spekuliere darauf, dass sich Pfizer die Nutzung der SVM einiges kosten lässt. Demnächst wird der Jahresbericht veröffentlicht. Dann wissen wir mehr.

[talis]

http://www.businesswireindia.com/Feeds/HT/bwirelease11906.as…


Source : Business Wire

Health Discovery Corporation Files for U.S. and Foreign Patent Protection of New Prostate Cancer Biomarker Discovery
New Prostate Cancer Biomarker Expression Signature is Highly Accurate in Identifying Prostate Cancer

Savannah, Georgia -- (Business Wire India) -- Tuesday, February 06, 2007 9:30:00 AM
Health Discovery Corporation ("HDC") (OTCBB: HDVY) announced that it has filed new patent applications in the United States Patent and Trademark Office and in the U.S. Receiving Office for the Patent Cooperation Treaty for U.S. and foreign patent protection for a newly discovered Prostate Cancer Biomarker Expression Signature which is highly accurate for identifying prostate cancer. This new Prostate Cancer Biomarker Expression Signature was demonstrated to have a very high degree of accuracy as demonstrated by an area under the ROC curve of 94%.

"This new and exciting biomarker discovery could play a significant role in a more accurate diagnosis of prostate cancer as well as providing important information for the development of new drug targets for the successful treatment of prostate cancer," commented Dr. Herbert A. Fritsche, Professor of Laboratory Medicine at the University of Texas M.D. Anderson Cancer Center and Chairman of HDC's Science Team. "As medicine becomes increasingly personalized, discoveries of this nature could facilitate the development of new diagnostic tests and innovative treatments for prostate cancer."

Stephen D. Barnhill, M.D., Chairman & CEO of HDC, said, "I firmly believe that this new Prostate Cancer Biomarker Discovery provides a significant opportunity towards providing a more accurate diagnosis of prostate cancer and important new information for identifying new therapeutic targets in treating this potentially devastating type of cancer. This is especially important since The World Health Organization (WHO) estimates that prostate cancer in men is expected to go up 40% worldwide in the next 25 years. HDC is eager to work with both diagnostic and pharmaceutical partners on developing prospective commercial applications for this important new discovery."

In addition, HDC has previously identified and reported additional Expression Signatures of biomarkers that are capable of distinguishing high-grade prostate cancers (Gleason Grade 4 and higher) from less malignant grades. More than 1 million men a year undergo biopsies of the prostate gland after the widely used cancer-screening test reveals moderately elevated levels of prostate specific antigen (PSA) in the blood. Only one in four of these biopsies find evidence of cancer, meaning that around 750,000 of those million plus biopsies were unnecessary. The ability to clearly distinguish between different cancer grades by accurately identifying biomarker expression signatures in tissue, blood, urine or semen, could reduce the number of unneeded biopsies while quickly identifying those men in urgent need of more aggressive treatment.

According to a recent paper published in the Journal of Urology by Dr. Tom Stamey at Stanford University Medical Center, a world-renowned expert on prostate cancer, and a Member of the HDC Science Team "The Era of PSA is over" because of the low accuracy rate of Prostate Specific Antigen in identifying clinically significant prostate cancer. Dr. Stamey believes that a new more accurate test is needed to effectively detect this type of cancer. PSA sales are estimated at over $350 million annually and represent 40% of all annual cancer serum biomarker revenues.

HDC has recently signed licensing agreements with Pfizer (NYSE: PFE), Epigenomics (Frankfurt, Prime Standard: ECX) and Bruker Daltonics (NASDAQ: BRKR).

Savannah-based Health Discovery Corporation (OTCBB: HDVY) is uniquely positioned in the field of pattern recognition. Through its broad patent portfolio and the efforts of its recognized scientific team, HDC is focused on commercializing its intellectual property in genomic and proteomic biomarker discovery, medical imaging, diagnostics, and pharmaceutical advancements in personalized medicine. The company's patent-protected technology also has significant application in non-medical fields that require manipulation and analysis of large, complex datasets such as insurance, financial markets, Internet search & spam, and homeland security.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

Media Contact Details
CONTACT: Health Discovery Corporation Daniel R. Furth 912-352-7488 [e-mail] www.healthdiscoverycorp.com





CONTACT:

Health Discovery Corporation
Daniel R. Furth
912-352-7488
[e-mail]
www.healthdiscoverycorp.com

http://www.businesswire.com

[talis]

http://www.sec.gov/Archives/edgar/data/1141788/0001188112060…

An dem Jahresbericht stört mich, dass ich nichts gefunden habe, was auf Einnahmen aus dem Pfizerdeal hinweist.
Es ist von Einnahmen in Höhe von $203,889 die Rede, obwohl bis zum 30.09.2006 bereits $195,883 eingenommen wurden. Ausserdem sind dem Unternehmen $101,111 zugeflossen, die nicht als Einnahmen deklariert wurden und über deren Herkunft nichts berichtet wurde.
„The net loss for the twelve months ended December 31, 2006 was $2,595,759“
Den Verlust im Vergleich mit den Einnahmen muss man sich erstmal vergegenwärtigen.

Ausserdem wird noch ein Patentstreit mit Ciphergen verhandelt.

„On June 26, 2006, we originally filed suit in the United States District Court for the Eastern District of Texas against Ciphergen Biosystems, Inc. (“Ciphergen”), alleging claims for infringment of three patents related to support vector machine technology and seeking monetary and injunctive relief. Ciphergen denied infringement, challenged the validity of the patents, and alleged counterclaims against us. We deny liability to Ciphergen under the alleged counterclaims. Pursuant to a motion filed by Ciphergen, the litigation has been transferred to the United States District Court for the Northern District of California.“

Dabei ist zu beachten, dass Dutton Associates Ciphergen mit Speculative Buy einstuft und so tut als wüssten sie nichts von den Patentstreiterein mit Health Discovery. Dabei wird es für eine der beiden Parteien hässlich enden.
http://www.stockhouse.com/news/news.asp?tick=CIPH&newsid=501…

Wer ein Investment in Health Discovery erwägt kann ja noch warten bis sich dieser Ausblick...

„The Company has been and continues to be in meaningful discussions with a variety of parties, which if successful, will result in significant revenue.“

...bewahrheitet und der Patentstreit mit Ciphergen zu Gunsten Health Discovery entschieden wurde.

[talis]

Press Release
Source: Health Discovery Corporation

Dear Fellow Shareholders,
On behalf of our entire organization, I am pleased to report that 2006 was a highly productive year for Health Discovery Corporation. I am very proud of HDC’s visible progress following our first revenue event at the end of 2005. Based on transactions completed in the latter part of 2006, our strengthened patent estate, and the pace and scope of our current deal flow, I believe we are on track to meet our long-term goals of sustainable revenue and profitability. In brief, I think your Company rests on a solid foundation that will support our growth for the foreseeable future.

When I corresponded with you last year, I described HDC’s recent emergence from the developmental stage and our ambitious plans and expectations as we embarked on our first full year as an operational company. In 2006, our licensing efforts resulted in customer contracts totaling $485,000 in cash receipts and identifiable future commitments, but excluding royalties. Far more importantly though, we advanced our business plan in several key areas, including:

• New license and development agreements with pharmaceutical and diagnostic companies in the U.S. and Europe

• Significant increase in the value of our patent portfolio

• Additional financing of $1,000,000

• Successful conclusion of our first patent infringement lawsuit

• Strategic consulting relationship with IPotential to help monetize our IP portfolio in the IT and communications markets

• Formation of a joint venture, SVM Capital, to apply our pattern recognition technology to financial markets.

Because these achievements are noteworthy in and of themselves, I’ve chosen to discuss them at greater length below. They are also essential building blocks for our business foundation, and a necessary springboard for our future efforts:

1. We signed licensing and/or development agreements with pharmaceutical and diagnostic companies in the US and abroad.

These agreements include combinations of up-front licensing fees, developmental fees, and royalties. Our licensing strategy provides HDC with revenue in the near term, as well as long term royalty revenue continuing for the life of the patents.

February 2006 – An expansion of our 2005 product development relationship with Clarient, a cancer diagnostics services company.

August 2006 – A worldwide license agreement with Bruker Daltonics, a leading developer of innovative life science tools based on mass spectrometry, to use our SVM technology in its ClinProTools™ clinical proteomics product line.

September 2006 – A worldwide license agreement with Epigenomics, a German methylation-based molecular diagnostics company, to use our SVMs to develop novel products for cancer treatment.

December 2006 – A worldwide license agreement with Pfizer, the world’s largest pharmaceutical company, to utilize HDC’s SVM and Fractal Genomic Modeling (FGM) technology in its research activities.

2. We significantly increased the value of HDC’s intellectual property (IP) portfolio with the issuance of two very important SVM-based U.S patents, as well as three foreign patents. Our recent U.S. biomarker patent applications also represent major advances in the art of biomarker discovery.

HDC’s patents have been carried on our balance sheet for about $3.3 million, which is what we paid to acquire them a few years ago (less subsequent amortization). However, many of our shareholders may not be aware that the actual cost to develop these assets in the years before then was vastly higher. The building of a patent portfolio is not unlike the planting of new vineyard: each can take a long time to mature, each requires continued attention and investment, and each can yield harvests of widely varying quality. Our goal at HDC is to produce rich and long-lived patent vintages for our shareholders. What follows is part of the essential process of maturation.


U.S. (SVM) Patents Issued (2006):

U.S. patent issued for “Computer-Aided Image Analysis" (covers image processing using multiple SVMs and applications for medical imaging, including mammography).

U.S. patent issued for "Methods of Identifying Patterns in Biological Systems and Uses Thereof". This is our revolutionary Recursive Feature Elimination (RFE) invention used to rank order genomic and proteomic data for molecular diagnostics, prognostics, and drug discovery. Despite its title, this patent's claims are not limited to biological systems.

Foreign (SVM) Patents Allowed (2006-2007):

In Israel, India and South Korea, entitled "Enhanced Knowledge Discovery from Multiple Data Sets Using Multiple Support Vector Machines". These patents include the use of an ensemble of SVMs and correspond to patents already issued to HDC in the U.S., Australia, China, France, Germany, Italy, Norway, Spain, and the UK.

U.S. (biomarker and image) Patent Filings (2006-2007):

"Computer-Aided Image Analysis" encompassing digital image analysis with ex vivo and in vivo applications.

"Biomarkers for Screening, Predicting and Monitoring Benign Prostate Hyperplasia (BPH)" claiming top biomarkers for BPH.

"Biomarkers for Screening, Predicting and Monitoring Prostate Cancer" claiming discovery on unregulated genes for prostate cancer.


HDC is presently speaking with certain firms (discussion below) about developing diagnostic tests using our BPH and prostate cancer biomarkers. Significantly, we used our own SVM-RFE patented inventions to discover these biomarkers. Of particular note is the 95% AUC (Area Under the Curve - a measure of accuracy) for our 4-gene prostate cancer biomarker, which our scientists believe is far more accurate than any other indicator now in use


3. We began the process of protecting HDC’s patent portfolio.

In June, we filed patent infringement lawsuits against Ciphergen Biosystems and Equbits. After four months of settlement discussions, Equbits agreed to a permanent injunction (in the form of a final consent judgment) barring it from any future use or sale of products using HDC’s patented SVM technology. The Ciphergen matter is still pending.

4. We initiated our approach to the high technology markets.

In August, we announced a strategic consulting partnership with IPotential, a leading intellectual property service provider in the high-tech arena to help us plan the monetization strategy for HDC’s IP portfolio in the IT and communications markets.

5. We extended our SVM reach into financial markets.

Early in 2007, we formed a joint venture, SVM Capital, with Atlantic Alpha Strategies to apply our SVM pattern recognition tools to quantitative investment analysis. SVMC’s President notes that research efforts to date show promise in developing computer-based investment and hedging techniques. The specific goal is to substantially reduce investment risk while providing superior, but not necessarily outsized returns for comparable asset classes. If SVMC can advance the predictive art sufficiently, the ultimate business objective is to create one of more funds that would appeal to conservative and risk-averse investors.


There are many “quant funds” successfully using different mathematics-based techniques, including neural networks, to assist in the investment decision-making process by uncovering patterns that might otherwise be impossible or too time-consuming to discern. To the best of our knowledge, none use SVM-based models. In broad terms, if SVM Capital can replicate in this arena the consistent superiority SVMs have shown, for example, over neural networks in hundreds of medical field studies, it could achieve an advantaged and patent-protected position in quantitative-based investments in equities, debt instruments, currencies and commodities.


Negotiations in Progress

1. HDC is in the final stages of negotiations with a large European pharmaceutical company to develop a companion diagnostic test using our discovered biomarkers as surrogates in the last phase of a clinical trial for its new drug to treat BPH (enlarged prostate). This company contacted HDC after we presented our BPH biomarker discovery at the World Biomarker Congress. If all goes well, we believe this will be the first attempt to incorporate a custom-made surrogate biomarker expression signature into a clinical trial for an existing drug. Working together with seven corporations and universities we’ve selected as our development partners, we believe HDC can indeed build a successful test. If the BPH drug ultimately receives FDA approval, the test, which HDC expects to own, could also be used to monitor patients after commercial launch of the drug.

This undertaking could hold much greater promise for HDC than may be evident from the above. For it is possible that the methodology we develop might be a model for an important component in the conduct of future clinical trials worldwide. The advantages of this novel approach could include reducing a trial’s duration and cost, providing more objective data, increasing patient safety by potentially reducing or eliminating placebos, and expediting the time to market for successful drugs. Almost as importantly, it may be able to provide information earlier in the trial process that a drug is not working, thus saving time, money and intellectual resources. At the recent Cancer Biomarker Conference in London, many biomarker experts at some of the world's largest drug firms showed a gratifying interest in our views on the subject. As the FDA has indicated support for this emerging approach to new drug development, your company could be well-positioned to benefit from our pioneering work.

2. We are in end-stage negotiations with a leading biotech company to develop an SVM-based diagnostic test to help interpret flow cell cytometry data for a particular medical condition. Our science team’s analysis of partial data provided to HDC demonstrates a successful proof of concept. If our partner accepts our conclusions, it opens a portal to similar work on diseases such as leukemia and lymphoma that are far more prevalent.


3. We have just entered discussions with the same biotech company and another diagnostics firm to develop a breast cancer prognostic test similar to the Oncotype DX test from Genomic Health and the new FDA-approved MammaPrint test from Agendia, a European firm. If we can reach agreement with either party, HDC will lead the development of this project and own some or all of the final FDA-approved product. We envision an exclusive relationship with only one of these firms, not both.

4. In connection with our presentations at the recent London Biomarker Conference, HDC has finally begun talks with a huge international healthcare company we have long pursued. At stake is licensing and product development using SVMs in diagnostic radiology, including mammography, PET scans, CT scans, MRI and other radiological images. HDC owns a number of SVM patents in this field that we think are very important.

5. We are in early talks with three companies about our recently-discovered 4-gene prostate cancer biomarker signature, for which we have filed a patent application. Given the accuracy (95% AUC, noted earlier) and disease-specific applicability of this biomarker, as well as the level of enthusiasm we discern at these firms, it is possible that discussions could progress at a much faster pace than we have experienced in the past.

6. Our London presentations also elicited interest from a European molecular diagnostics company that has initiated serious inquiry about the applicability of our RFE-SVM pattern recognition technology to MicroRNA expression signature discovery and to circulating tumor cells to identify micro-metastasis in blood.

7. Finally, we have been in continuing but still embryonic discussions with a few clinical labs to provide commercial outlets for biomarker-based clinical tests to be developed and wholly or partly owned by HDC. With one or more such partners, HDC may be able to market tests directly to physicians. The selection of any particular clinical lab partner may be incorporated into a specific license and product development deal.

Additional Funding Received

HDC solicited and received $1 million in new debt funding in September 2006. This investment was provided in its entirety by William F. Quirk, Jr., a member of our Board of Directors and HDC’s second largest shareholder. Mr. Quirk agreed to this capital infusion to allow HDC sufficient time to fully implement its business plan.

Shareholder Relations

Communicating with stockholders is a vital task for all publicly-held companies, but smaller firms like HDC are often faced with a conundrum. What may be trivial for a large company, and thus something not worth disclosing, could be quite important to HDC. Your management constantly strives for a balance between providing timely information to our shareholders and preserving the confidentiality of sensitive negotiations. We will continue to respond to inquiries in a way that is informative but still consistent with confidentiality requirements and regulations on disclosure. Indeed, we welcome these opportunities because our share price seems to suffer from misconceptions that a dearth of information and insights can often engender. But we know we can do better in this area, and improving our ability to keep you well-informed is one of our goals for 2007.

To this end, our first shareholders meeting will be held in May in Savannah. We have accepted invitations to present at two more professional conferences later this year. Our website is being improved in an effort to make it as user-friendly and informative as possible. We plan to cultivate more newspaper and trade journal interviews that lead to articles published about HDC. Later this year, we expect to submit to a prestigious peer-reviewed medical journal a paper about our new prostate cancer biomarker. And finally, we intend to participate more actively in Wall Street investor conferences and to make a concerted effort to meet with groups of investors more regularly.

Shareholders Special Meeting

Our very first meeting of shareholders in May will be a most important event in HDC’s development, as it is likely to set the stage for our future. Each shareholder will soon receive a proxy statement which I hope you will review very carefully. In particular, your Board of Directors has concluded that changing HDC's state of incorporation from Texas to Georgia will contribute importantly to our future success. Our headquarters is in Georgia, most of our employees are in Georgia as will be our future hires, the vast majority of our business is conducted in Georgia, and Georgia law affords Georgia-domiciled companies like ours great flexibility. The proxy statement explains all of this in great detail, and I strongly urge you to VOTE “YES” on this request. It is imperative that shareholders return their proxies because abstentions count as “NO” votes. Texas law requires a 2/3 majority of all outstanding shares to reincorporate, so every vote is important. Proposals to give HDC greater financial flexibility are also important, especially those to increase the number of authorized common shares and to create a class of preferred stock. For all who can attend, this meeting should be an excellent opportunity to meet with and assess the quality of your management team and board members, and to get better insights into our business environment, our strategy and how we expect to achieve our goals.

In Closing

I fully intended that my letter to you this year contain far more substance and detail than last year’s. I think this progression is quite natural for a company that has made great strides in transforming itself into an operating enterprise. While the transit of a duck across a pond appears rather placid, there’s actually some very vigorous paddling going on just under the surface. This analogy may be helpful in appreciating the difference between some external perceptions of HDC of late, and the reality. As to the “paddling”, your management team and board members have indeed worked tirelessly to secure your Company's future in the past year. And just as importantly, a superb cadre of individuals on our world-renowned science team and within our professional firms has endowed HDC with a depth and reach far greater than might be imagined for a firm of our size. Our introduction to some of the world’s largest and most respected corporations in the health field is due in no small measure to the standing and reputation of these highly accomplished professionals. We believe our shareholders are well-served by their dedication to HDC.

On behalf of our entire committed team, I thank you very much for your continued support and interest in HDC. I hope our performance in the year ahead fully justifies your confidence in us.



Stephen D. Barnhill, M.D.
Chairman & CEO

In connection with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), Health Discovery Corporation (the "Company") is hereby providing cautionary statements identifying important factors that could cause the Company's actual results to differ materially from those projected in forward-looking statements (as such term is defined in the Reform Act) made by or on behalf of the Company herein, in other filings made by the Company with the Securities and Exchange Commission, in press releases or other writings, including in electronic form on its internet web site(s), or orally, whether in presentations, in response to questions or otherwise. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will result," "are expected to," "anticipated," "plans," "intends," "will continue," "estimated," and projection") are not historical facts and may be forward-looking and, accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from any future results or performance expressed or implied by such forward-looking statements. These factors are described in further detail in the Company's Annual Report on Form 10-K and in other filings by the Company with the Securities and Exchange Commission and include, but are not limited to, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to collaborate with and fund third parties on their drug discovery activities, the ability of our collaborators and of Health Discovery to meet drug discovery objectives tied to milestones and royalties, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, and our ability to attract and retain experienced scientists and management. The Company cautions that these factors could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors. Further, management cannot assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

close window

[talis]

wenn man ausser den Pressemitteilungen auch noch aufmerksam verfolgt, was auf Raging Bull Wissenswertes über Health Discovery zusammengetragen wird, erkennt man hier nach und nach
die Feinstruktur eines embryonalen Ten+baggers.

[alysant]

Kauf nur in US sinnvoll, da in D kein Volumen !

[alysant]

ist definitiv auf meiner Kaufliste, und zwar bei ca. 0.10 US-$, da ich Zeit habe

[talis]

Was ich auf Raging Bull bezüglich des Pfizerdeals gefunden habe will ich hier kurz festhalten, damit es nicht verlorengeht.
Pfizer ist unaufgefordert von sich aus auf Health Discovery zugegangen und man hat 1 Jahr verhandelt bis es zum Vertragsabschluss kam. Finanzielle Vereinbarungen werden geheim gehalten.

Pfizer hat bei der fehlgeschlagenen Entwicklung eines Medikaments 1 Mrd. $ verloren, als sich herausstellte, dass dieses Medikament toxisch war. Auf RB hiess es, Pfizer hätte sich diese Mrd. $ sparen können, wenn sie rechtzeitig Ihre Daten mit der Support Vector Machine ausgewertet hätten. Soll heissen, es kann auch eine sehr wertvolle Information sein, wenn man nur rechtzeitig herausfindet, dass etwas nicht funktioniert.

[talis]

HEALTH DISCOVERY CORPORATION AND IPOTENTIAL ANNOUNCE
STRATEGIC CONSULTING AGREEMENT
SAVANNAH, GA and SAN MATEO, CA – August 3, 2006 – Health Discovery Corporation
(HDC) (OTC Bulletin Board: HDVY), an emerging leader in pattern recognition technology, and
IPotential, the technology industry’s leading strategic intellectual property (IP) service provider,
today announced they have entered into a comprehensive strategic relationship. The two
companies will work together to monetize and license HDC’s IP portfolio in the IT and
communications markets.
“This relationship with IPotential represents a broad new opportunity for our company,” said
Stephen D. Barnhill, M.D., HDC’s Chairman and CEO. “To date, HDC’s Support Vector
Machines (SVM) and mathematical expertise have been focused exclusively on the medical
arena. As we now undertake to position our SVMs in fields where we have not previously
licensed, we concluded that partnering with IPotential’s highly knowledgeable and
extraordinarily well-connected professionals would benefit both HDC and the many companies
that can productively utilize our IP in their operations. We believe that IPotential’s thorough
knowledge of these markets will substantially leverage our efforts in targeting and successfully
negotiating license opportunities.”
“We are pleased to initiate our relationship with such a unique innovator like Health Discovery
Corporation,” said Ron Epstein, CEO of IPotential. “HDC’s seminal SVM patents have broad
applicability wherever large amounts of complex data must be manipulated mathematically.
SVM technology will play a critical role in the development of the next generation of Internet
search and anti-spam as well as a broad array of artificial intelligence products. We know that
SVMs using HDC’s patented technologies are broadly deployed across many markets and we
look forward to working with the company in both publicizing and protecting its valuable IP.”
About Health Discovery Corporation
Savannah-based Health Discovery Corporation is uniquely positioned in the field of pattern
recognition technology. Through the application of its patent protected technology, HDC is a
biology-oriented biomarker and pathway discovery company providing all aspects of First-Phase
Biomarker Discovery. The Company's pattern recognition tools have significant potential in
other sizable markets such as radiology, Internet search and spam, homeland security, financial
futures, and other areas where analysis of large volumes of complex data is required. For more
information, please visit http://www.healthdiscoverycorp.com.
About IPotential
IPotential is the technology industry’s leading strategic intellectual property service provider. Its
independent brokerage, IPotential Patent Brokerage Services (IPBS), is the market maker for
technology patents. With experience in buying and selling thousands of patents, IPBS helps its
clients through the complicated legal, business and technical process of licensing, selling or
buying patents. Its founders have more than 25 years of patent transaction experience at leading
Silicon Valley companies. For more information, please see http://www.ipotential.com.
This news release contains "forward-looking statements" within the meaning of Section 27a of
the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although
the respective management teams of HDC and IPotential believe that the expectations reflected
in such forward-looking statements are reasonable, they can give no assurance that such
expectations will prove correct.
CONTACTS: Daniel R. Furth Joe Chernesky
Health Discovery Corporation IPotential
[e-mail] [e-mail]
[phone] [phone]

[talis]

Health Discovery im Patentstreit mit Ciphergen mit Teilerfolg.



Patent rejection could cost Ciphergen $2M
East Bay Business Times - April 6, 2007
by Michael Fitzhugh

Ciphergen Biosystems Inc. risks missing a $2 million payment unless it can convince U.S. patent officials to reverse a final action on a key patent, according to an April 2 regulatory filing.

At stake is a patent on what the company says is "directed to a fundamental process" in diagnostic technology it has cross-licensed to Bio-Rad Laboratories Inc. of Hercules. The $2 million is a holdback in part of the asset purchase agreement Ciphergen negotiated with Bio-Rad.

Ciphergen sold its life science research business to Bio-Rad for $19 million in November 2006, restructuring itself to focus on diagnostics. In a Feb. 23 statement, Ciphergen alerted investors that "an additional $2 million is receivable upon the successful resolution of a patent matter." The filing appears to be the first public update on that matter's status.

The technology covered, Surface Enhanced Laser Desorption/Ionization (SELDI), supports the Fremont company's work in developing cancer and women's health diagnostics. The technology is covered by 33 related patents, said a Ciphergen representative.

In March, the U.S. Patent and Trademark office issued a final action rejecting all of the claims of the patent. Ciphergen has six months to advocate for the patent's validity, after which it may make further appeals.

However, it says that if the patent's claims are canceled or significantly narrowed in scope, the company may be unable to block competitors from using the technology, denting Ciphergen's revenue.

In July 2005, Ciphergen signed a deal to work with Quest Diagnostics through next year, developing and commercializing diagnostic tests based on the technology.

Ciphergen gained rights to the technology through sublicenses from Molecular Analytical Systems Inc., which holds an exclusive license to SELDI patents from the owner, Baylor College of Medicine.

[alysant]

Man muß sich mit der Materie intensiv auseinandersetzen, was gar nicht so einfach ist; bin selber gerade dabei.

mein Fazit:

exzellenter Geheimtipp

meine Strategie:

günstiger Einstieg um 0.10 US-$ und dann lange liegenlassen

[alysant]

Antwort auf Beitrag Nr.: 28.929.928 von alysant am 21.04.07 12:55:22

bestätige mich voerst selber:

Kauf vorgemerkt bei 0.10 US-$ !

[alysant]

Antwort auf Beitrag Nr.: 28.974.747 von alysant am 24.04.07 17:32:17

ging heute ruck-zuck von 0.105 auf 0.125

[talis]

Man beachte diese Aussage im letzten shareholderletter.

In 2006, our licensing efforts resulted in customer contracts totaling $485,000 in cash receipts and identifiable future commitments, but excluding royalties.

Health Discovery hat es ganz eindeutig auf die royalties abgesehen. Es fehlt eigentlich nicht mehr viel und es kann kräftig Bewegung in den Kurs kommen. Sei es, es werden schnell neue Lizenzpartner gewonnen oder ein Produkt kommt auf den Markt entwickelt mit der Unterstützung der Technologie von Health Discovery.

Ich frag mich nur, wer da dauernd bereit ist zu verkaufen.

[alysant]

kommt da nicht tgl. der Quartalsbericht ?

[alysant]

Antwort auf Beitrag Nr.: 29.273.165 von alysant am 11.05.07 17:54:05

Talis, muß ich immer alles selber machen ? Du bist doch hier der Profi !
=================================================================

Bericht wurde am 15.5. bei SEC eingereicht. Quartalsverlust halbiert von 1 Mio. auf 500.000,--, macht sich optisch gut, da Verlust per share nun 0.00 nach 0.01

keine Umsätze, aber Bilanz i.O., vor allem im Vergleich zum anderen pink shit Schrott

americanbulls.com geben buy

meine Prognose aktuell:

strong buy bei 0.10 US-Dollar

Ziel kurzfristig: 0.15 US-Dollar

om0

[talis]

Antwort auf Beitrag Nr.: 29.450.337 von alysant am 24.05.07 13:49:48

auf der Einnahmenseite hat sich nicht viel getan im 1. Quartal!

die Ankündigungen im Shareholderletter sollten auch mal so langsam zu was führen.

Die Zeit tickt.

[alysant]

Antwort auf Beitrag Nr.: 29.458.889 von talis am 24.05.07 22:26:13

ist aber bei dem Bio-Tech-Zeug normal, zumindest at the very beginning

[alysant]

stabil bei 0.10, aber nix los

[alysant]

Antwort auf Beitrag Nr.: 29.526.813 von alysant am 29.05.07 16:59:50

glaube allmählich, die lesen hier mit:

0.115 vol. 190.000

H/T

0.115
0.10

[alysant]

Antwort auf Beitrag Nr.: 29.537.788 von alysant am 30.05.07 12:16:55

st. 270.000 zwischen 0.09 und 0.11

[talis]

aus RB

By: burroak0
01 Jun 2007, 04:29 PM EDT
Msg. 9587 of 9609
Jump to msg. #

Patent Suit Court Docket 6-1-07:

5-31-07: HDC and CIPH filed joint stipulation to extend Initial Case Management Statement to July 20 and Case Management Conference to July 27, because initial terms for settlement have been agreed upon, and more time is required to complete final terms of settlement.

d.h. Health Discovery und Ciphergen steuern in ihrem Patentstreit auf eine Einigung zu

[alysant]

Antwort auf Beitrag Nr.: 29.669.519 von talis am 06.06.07 17:43:15

kommt auch bald ein buy-confirmed von americanbulls.com

[alysant]

Antwort auf Beitrag Nr.: 29.684.192 von alysant am 07.06.07 14:13:31

heute noch kein Vol.

0.09 : 0.10

[talis]

Ich wollte mich hier nochmal äussern, um sicher zu gehen, dass die Versprengten, die hier zufällig mitlesen, das Wesentliche verstanden haben. Die Entwicklung der Diagnostikmethoden, die Health Discovery vorantreibt ist lediglich ein Anwendungsbereich ihrer Technologie. Der Kernpunkt der Angelegenheit ist die Support Vector Machine. Dies ist ein mathematischer Algorithmus auf den Health Discovery das Monopol hat. Man muss nur die Gerichte davon überzeugen. Wenn sich zwischen Health Discovery und Ciphergen bezüglich ihres Patentstreits eine Einigung abzeichnet steht man jetzt kurz vor der Anerkennung. Sobald es eine Einigung gibt, folgen vermutlich weitere Deals mit weiteren Lizenznehmern, die sich bis jetzt noch zurückhalten.

[alysant]

talis kennt sich fundamental hier am besten aus, ist auch sein baby !

Ich halte den Wert für spekulativ kaufenswert um 0.10 aufgrund beiläufiger Beobachtung.

gestern:

0.104 Vol. 35.000

H/T

0.104
0.092

[talis]

http://www.allbusiness.com/services/business-services/401967…

Health Discovery Corporation and Atlantic Alpha Strategies, LLC Announce Formation of Joint Venture.
Publication: Business Wire
Date: Tuesday, January 23 2007
Subject: Biotechnology industries (Joint ventures)

New Company Will Apply HDC's State-of-the-Art Support Vector Machine Technology to Quantitative Investment Analysis

SAVANNAH, Ga. -- Health Discovery Corporation ("HDC") (OTCBB: HDVY) announced today that it had entered into a binding agreement with Atlantic Alpha Strategies, LLC ("A-A")
to explore and exploit the potential applicability of HDC's Support Vector Machines ("SVM") to quantitative investment management techniques. An equally owned joint venture, SVM Capital LLC, will be formed to advance these objectives. Among other considerations, HDC will contribute a worldwide exclusive license for the use of SVMs in financial markets and A-A will contribute an historical database for equity, debt, currency and commodities markets.

"To date, our research with HDC is a highly promising start towards our goal of a superior risk-to-reward investment model," said Mark Moore, Ph.D., a founding partner of A-A and the President of SVM Capital. "Our preliminary findings indicate not only higher than average returns but also major reductions in volatility. These results are quite remarkable considering that we are still at a very early stage of development and have not yet fully implemented all of the technological advantages of the SVM algorithms."

According to William F. Quirk, Jr., a member of HDC's Board of Directors, "We've always known that SVM pattern recognition applications far transcend the pharma/biotech arena that has thus far defined HDC, and our patents actually reflect this fact. Hundreds of studies in medical research confirm the consistent superiority of SVMs to other popular mathematical tools, such as neural networks, that are widely used in quantitative investment techniques. If SVM Capital can now develop predictive financial models and if these performance differentials can be maintained, it could signal a major advance in investment management and hedging techniques that cannot be duplicated because of our patent protection."

"HDC is most fortunate to partner with a financial markets domain expert such as Mark Moore," noted Stephen D. Barnhill, M.D., HDC's Chairman and CEO. "This arrangement brings an entirely new dimension to HDC's technology portfolio by demonstrating our willingness to work with firms outside the medical arena to leverage our technological strengths without overextending our management capabilities. Joint ventures such as this can create new and exciting revenue opportunities for HDC which may prove quite beneficial for our shareholders."

Savannah-based Health Discovery Corporation (OTCBB: HDVY) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery(sm).
The Company's SVM and other pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, Internet search and spam, homeland security, financial futures, and other areas where analysis of large volumes of complex data is required.

Atlantic-Alpha Strategies was founded in 2006 to manage a fully-hedged equity arbitrage fund based on Dr. Moore's proprietary Pairs Trading program. This in turn is the culmination of his particular expertise in developing specialized logic structures for value decisions in financial markets since he became a General Partner (1988-1992) of Millennium Partners, an international hedge fund. Dr. Moore's career has been focused on quantitative approaches for a variety of investment vehicles in the options, commodities, equities and debt markets.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

[alysant]

Antwort auf Beitrag Nr.: 30.148.305 von alysant am 22.06.07 14:37:56

0.09 scheint der Boden zu sein, der hält

[talis]

Press Release Source: Health Discovery Corporation

Health Discovery Corporation Settles Patent Infringement Suit against Ciphergen Biosystems, Inc.
Friday July 6, 9:27 am ET
Ciphergen to License HDC's Support Vector Machine Technology

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation ("HDC") (OTCBB:HDVY - News) today announced that its patent infringement action against Ciphergen Biosystems, Inc. has been settled. Under the terms of the agreement, Ciphergen will pay $600,000 to HDC and receive a non-exclusive license to use HDC's support vector machines in applications for Ciphergen's proprietary SELDI-based technologies. Ciphergen also dropped all counter-claims against HDC.

"This settlement is an excellent resolution for our company and shareholders," said Stephen D. Barnhill, M.D., HDC's Chairman and CEO. "It is also the second favorable outcome in both of the patent infringement suits we've filed, adding credence and momentum to our ongoing licensing efforts. HDC remains firmly committed to monetizing our valuable intellectual property through close collaboration and development with our business partners, but we will also continue to protect our patent portfolio through robust enforcement action when necessary."

Savannah-based Health Discovery Corporation (OTCBB:HDVY - News) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery sm. The Company's SVM and RFE-SVM pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct.


Contact:

Health Discovery Corporation
Daniel R. Furth, 813-716-4783
[e-mail]
www.healthdiscoverycorp.com

[alysant]

Antwort auf Beitrag Nr.: 30.523.776 von talis am 06.07.07 16:09:08

0.10 (Doll.) Vol. 64.000

Meldung wirkt sich positiv auf Kurs aus.

[talis]

Antwort auf Beitrag Nr.: 30.525.723 von alysant am 06.07.07 17:54:05

Nach der Meldung über den beigelegten Patentstreit ist Health Discovery für mich ein klarer Kauf.

[alysant]

Antwort auf Beitrag Nr.: 30.526.120 von talis am 06.07.07 18:20:32

dto. vol. 90.000

[alysant]

Antwort auf Beitrag Nr.: 30.527.781 von alysant am 06.07.07 20:24:45

0.10 vol. 143.000

[talis]

Antwort auf Beitrag Nr.: 30.540.603 von alysant am 07.07.07 15:56:01

Es ist auch nicht ausgeschlossen, dass HDC irgendwann einmal Patentklage gegen Microsoft einreicht.

[talis]

Health Discovery in guter Gesellschaft

http://www.clinicalbiomarkers.net/index.asp

[alysant]

Antwort auf Beitrag Nr.: 30.567.246 von talis am 08.07.07 15:11:54

very good sign

[talis]

Press Release Source: Ciphergen Biosystems, Inc.

Ciphergen Biosystems Licenses More Than 25 Patents From Health Discovery Corporation
Tuesday July 10, 12:10 pm ET
--Settles Patent Suit--

FREMONT, Calif., July 10 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News) today announced that it had entered into a license and settlement agreement with Health Discovery Corporation ("HDC") (OTCBB: HDVY - News) pursuant to which it licensed more than 25 patents covering HDC's support vector machine technology for use with SELDI technology. Under the terms of the agreement, Ciphergen receives a world-wide, royalty-free, non-exclusive license for life sciences and diagnostic applications of the technology and has access to any future patents resulting from the underlying intellectual property in conjunction with use of SELDI systems. In connection with the agreement, Ciphergen will pay a total of $600,000 over a two-year period to HDC. The agreement settles all disputes between the companies.

"With this agreement, we are pleased to have enabled Ciphergen and SELDI users easy and flexible use of HDC's intellectual property," said Gail S. Page, Chief Executive Officer and President. "Moreover, we were able to obtain a broad, comprehensive license without significant expenditure of time and dollars."

About Ciphergen

Ciphergen Biosystems, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Ciphergen, along with its scientific collaborators, has ongoing diagnostic programs in oncology/hematology, cardiology and women's health with an initial focus in ovarian cancer. Ciphergen is based in Fremont, California. More information about Ciphergen can be found on the Web at: http://www.ciphergen.com .

Safe Harbor Statement

This news release contains forward-looking statements that involve significant risks and uncertainties, including those that can be found in Ciphergen's Form 10-K for the year ended December 31, 2006, and in Ciphergen's periodic reports on Form 10-Q and Form 8-K. Statements in this release are based upon information available to Ciphergen as of the date of the release.

Information and announcements involving Ciphergen's expectations, beliefs, hopes, plans, intentions or strategies regarding the future are forward- looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. We claim the protection of such safe harbor, and disclaim any intent or obligation to update any forward- looking statement contained in this document as a result of new information, future events or otherwise. These statements are not guarantees of future performance and actual results could differ materially from our current expectations.

NOTE: Ciphergen is a registered trademark of Ciphergen Biosystems, Inc.


Source: Ciphergen Biosystems, Inc.

[alysant]

vol. 217.000 mit high 0.12

[alysant]

vol. 267.000 0.10

Geduld !

[alysant]

Antwort auf Beitrag Nr.: 30.631.345 von alysant am 11.07.07 14:30:15

0.073 - kleiner Schwächeanfall

Talis, was sagst Du als Fundamentalist ?

[alysant]

0.08 vol. 175.000

Anfall vorbei

[alysant]

Antwort auf Beitrag Nr.: 30.878.645 von alysant am 27.07.07 16:21:28

0.083 vol. 286.000

H/T

0.083
0.073

Die "americanbulls" (immer mit Vorbehalt zu genießen) geben ein buy-if. Bei buy confirmed und dem engen Markt sind wir schnell wieder bei 0.12 +

[talis]

Health Discovery Corporation Announces Allowance of New U.S. Patent Covering SVM Pre-Processing Methods
Monday July 30, 11:11 am ET

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (("HDC") (OTCBB:HDVY - News) announced that last week the U.S. Patent and Trademark Office issued a notice of allowance on its patent application entitled "Method of Using Kernel Alignment to Extract Significant Features from a Large Dataset." The new patent covers a novel pre-processing technique for use with SVMs, which was developed by Nello Cristianini, a recognized authority in the field of support vector machines and co-author of the widely-referenced books, An Introduction to Support Vector Machines and Kernel Methods for Pattern Analysis.

ADVERTISEMENT
The application, which is a continuation of Patent No. 6,944,602, entitled "Spectral Kernels for Learning Machines," claims a method of pre-processing data referred to as "kernel alignment." The kernel alignment technique has been adopted by a number of researchers in the field for use in feature selection as well as kernel optimization. Kernel optimization is important for ensuring accuracy of classifications performed by SVMs and other learning machine. Feature selection methods are critical in reducing processor run time when analyzing the high volumes of data, such as that encountered with gene expression data and related information for discovery of biomarkers. Examples of uses of kernel alignment include gene expression analysis for biomarker identification and medical diagnostics, protein homology detection, identification of quantitative structure activity relationships (QSARs) for potential drug leads, and image reconstruction, to provide just a few examples.

Once the USPTO issues the patent described above, Health Discovery Corporation will hold the exclusive rights to 23 issued U.S. and foreign patents covering uses of SVMs for discovery of knowledge from large data sets. The issued patents cover methods and systems for pre-processing of data to enhance knowledge discovery using SVMs, analysis of data using multiple support vector machines and for multiple data sets, and providing SVM analysis services over the Internet. HDVY's pending U.S. and foreign patent applications cover numerous improvements to and applications of SVMs including computer-aided image analysis using SVMs, with particular application to diagnosis using medical images, methods of feature selection for enhanced SVM efficiency and biomarkers for colon cancer, prostate cancer, BPH and renal cancer discovered with these methods, and use of SVMs for analysis of spectral data, such as mass spectrometry data used for protein analysis.

"This recent Notice of Allowance issued by the USPTO is great news for our company and shareholders as it represents an increase in both size and scope of our valuable patent portfolio," said Stephen D. Barnhill, M.D., HDC's Chairman and CEO. "The continued strengthening of our IP estate is a critical part of our business strategy that gives momentum to our ongoing licensing initiatives and our concurrent patent protection efforts as evidenced by the favorable outcome of our most recent infringement case with Ciphergen. We remain committed to monetizing our technology through expansion of our patent portfolio, collaboration with our licensing partners, and protection of our intellectual property rights when necessary."

Savannah-based Health Discovery Corporation (OTCBB:HDVY - News) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery(sm). The Company's SVM and RFE-SVM pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.


Contact:

Health Discovery Corporation
Daniel R. Furth, 912-443-1987
[e-mail]
www.healthdiscoverycorp.com

Source: Health Discovery Corporation

[talis]

Clarient and Health Discovery Corporation Initiate Alliance with Licensing Agreement for New Molecular Diagnostic Test for Prostate Cancer
Tuesday July 31, 6:00 am ET
First Proprietary Molecular Diagnostic Test in Clarient's Novel Marker Program

ALISO VIEJO, Calif. and SAVANNAH, Ga., July 31 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT - News), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, and Health Discovery Corporation (OTC Bulletin Board: HDVY - News) today jointly announced an alliance that begins with the commercialization of HDC's new prostate cancer marker. Under the terms of the agreement, Clarient obtained an exclusive license to HDC's prostate cancer marker and plans to immediately initiate the commercialization process for the test. In turn, HDC will receive a 30 percent royalty for all prostate cancer tests performed by Clarient utilizing the HDC marker discovery (based on reimbursements received by Clarient from third parties for such tests). The exclusive agreement provides Clarient with a unique 4-gene test that may enhance the early detection and staging of prostate cancer, thereby helping doctors make better decisions on diagnosing this disease and determining more appropriate, patient specific treatment plans.

ADVERTISEMENT
The prostate cancer test will be the first molecular test in Clarient's novel marker program, and the larger ongoing relationship between Clarient and HDC could also result in additional diagnostic and prognostic tests developed by HDC and commercialized by Clarient. HDC will lead the research effort through the application of its patent protected SVM technology. Clarient will have a right of first refusal to license and commercialize any subsequent cancer tests resulting from HDC's development endeavors. Clarient anticipates that it will begin validation work on HDC's prostate cancer marker immediately and follow with appropriate clinical studies to support the preliminary findings. Once the clinical studies are completed, Clarient will seek the necessary regulatory approvals and clearances.

"Prostate cancer is one of the leading causes of death for men," said Ron Andrews, President and CEO of Clarient, Inc. "Today, there are more than 100 new therapeutics in various phases of clinical trials aimed at treating the disease. Our agreement with HDC offers Clarient the opportunity to be a larger player in this rapidly expanding diagnostic marketplace."

Andrews continued, "As a result of this agreement, Clarient takes an important step toward further differentiating its service offering and moves the Company closer to its goal of a leadership position in the characterization and assessment of cancer. The right to develop and market HDC's gene set provides Clarient with one of the most advanced tools available to distinguish various grades of prostate cancer. Validating a marker will also allow us to work with therapeutic companies to provide access to valuable information as they select patient cohorts for future clinical trials."

Andrews further stated, "We are very enthusiastic about the growing number of opportunities for our novel marker program. This program will focus on the development of molecular diagnostic tests and capabilities to further clarify the complexity of cancer and is part of our overall strategy to deliver high value information to our community healthcare partners."

"The World Health Organization estimates that prostate cancer in men is expected to increase 40 percent worldwide in the next 25 years," said Stephen D. Barnhill, M.D., HDC's Chairman and CEO. "Current prostate cancer screening sales are estimated to be more than $350 million annually and represent 40 percent of all annual cancer serum biomarker revenues. More than a million men a year undergo biopsies of the prostate. There is tremendous market opportunity here."

Barnhill continued, "This new commercialization partnership with Clarient is a giant step forward for our company. Clarient's specialized expertise in cancer testing and its state-of-the-art anatomic pathology clinical laboratory will provide HDC with the ability to quickly commercialize and make available to doctors and patients our new diagnostic and prognostic marker discoveries. This is just one example of how our two companies can make an impact on a critical area of cancer care, together."

About Clarient

Clarient combines innovative technologies with world class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies.

The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics, Inc. partner company. For more information, visit http://www.clarientinc.com.

About Safeguard

Safeguard Scientifics, Inc. (NYSE: SFE - News), a holding company, builds value in growth-stage technology and life sciences businesses. Safeguard provides growth capital as well as a range of strategic, operating and management resources to our partner companies. Safeguard participates in growth buyout financings, including corporate spin-outs and management buyouts, expansion financings, industry consolidations and early-stage financings. http://www.safeguard.com

About Health Discovery Corporation

Savannah-based Health Discovery Corporation (OTC Bulletin Board: HDVY - News) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery(SM). The Company's SVM and other pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, Internet search and spam, homeland security, financial futures, and other areas where analysis of large volumes of complex data is required.

The statements herein regarding Clarient, Inc. and HDC contain forward- looking statements that involve risks and uncertainty. Future events and Clarient's actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to: Clarient's ability to validate and/or obtain any necessary regulatory clearances or approvals for the commercialization of HDC's prostate cancer novel marker and any other novel markers that may be developed by HDC or other third parties and licensed to Clarient; Clarient's ability to successfully commercialize novel markers and the acceptance of the relevant laboratory tests in the marketplace; whether Clarient and HDC are able to reach agreement with respect to the licensing terms for future novel makers developed by HDC; Clarient's ability to obtain favorable third party payer reimbursement for laboratory tests; unanticipated expenses or liabilities or other adverse events affecting Clarient's laboratory business; uncertainty of success in identifying and developing new diagnostic tests or novel markers; Clarient's ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, and risks detailed from time to time in the Clarient's and HDC's SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to laboratory services, revenues and results of operations may not be indicative of future results for the reasons set forth above.

Clarient and HDC do not assume any obligation to update any forward- looking statements or other information contained in this document.

Contact:

Matt Clawson Daniel R. Furth
Allen & Caron, Inc. Health Discovery Corporation
[e-mail] [e-mail]
Len Hall (media) [phone]
[e-mail]
[phone]

John Baldissera
BPC Financial
[phone]


Source: Clarient, Inc.

[alysant]

Antwort auf Beitrag Nr.: 30.919.649 von alysant am 29.07.07 17:34:21

0.08 Vol. 414.000

H / T

0.095
0.08

Interesse steigt enorm ( Vol.) und auch Kurs - unter Schwankungen

[alysant]

Antwort auf Beitrag Nr.: 30.954.450 von alysant am 31.07.07 17:59:26

vol. bisher 500.000

[alysant]

Antwort auf Beitrag Nr.: 30.955.465 von alysant am 31.07.07 18:57:51

wird heute über 1 Mio.

hoffentlich folgt dem auch der Kurs

[talis]

Antwort auf Beitrag Nr.: 30.950.815 von talis am 31.07.07 14:29:28

Ich fasse zusammen, was ich in den Amiforen über die letze news an Meinungen gefunden habe.

Markteinführung des Biomarkers über Prostatakrebs vermutlich kurzftistig erreichbar, vermutlich kein FDA approval notwendig.

Beispielrechnung:
Zu Anfang 20000 Patienten mal 1000 $ (Kosten der Diagnose) davon 30% royalties = 6 Mio $ Einnahmen für HDC.

Ich frage mich nur, wer gestern verkauft hat.

[alysant]

Antwort auf Beitrag Nr.: 30.965.954 von talis am 01.08.07 13:25:52

Frage, wer hat gekauft:

Vol. 880.000

[talis]

Antwort auf Beitrag Nr.: 30.965.954 von talis am 01.08.07 13:25:52

Korrektur:

1000$ für einen Test ist vermutlich viel zu viel aber lassen wir uns überraschen

[alysant]

bei 0.079 sell confirmed bei "americanbulls.com"

Das ist ein klares Kaufsignal, da der Laden gerade hier immer falsch liegt (nach seiner Kurs-Historie)

[alysant]

Antwort auf Beitrag Nr.: 30.967.297 von alysant am 01.08.07 15:05:28

quod erat demonstrandum:

0.09 (Geld) vol. 79.000

H/T

0.090
0.079

[alysant]

Antwort auf Beitrag Nr.: 30.970.113 von alysant am 01.08.07 17:48:08

vol. 155.000

ich denke, wir sehen heute noch 0.10.

[alysant]

Antwort auf Beitrag Nr.: 30.970.347 von alysant am 01.08.07 18:03:25

nicht 0.10, aber

0.09 vol. 292.000

[talis]

Zusammengetragen von RB:

Clarient wird in 3-4 Monaten den Krebstest auf Prostata fertig haben. Das ist ein Gewebetest mit einem Volumen von 15 Mio$.

Bei 30% royalties sind das 4,5 Mio$ für HDC

Clarient hofft aus dem Gewebetest einen Bluttest machen zu können. Dann wird man PSA verdängen können.
Unser Test hat eine accuracy von immerhin 95%, während der PSA-Test mangelhgaft ist.
Volumen dann 350 Mio$. D.h. 1$ pro Aktie für HDC.

[talis]

ZUSAMMENFASSUNG

HEALTH DISCOVERY CORP. REGISTERED SHARES O.N., WKN: (784597)

Health Discovery hält Patente auf mathematische Algorithmen (Support Vector Machine), die es ermöglichen lernende Software zu erstellen. Immer dann wenn grosse Datenmengen auftreten kommt diese zum Einsatz, da man damit in der Lage ist, signifikante Daten herauszufiltern. Health Discovery konzentriert sich bei den Anwendungsgebieten auf die klinische Forschung. Andere Anwendungsgebiete wie die Finanzsphäre oder die IT-Branche, siehe homepage. Health Discovery konzentriert sich also auf die klinische Forschung und sucht dabei nach Biomarkern für die Diagnostik. Biomarker sind noch relativ neu. Biomarker sind Stoffe, die immer im Zusammenhang mit einer bestimmten Krankheit auftreten und verschwinden. D.h. anstatt die Symptome einer Krankheit zu beobachten, beobachtet man, die Biomarker. Dies ist ein Verfahren, das auch von der FDA unterstützt wird, da es die klinischen Tests beschleunigt und effektiver macht. Health Discovery hat sich bereits einige Biomarker patentieren lassen (siehe homepage) und sucht nun nach Partnern für die Vermarktung. Der Anfang wurde gemacht mit der Lizenzpartnerschaft mit Clarient über den Biomarker für Prostatakrebs, siehe Pressemitteilung.

Nach Aussagen von Clarient wird in 3-4 Monaten der Test so weit sein, um ihn Pharmafirmen anbieten zu können. Clarient geht von einem Gesamtvolumen über 15 Mio $ in 2008 aus. Bei 30% royalties sind das 4,5 Mio $ für Health Discovery. Es handelt sich hierbei um einen Gewebetest, wie er nach Biopsien angewendet wird. Clarient hofft aus dem Gewebetest einen Bluttest machen zu können, und wäre sich bei Gelingen sicher, PSA verdrängen zu können. PSA ist der bisherige Test für die Erkennung von Prostatakrebs, der ein Gesamtvolumen von 350 Mio $ p.a. ausmacht. Das entspräche bei 30% royalties ca 1 $ pro Aktie für Health Discovery. (siehe Raging Bull). Health Discovery hat bei einem Kurs von 0,085 $ eine Marktkapitalisierung von 10 Mio $.

Health Discovery verfolgt ausserdem die Vermarktung der Support Vector Machine. Es gibt bereits Lizenznehmer, wie z.B. Pfizer. Hier sind u.U. auch noch royalties zu erwarten. Nach Aussagen von Health Discovery benutzen bereits zahlreiche Forscher die Support Vector Machine. Man muss sie nur noch dazu bringen, dafür zu bezahlen. Sie wollen natürlich nicht bezahlen, was sie gewohnt sind, umsonst zu haben. Daher wird Health Discovery seine Patente durch Patentklagen schützen. Es gibt bereits zwei erfolgreich beendete Auseinandersetzungen, wobei der erste sich nicht, der zweite nämlich Ciphergen heftig gewehrt hat. Ciphergen hatte sogar Gegenbehauptungen aufgestellt, die aber allesamt fallengelassen werden musste. Es endete mit einer Durchsetzung der Rechte von Health Discovery und einer Zahlung über 600000 $. Die Anwälte wurden auf Kontingentbasis bezahlt, so dass mindestens 360000 $, zahlbar über 2 Jahre hinweg, bei Health Discovery ankamen (Quelle: RB).

Unbedingt limitiert in USA ordern.



diese Aktie hat keiner auf dem Radar!

[talis]

Press Release Source: Health Discovery Corporation

Health Discovery Corporation Announces Allowance of New U.S. Patent and Issuance of a European Patent Covering Fractal Genomics Modeling Technology
Monday August 6, 11:37 am ET
HDC's Portfolio Will Include 26 Issued U.S. and Foreign Patents Covering Uses of SVM and FGM Technology

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (OTC Bulletin Board: HDVY - News) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application entitled "Method for the Manipulation, Storage, Modeling, Visualization and Quantification of Datasets." Once issued, the patent will be the second of a series of applications covering the Fractal Genomics Modeling (FGM) Technology to issue. This patent covers use of the FGM technology for identifying patterns within a dataset by recognizing repeated data strings within a long sequence of data, then associating each repeated string with a single point within a grid. The points are then used to create a visual map which is capable of graphically representing the complete dataset. The claims of the new patent are not limited to biotechnology applications, but also encompass application of the FGM technology to pattern recognition within other types of data.

The FGM technology has been used to recognize patterns within gene expression data and causal relationships between genes to identify biomarkers that may be useful in developing potential treatments, diagnoses or prognoses of diseases, including HIV and leukemia. In addition to its applications in biomarker discovery, FGM technology has clear applications in data compression for image data and other data types that involve datasets made up of repeated data strings of varying lengths.

Health Discovery Corporation also reported that the European Patent Office has recently granted a new patent covering the FGM technology. The claims of European Patent No. 1252588 correspond to those of the first issued U.S. patent covering the FGM technology, Patent No. 6,920,451, which provides for either graphical or mathematical mapping of the points that represent strings of data.

Once the USPTO issues the new FGM patent, Health Discovery Corporation will hold the exclusive rights to 26 issued U.S. and foreign patents covering uses of SVM and FGM technology for discovery of knowledge from large data sets. Other issued patents cover methods and systems for pre-processing of data to enhance knowledge discovery using SVMs, analysis of data using multiple support vector machines and for multiple data sets, and providing SVM analysis services over the Internet. HDVY's pending U.S. and foreign patent applications cover numerous improvements to and applications of SVMs including computer-aided image analysis using SVMs, with particular application to diagnosis using medical images, methods of feature selection for enhanced SVM efficiency and biomarkers for colon cancer, prostate cancer, BPH and renal cancer discovered with these methods, and use of SVMs for analysis of spectral data, such as mass spectrometry data used for protein analysis.

"The intelligent growth of HDC's patent portfolio is a critical component of our business plan," said Stephen D. Barnhill, M.D., HDC's Chairman and CEO. "Expansion of our dynamic patent estate underscores our commitment to increasing shareholder value including additional patent protection of our core pattern recognition technology and similar protection of our discoveries resulting from the application of that technology. Regularly increasing the strength of our patent portfolio allows HDC to grant its licensing partners a much better commercial offering with vastly improved potential for protection."

Savannah-based Health Discovery Corporation is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery(sm). The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct.


Contact:

Health Discovery Corporation
Daniel R. Furth, 912-443-1987
[e-mail]
www.healthdiscoverycorp.com

Source: Health Discovery Corporation

[alysant]

ca. 300.000 vol. zu 8 / 9

[alysant]

0.085 vol. 609.000

steigendes Vol. signalisiert steigendes Interesse - Kurs wird dem folgen

[talis]

Antwort auf Beitrag Nr.: 31.061.649 von alysant am 07.08.07 11:21:27

ja, aber irgendwer scheint hartnäckig verkaufen zu wollen, trotz guter Nachrichten.

Ich hoffe, HDC hat nicht irgendwo eine Leiche im Keller.

[alysant]

Antwort auf Beitrag Nr.: 31.063.811 von talis am 07.08.07 14:04:16

habe hierzu bei yahoo.com gelesen, daß es keine insider sein sollen, sondern welche aus persönlichen Motiven

[talis]

Das Shareholdermeeting, der Umzug von Texas nach Georgia und der Patentstreit mit Ciphergen hat viel der Zeit HDCs in Anspruch genommen. Nachdem dies alles vollbracht ist, kann sich HDC voll auf die Verhandlungen mit potentiellen Lizenznehmern konzentrieren. Folgerichtig kam nach weniger als einem Monat nach der Beilegung des Patentstreits mit Ciphergen der Vertrag mit Clarient zustande. Ich tippe, dass noch im August ein weiterer Abschluss hinzukommt. Hoffentlich mit einer ordentlichen Vorabzahlung, damit die Kasse klingelt und der Kurs steigt.

[talis]

http://www.sec.gov/Archives/edgar/data/1141788/0001188112070…

Upon the relevant approval or clearance by the FDA of the diagnostic test for prostate cancer, the foregoing license shall become an exclusive license within the Field of Use in the Licensed Territory with respect to the commercial reference laboratory field and a nonexclusive license with respect to the academic and research fields.

...so ganz ohne die FDA geht es doch wohl nicht...

[talis]

Press Release Source: Health Discovery Corporation

Health Discovery Corporation Announces Stock Purchase Agreement
Thursday August 16, 9:15 am ET

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation ("HDC") (OTCBB:HDVY - News) today announced in its second quarter 10QSB that it has entered into a stock purchase agreement with several financial institutions and other accredited investors, two of whom have agreed to serve on the board upon closing. Under the terms of the private placement, HDC expects to raise a minimum of $1,500,000 to a maximum of $2,500,000 in new equity funding. In addition, the Company's current note holders intend to convert approximately $2,000,000 of existing debt into equity. The deal is anticipated to close on or before September 7, 2007.

"I believe this deal offers HDC a tremendous opportunity to capitalize on the demonstrable momentum of our recent successes," said Stephen D. Barnhill, M.D., HDC's Chairman and Chief Executive Officer. "When we close this deal, we expect that the equity infusion and the related debt conversion will give us a completely restructured balance sheet. The resulting financial strength will allow us to fuel our biomarker discovery efforts, increase the pace of our licensing and development opportunities with our collaborative partners, and continue the enhancement and protection of our valuable patent estate."

Savannah-based Health Discovery Corporation (OTCBB:HDVY - News) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery(sm). The Company's SVM and other pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, Internet search and spam, homeland security, financial futures, and other areas where analysis of large volumes of complex data is required.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct.


Contact:

Health Discovery Corporation
Daniel R. Furth, 912-443-1987
www.healthdiscoverycorporp.com
[e-mail]

Source: Health Discovery Corporation

[alysant]

0.09

Der Titel behauptet sich in den Wirren der Börsen

[talis]

Antwort auf Beitrag Nr.: 31.187.061 von talis am 16.08.07 16:21:53

Health Discovery hat nun eine Finanzierung, die mindestens 1 Jahr reicht.
1,5 Mio $ mindestens, maximal 2,5 Mio $ im Private Placement gegen Aktien zum Kurs von 0,08 $.
Ausserdem erklären sich die Glaübiger bereit für ihre Kredite (2 Mio $) im Tausch Aktien auch zum Kurs von 0,08 $ zu akzeptieren. Damit kommen insgesamt zusätzlich 58 Mio Aktien hinzu. Wenn man die warrants dazuzählt, die auch noch ausgegeben wurden, kann man davon ausgehen, dass irgendwann die autorisierte Zahl von 300 Mio Aktien erreicht wird.

Bemerkenswert ist wie bereitwillig die Investoren Health Discovery Geld gegeben haben. Einfach Geld gegen Aktien. Nichts mit Zinsen und Verpfändung der Patente als Sicherheit wie man es bei anderen Aktien gesehen hat

[talis]

Antwort auf Beitrag Nr.: 31.209.087 von alysant am 17.08.07 18:31:05

Die jetzige Marktkapitalisierung ist zum tot

Damit hast Du recht.

Lange bleibt der Kurs nicht mehr da unten.

[talis]

@alysant

Health Discovery veröffentlicht eine substanzielle News nach der anderen. Aber der Kurs rührt sich nicht. Spätestens nach der geglückten Finanzierung der letzten Woche bin ich mir aber sicher, dass HDC keine Leiche im Keller hat. Bald geht´s nach Norden.

Es dauert auch nicht mehr lange dann wird es in diesem Board mehr als nur 2 Alleinunterhalter geben.

[Bachalor]

[talis]

Antwort auf Beitrag Nr.: 31.221.404 von Bachalor am 19.08.07 13:05:04

Heureka, Du hast´s gefunden.

[Bachalor]

Antwort auf Beitrag Nr.: 31.221.435 von talis am 19.08.07 13:13:03

ich finde den thread seit anfang an
habe ihn bei den favoriten

[talis]

Ich kann übrigens nur jedem empfehlen, persönlich bei Dan Furth von HDC anzurufen, damit man einen Eindruck bekommt. (mail schreiben nützt hier nichts)

[talis]

ein Auszug aus dem filing

http://www.sec.gov/Archives/edgar/data/1141788/0001188112070…



In connection with the closing of the Private Placement, we also plan to increase the size of our Board of Directors and add two additional outside directors, who we expect to participate as investors in the Private Placement. We are very excited about these two individuals becoming members of our Board of Directors and believe that the guidance, advice and contacts they bring will greatly benefit the Company as we continue to execute our business plan with a completely recapitalized balance sheet.

Erst nehmen 2 Investoren am Private Placement teil, anschliessend gehören sie zum Direktorium.
Das ist sowas ähnliches wie ein Insiderkauf

[talis]

Health Discovery Corporation Receives Notice of Acceptance of Australian Patent Application Covering Biomarker Selection Using SVMs
Monday August 20, 9:15 am ET

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (HDC) (OTCBB:HDVY - News) today announced that IP Australia, the Australian patent office, has published the Notice of Acceptance of HDC's patent application covering the use of recursive feature elimination in support vector machines (RFE-SVM) for identification of determinative genes for diagnosis, prognosis and treatment of disease. RFE-SVM is a mathematical selection/filtering process that successively eliminates the least important of many data features, then ranks each of the most significant of the relatively few features remaining for simultaneous use in classifying the data using SVMs. The most significant benefit is an increase in the accuracy and usefulness of the classification results, particularly when analyzing voluminous data, such as that encountered during the analysis of genetic and proteomic data.

The accepted claims in the application include coverage of specific genetic biomarkers identified using RFE-SVM for diagnosing prostate cancer and for separating benign prostate hyperplasia (BPH) from prostate cancer. Following issuance, this will be HDC's second Australian patent covering the RFE-SVM method for analysis of data.

The RFE method was first reported in 2002 in an article by authors Isabelle Guyon and Vladimir Vapnik, both members of HDC's Scientific Advisory Board, Stephen Barnhill, HDC's Chairman and CEO, and Jason Weston. The article, entitled "Gene Selection for Cancer Classification Using Support Vector Machines," published in the journal Machine Learning, has been widely cited in subsequent publications, recognizing the significance of the RFE method within the SVM field.

"We are very excited to receive yet another international patent Notice of Acceptance," said Stephen D. Barnhill, M.D., HDC's Chairman and CEO. "The continued international expansion of our patent portfolio adds significantly to the increasing value of the HDC patent portfolio."

Once IP Australia issues the new RFE-SVM patent, Health Discovery Corporation will hold the exclusive rights to 27 issued U.S. and foreign patents covering uses of SVM and FGM (fractal genomics modeling) technology for discovery of knowledge from large data sets. Other issued patents cover methods and systems for pre-processing of data to enhance knowledge discovery using SVMs, analysis of data using multiple support vector machines and for multiple data sets, and providing SVM analysis services over the Internet. HDC's pending U.S. and foreign patent applications cover numerous improvements to and applications of SVMs including computer-aided image analysis using SVMs, with particular application to diagnosis using medical images, methods of feature selection for enhanced SVM efficiency and biomarkers for colon cancer, prostate cancer, BPH and renal cancer discovered with these methods, and use of SVMs for analysis of spectral data, such as mass spectrometry data used for protein analysis.

Savannah-based Health Discovery Corporation (OTCBB:HDVY - News) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery(sm). The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.


Contact:

Health Discovery Corporation
Daniel R. Furth, 912-443-1987
[e-mail]
www.healthdiscoverycorp.com

Source: Health Discovery Corporation

[talis]

weitere Patentanmeldung

http://biz.yahoo.com/bw/070822/20070822005655.html?.v=1


Press Release Source: Health Discovery Corporation

Health Discovery Corporation Announces Grant of New Japanese Patent and Acceptance of Australian Patent Application Covering HDC'S SVM-Based Image Analysis Technology

[talis]

Health Discovery Corporation Announces Two Additions to its Board of Directors
Tuesday August 28, 12:52 pm ET
Dr. Richard Caruso, Founder and Chairman of Integra LifeSciences Corp., and Jimmy Woodward, Senior Vice President and Chief Financial Officer of Flowers Foods, Inc., Elected to Board

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation, Inc. ("HDC") (OTCBB:HDVY - News) today announced that it has expanded its Board of Directors to five members with the addition of Richard Caruso, Ph.D. and Jimmy Woodward. Dr. Caruso is the Founder and Chairman of Integra LifeSciences Corp. (NASDAQ:IART - News) and the 2006 recipient of the prestigious Ernst & Young Entrepreneur of the Year Award. Mr. Woodward is the Senior Vice President and Chief Financial Officer of Flowers Foods, Inc. (NYSE:FLO - News)

"We are truly excited to welcome both Richard and Jimmy to our Board," said Stephen D. Barnhill, M.D., HDC's Chairman and CEO. "These two proven business leaders offer HDC a wealth of financial, managerial and entrepreneurial experience. Their expertise and broad perspective will be invaluable in helping HDC achieve its strategic objectives."

Richard E. Caruso, Ph.D., founded Integra LifeSciences in 1989 and now serves as its Chairman. Integra is credited with the creation of a new branch of medicine known as Regenerative Medicine whereby the human body is enabled to re-create its own parts. Integra's annual sales are some $400 million and it employs 2,000 associates. In 1978, Dr. Caruso founded the Provco Group to organize and fund entrepreneurs and complex business activities. Provco now manages $500 million in assets and focuses on manufacturers lease programs, venture financing, real estate, alternate energy, leveraged buyouts, reorganizations, personal property and investment strategies. From 1969 to 1992, Dr. Caruso was a principal of LFC Financial Corp which originated $3 billion in creative lease and project finance transactions. Dr. Caruso received his B.S. degree from Susquehanna University, an M.S.B.A. degree from Bucknell University, and his Ph.D. from the London School of Economics.

Jimmy M. Woodward is Senior Vice President and Chief Financial Officer of Flowers Foods, a $2 billion producer of packaged bakery foods for retail and foodservice customers. He recently announced his retirement from Flowers, effective September 15, 2007, but he will continue to serve as an advisor for financial and related matters. A valued member of Flowers' management team since 1985, Mr. Woodward served as a senior financial executive in several leadership positions and is credited with guiding it's financial strategy and leading the development of internal accounting systems to meet the ever-changing regulatory requirements of large public companies. He previously served on the board of directors of Keebler Foods, Inc., PRG-Schultz International, Inc. (NASDAQ: PRGX - News) and Integrity Media Inc. Mr. Woodward earned his B.A. degree in accounting from Florida State University.

Savannah-based Health Discovery Corporation (OTCBB:HDVY - News) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery(sm). The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.


Contact:

Health Discovery Corporation
Daniel R. Furth, 912-443-1987
[e-mail]
www.healthdiscoverycorp.com

Source: Health Discovery Corporation, Inc.

[alysant]

Antwort auf Beitrag Nr.: 31.319.851 von talis am 28.08.07 19:17:13

wieder Chance im Bereich 0.075

Akkumulieren und Geduld sind angesagt !

[Bachalor]

Antwort auf Beitrag Nr.: 31.319.851 von talis am 28.08.07 19:17:13

melzer hat mir sofort einen prof. aus der uni ffm empfohlen
er hatte ihm bescheid gegeben

der patient wohnt hier bei mir in der nähe
er hatte auch die tübinger empfohlen,aber da patient her liegt,war das einfacher

[talis]

Antwort auf Beitrag Nr.: 31.320.313 von Bachalor am 28.08.07 19:36:38

wenn ich mal einen Arzt brauche, weiss ich ja, an wen ich mich wenden kann.

ich habe quasi einen Standortvorteil und ausserdem gute Connections

[Bachalor]

Antwort auf Beitrag Nr.: 31.320.508 von talis am 28.08.07 19:44:00

deswegen habe ich dich ja auch gefragt


selbst friebe hatte mir einen aus essen empfohlen


melzer hat 4 jahre in tübingén bei prof buess gearbeitet
buess ist chef des deutschen ärztekongresses
wohnt jetzt 2 straßen weiter wie melzer(wenn der nicht in irland ist)




noch ist dein thread sehr ruhig
mal sehen wie lange noch

ist halt sehr wenig handel

[talis]

Antwort auf Beitrag Nr.: 31.320.611 von Bachalor am 28.08.07 19:47:50

ich habe heute im Grant Life ein bisschen Werbung gemacht.

Ich kann versuchen die Pferde zur Tränke zu führen. Saufen müssen sie selber.

Health Discovery hält übrigens mehr Patente auf die Support Vector Machine als alle anderen aus der IT-Branche. nur z.B.

[Bachalor]

Antwort auf Beitrag Nr.: 31.320.713 von talis am 28.08.07 19:52:02

kapiere ich doch nicht

muss wech
zur krankengymnastik nach vorlagen von melzer
lieber so 3 mal die woche
wie gefährliche op


schönen abend noch

werde mal mal wieder kommen
muss nach esslingen
hoffe echec hat dann mal zeit


n8

[alysant]

Antwort auf Beitrag Nr.: 31.320.611 von Bachalor am 28.08.07 19:47:50

Der Handel ist an manchen Tagen doch recht rege und auch der thread hat sich belebt (sh. Aufrufe).

Werd scho wern

[talis]

Antwort auf Beitrag Nr.: 31.320.966 von alysant am 28.08.07 20:02:45

akkumuliert hab ich schon

da geht nix mehr

[talis]

aus dem yahoo-Board. Da kennt sich jemand aus

This is a major event. Dr. Caruso is a genious and anything he touches turns to gold. He also has access to tremendous venture capital that could invest in HDVY.

[talis]

Das neue Direktoriumsmitglied wird sich genau überlegt haben, was er tut, bevor er bei HDC eingstiegen ist.


Richard E. Caruso, Ph.D.
Founder, The Uncommon Individual Foundation

HEADLINE:
Richard Caruso Wins 2006 Entrepreneur of the Year




“By all means, become the Entrepreneur of Your Own Life by Discovering, Understanding and Releasing the Uncommon Individual that resides within yourself.”

Richard E. Caruso, Ph.D. founded Integra LifeSciences Corporation (“Integra”) in 1989. Dr. Caruso currently serves as the company’s Chairman. With the acquisition of Telios Pharmaceuticals, Inc. in San Diego, CA in August 1995, Integra became a publicly-held company listed on the National NASDAQ Market under the symbol “IART”. Integra envisioned and then created a new branch of medicine now known as Regenerative Medicine where the body is enabled to re-create its own parts.

In 1998, Dr. Caruso recruited Stuart Essig from Goldman Sachs as Integra’s President and Chief Executive Officer. Currently, Integra has annual sales of approximately $400,000,000 with approximately 2,000 associates.

In 1978, Dr. Caruso founded The Provco Group (“Provco”), a group or amalgamation of businesses or activities which organizes and provides funding for a variety of complex business activities. In each transaction where Provco participates financially, it also participates in either selecting management or directly in management. Currently, Provco manages $500,000,000 in assets and concentrates in the following areas: manufacturers lease programs, venture financing, real estate, alternate energy, leveraged buyouts, reorganizations, personal property and investment strategies.

From 1969 to 1992, Dr. Caruso was a principal of LFC Financial Corp (LFC), located in Radnor, PA that originated approximately $3,000,000,000 of creative lease and project finance transactions. When he left LFC in 1992, he was a Director and held the position of Executive Vice President. Prior to joining LFC, Dr. Caruso was associated with Price Waterhouse & Co. in Philadelphia, PA where he practiced as a certified public accountant and auditor.

Dr. Caruso is also a founding shareholder of Interactive Investor International (www.iii.co.uk) (1996), once publicly-traded on NASDAQ and the London Stock Exchange (acquired by an Australian insurance group, of Advanced Voting Solutions, Inc. – 1999 (www.advancedvoting.com), a privately-held, touch screen voting company, and of First Sterling Bank which, after a series of mergers with Prime Bank, Summit Bank and Fleet Bank, is now part of Bank of America. Dr. Caruso also founded Tenly Enterprises in 1982 which acquired and operated Rustler Steak Houses before their sale to Sizzlers.

Dr. Caruso has more than 25 years of experience in entrepreneurial and finance type ventures. He has and continues to be actively involved in a variety of domestic and international business activities. He has a broad base of business experience and maintains an active involvement in the academic community in both the United States and Europe.

In 2000, Dr. Caruso was the recipient of the New Jersey Entrepreneurial Leadership Award in Biomaterial Science.

In 2006, Dr. Caruso was the award recipient for the prestigious Ernst & Young and Kauffman Foundation sponsored Entrepreneur of the Year Award for his work with Integra LifeSciences Corporation.

Dr. Caruso is also the Founder and Director of The Uncommon Individual Foundation, a non-profit foundation which encourages individuals to form and follow their dreams of personal success and, in effect, become the entrepreneurs of their personal lives (www.uncommonindividualfoundation.org).

Dr. Caruso has served, or is serving, on the Boards of Susquehanna University, The Baum School of Art, the Business Performance Group of the London School of Economics, First Sterling Bank, Advanced Voting Solutions, Inc. and American Capital Mutual Funds and the Medici Archive Project. Dr. Caruso is also an advisor to Quaker BioVenture, a venture capital firm dedicated to investing in lifescience technology. He received a B.S. degree from Susquehanna University, M.S.B.A. degree from Bucknell University, and a Ph.D. degree from the London School of Economics, University of London (U.K.).

[alysant]

Antwort auf Beitrag Nr.: 31.320.966 von alysant am 28.08.07 20:02:45

0.079 vol. 229.000

[alysant]

Antwort auf Beitrag Nr.: 31.333.721 von alysant am 29.08.07 19:37:18

vol. 364.000 - schon mal was !

[talis]

Eine Adresse, die in letzter Zeit immer wieder als Verkäufer aufgetreten ist, indem sie den ask drückte, ist heute nicht in Erscheinung getreten. Ich meine UBSS.

Das Ende der Verkaufsbereitschaft?

[talis]

Am Labor Day zum Zeitvertreib ein Zitat aus dem letzten Quartalsbericht

...management believes revenue generation will continue, additional licensing agreements will be obtained in the near-term...


Wenn HDC es ernst meint, müsste im September die nächste Lizenzvereinbarung getroffen werden.

[talis]

solange das Private Placement nicht abgeschlossen ist, bleibt der Kurs bei 0,08 $ festgeparkt.
Für nächste Woche erwarte ich, dass es dann nach oben geht.
Bei den Aussichten, den HDC hat, könnte der Kurs genauso gut bei 0,5 $ stehen.

[alysant]

range von 0.07 bis 0.10

empfohlene Strategie:

Kauflimit 0.07 zum Abstauben

[talis]

Antwort auf Beitrag Nr.: 31.394.740 von alysant am 05.09.07 10:56:25

zur Orientierung hilft auch ein Blick in Level2

http://investorshub.advfn.com/boards/quotes.asp?ticker=HDVY&…

[talis]

Schlussstand 0,074 $

dem Kursverlauf zufolge könnte man glatt meinen, hier ist irgendwas faul

[talis]

Antwort auf Beitrag Nr.: 31.394.740 von alysant am 05.09.07 10:56:25

alysant,

Womöglich bekommst Du recht, wenn heute eine völlig unterbewertete Aktie noch weiter runtergeht
und zu 0,07 $ den Besitzer wechselt.

[alysant]

Antwort auf Beitrag Nr.: 31.415.580 von talis am 06.09.07 15:07:57

Die Bewertung ist immer ein Thema für sich:

bei USXP z.B. ist der Kurs 0.0004 = Marktkapitalisierung bei von mir vermuteten 50 Mrd. :

20 Mio. Dollar - Unternehmen pleite bei totaler Aussichtslosigkeit

============================================

HDVY wird sich letztendlich durchsetzen.

Strategie:

günstig kaufen, ev. nachkaufen und warten

[talis]

Antwort auf Beitrag Nr.: 31.416.028 von alysant am 06.09.07 15:36:36

poste das mal in deinem USXP-thread
vielleicht fällt ja bei dem einen oder anderen der Groschen, wenn er hört, HDVY hat eine Marktkapitalisierung von 9 Mio $ und einiges an Potential.

[alysant]

Antwort auf Beitrag Nr.: 31.416.157 von talis am 06.09.07 15:44:06

bei denen (den meisten) ist Hopfen und Malz verloren, das würde nichts bringen

[talis]

Antwort auf Beitrag Nr.: 31.416.280 von alysant am 06.09.07 15:49:27

dann sollen die bleiben, wo sie sind,
bloss keine Perlen vor die Säue werfen

[alysant]

Antwort auf Beitrag Nr.: 31.416.377 von talis am 06.09.07 15:53:08

Ich habe schon Fahnenflüchtige beobachtet:

Sie gehen zu PAIM, zwar auch Scheiß, aber kalkulierbarer und die alte Schlampe Sister Pearl = Elvira Gamboa hat von Zeit zu Zeit immer wieder eine neue Schweinerei parat, die für einen temporären vehementen Kursanstieg sorgt. Man muß dort allerdings lange warten und den richtigen Zeitpunkt erwischen.

[talis]

Antwort auf Beitrag Nr.: 31.417.468 von alysant am 06.09.07 16:38:10

von RB kopiert:
Ein Anruf bei HDC mit entsprechender Erkenntnis. Wie ich schon mal sagte: hier ist nichts faul, keine Leiche im Keller. 9 Mio$ Mcap ist völlig lächerlich


ALL,
I just spoke with Dan!!! They have No idea why we are being held down. There is no logic to it. However, the company is extremeley up-beat and excited about many of the things in the works. The private placment should take place soon. I STRONGLY RECOMMEND anyone who has a doubt in thier mind to CALL THE COMPANY!!JMHO!
See-Ya, TRYN

[alysant]

0.075 vol. 320.000

H/T

0.078
0.07

[alysant]

Antwort auf Beitrag Nr.: 31.421.299 von alysant am 06.09.07 20:18:11

fast 500.000 mit Boden: 0.07

[alysant]

Antwort auf Beitrag Nr.: 31.422.089 von alysant am 06.09.07 20:53:19

600.000 = sehr hoch, das Interesse wächst, werte ich mal positiv

[alysant]

gestern nur 22.000 mit 0.07

[talis]

Antwort auf Beitrag Nr.: 31.462.703 von alysant am 08.09.07 14:00:01

am Montag dann:

Kaufen Marsch Marsch

[alysant]

Antwort auf Beitrag Nr.: 31.493.544 von talis am 09.09.07 21:52:47

0.07 zu Beginn, hoffentlich der ultimative Boden

[talis]

Antwort auf Beitrag Nr.: 31.502.699 von alysant am 10.09.07 16:00:33

vom Verkaufsdruck der letzten Woche ist im Augenblick nichts mehr zu sehen.

0,069 zu 0,08

[talis]

Health Discovery Corporation Receives $2.1 Million Cash Investment and Effects Debt Conversion
Monday September 10, 3:40 pm ET

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation, Inc. ("HDC") (OTCBB: HDVY - News) today announced that it has closed an equity investment totaling $2.1 million with a financial institution and other accredited investors. As a sign of confidence in the company's direction and business prospects, each outside director also participated in this financing. In addition, HDC announced that a total of approximately $2.1 million of its previously issued secured debt will be converted into equity.

"This financing is a major success for HDC particularly in light of today's highly volatile capital markets," said Stephen D. Barnhill, M.D., HDC's Chairman and CEO. "The combination of new cash proceeds and the conversion of this debt results in an increased equity base of about $4.2 million for HDC. Our strengthened financial position allows us to focus on executing a business plan that features more biomarker discoveries, licensing and development opportunities, and continued enhancement and protection of our valuable patent estate. And, very importantly, I think the breadth of experience of many of our new highly sophisticated investors could be an especially useful resource for developing new business opportunities and increasing investor awareness of our potential."

Savannah-based Health Discovery Corporation (OTC BB: HDVY - News) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery(sm). The Company's SVM and other pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, Internet search and spam, homeland security, financial futures, and other areas where analysis of large volumes of complex data is required.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct.


Contact:

Health Discovery Corporation
Daniel R. Furth, 912-443-1987
[e-mail]
www.healthdiscoverycorp.com

Source: Health Discovery Corporation, Inc.

[talis]

Antwort auf Beitrag Nr.: 31.511.969 von talis am 10.09.07 21:46:24

hier die Details

http://www.sec.gov/Archives/edgar/data/1141788/0001188112070…


...so langsam sollte der Groschen fallen

[alysant]

Antwort auf Beitrag Nr.: 31.510.331 von talis am 10.09.07 20:47:52

auch 0.08 Schluß

[talis]

Seit threaderöffnung hat HDC...

...einen Patentstreit gewonnen, was die Werthaltigkeit der Patente beweist
...eine Lizenzvereinbarung mit Clarient abgeschlossen
... eine günstige Finanzierung erreicht, dessen Konditionen sich sehen lassen können
... den letztjährigen Unternehmer des Jahres als neiúen Direktor für sich gewonnen
und quasi einen Insiderkauf da sich die neuen Direktoren an dem Private Placement beteilgt haben.

Das alles spricht für einen ------------------------STRONG BUY

[alysant]

Antwort auf Beitrag Nr.: 31.525.440 von alysant am 11.09.07 12:31:29

dto. bei gutem Vol.:

strong buy

[talis]

Press Release Source: Health Discovery Corporation

Health Discovery Corporation Announces Grant of New Korean Patent Covering SVM Technology
Wednesday September 26, 10:24 am ET

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation ("HDC") (OTCBB:HDVY - News) today announced that the South Korean Intellectual Property Office has granted Patent No. 724104 on HDC's claims covering a tiered arrangement of SVMs that provides for the analysis of multiple data sets, such as distinct data types, to produce a single output. Any number of tiers can be used to optimize the analysis results. One application of this inventive technology is in medical diagnosis, in which a diagnosis can be performed using a combination of digital image data and gene expression data. Counterparts of this patent have already issued in the U.S., as Patent No. 6,658,395, as well as in Australia, China, Europe, Israel and Norway, and are pending in several other countries.

With this new patent and the upcoming issuance of several recently allowed applications, Health Discovery Corporation will hold the exclusive rights to 28 issued U.S. and foreign patents covering uses of SVM and FGM (fractal genomics modeling) technology for discovery of knowledge from large data sets. Other issued patents cover methods and systems for pre-processing of data to enhance knowledge discovery using SVMs, analysis of data using multiple support vector machines and for multiple data sets, and providing SVM analysis services over the Internet. HDC's pending U.S. and foreign patent applications cover numerous improvements to and applications of SVMs including computer-aided image analysis using SVMs, with particular application to diagnosis using medical images, methods of feature selection for enhanced SVM efficiency and biomarkers for colon cancer, prostate cancer, BPH and renal cancer discovered with these methods, and use of SVMs for analysis of spectral data, such as mass spectrometry data used for protein analysis.

"This recent addition to our patent estate underscores our ongoing commitment to the development and protection of our core SVM technology," said Stephen D. Barnhill, M.D., HDC's Chairman and CEO. "We will continue to expand our patent estate into the important worldwide markets where the SVM technology is utilized and we fully intend to protect our valuable intellectual property in those same markets for our shareholders and our customers alike."

Savannah-based Health Discovery Corporation (OTCBB:HDVY - News) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery(sm). The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.


Contact:

Health Discovery Corporation
Daniel R. Furth, 912-443-1987
[e-mail]
www.healthdiscoverycorp.com

Source: Health Discovery Corporation

[Kaltental]

Antwort auf Beitrag Nr.: 31.544.849 von alysant am 12.09.07 12:55:11

bist so davon überzeugt?

wurde grad vom wax darauf aufmerksam gemacht.

Könnte ja mal Zeit werden, das wir hier langsam und gemächlich die Bude hier mit etwas Leben füllen.

Kann mir jemand bitte auf den ersten Moment auf etwaige Gefahren hinweisen?

Ich such zwar jetzt welcber noch danach, aber z.B. massig Cobvertibles usw.

Chart schaut echt danach aus, als dass nun endlich die Trendwende da ist.

[talis]

Antwort auf Beitrag Nr.: 31.761.497 von Kaltental am 27.09.07 13:06:41

zu Gefahren:
das Unternehmen ist durchfinanziert.
die Bedingungen des PP lassen sich sehen.

[talis]

Antwort auf Beitrag Nr.: 31.761.497 von Kaltental am 27.09.07 13:06:41

ruf mal bei Dan Furth an, wenn Du gut englisch kannst.
Ich habs schon probiert, bin aber kein native speaker. und hab nur die Hälfte verstanden.



Poste dann hier Deinen Eindruck von HDC.

[cultom4president]

Antwort auf Beitrag Nr.: 31.762.277 von talis am 27.09.07 14:03:31

Servus Talis,

netter kleiner Thread den du dir hier aufgebaut hast. Habe mir jetzt mal dein Unternehmen etwas genauer angeschaut. SVM sagte mir vom Studium her noch etwas!

Wie schaut im Moment der Stand der Dinge aus. HDC notiert ja noch immer in den Pinks und wird dort sicher noch eine Weile bleiben, oder gibt es anders lautende Bestrebungen? Gibt es Fortschritte beim Deal mit Clarient - wann erwartest du Fortschritte bei den Tests? Wie siehst du die weitere finanzielle Absicherung. 300 Mio Aktien bei voller Dilution ist ja doch ein ganz schönes Stück.

cultom

[alysant]

Antwort auf Beitrag Nr.: 31.761.497 von Kaltental am 27.09.07 13:06:41

melde gehorsamst, daß ja, bin aber zurzeit durch Kur und psychotherapeutische Sitzungen etwas abgelenkt.

Gruß

Aly

[alysant]

Antwort auf Beitrag Nr.: 31.502.699 von alysant am 10.09.07 16:00:33

0.105 Vol. 320.000

H/T

0.105
0.095

0.07 scheint sich als ultimativer Boden zu entpuppen und ist zum Nachmischen bestens geeignet.

[talis]

Antwort auf Beitrag Nr.: 31.770.808 von cultom4president am 27.09.07 23:45:45

hallo Cultom,

zum Fortschritt der Tests kann ich nur soviel sagen wie ich weiter vorne in der Zusammenfassung beschrieben habe, was ich wiederum von Raging Bull hab (klingt glaubwürdig). Die Investorenkonferenz von Clarient dazu hab ich mir auch angehört, bin aber kein nativespeaker. Im letzten filing berichtete HDC, dass man Mitte 2008 mit Einnahmen daraus rechnet. Den Gewebetest hat man wohl sicher, aber kaum auszudenken, wenn man es hinbekommt einen Bluttest zu entwickeln. Und wenn nicht HDC hat ja noch einiges mehr zu bieten.

Was das Marktsegment betrifft, seh ich die Sache äusserst gelassen.

Es nützt hier übrigens nichts zu Infozwecken HDC anzumailen. Es empfiehlt sich anzurufen, was ich schon gemacht habe, habe aber nur die Hälfte verstanden. Vielleicht kannst Du es ja mal probieren und Deinen Eindruck schildern. Das würde in diesem thread noch fehlen.

Ich hoffe demnächst genügend Zeit zu haben. Das reale Leben hat mich nämlich gerade nach Köln verschlagen.

gruss
talis

[alysant]

Antwort auf Beitrag Nr.: 31.771.937 von alysant am 28.09.07 09:10:35

0.107 - ein Ausbruch ?

[talis]

Antwort auf Beitrag Nr.: 31.770.808 von cultom4president am 27.09.07 23:45:45

cultom,
zu den Finanzen: laut filing reicht das Geld aus dem PP für ca. ein Jahr. Wenn der Kurs die 0,14 übersteigt kommen die warrants ins Spiel. Wenn die gezogen werden dürfte die Finanzierung kein Thema mehr sein.(Das Alles erst mal ohne mögliche Einnahmen)
Nach demPP waren wir bei 171 Mio Aktien, mit den Warrants über 250 Mio. Vermutlich werden irgendwie die restlichen bis 300 Mio auch noch ausgeschöpft. Allerdings der freefloat liegt nur bei 65 Mio Aktien.

Interessant wäre zu überlegen, was HDC mit den 30 Mio Vorzugsaktien vor hat. Die gibt es nämlich auch noch...!
Ich kann mich erinnern, dass Bill Gates Vorzugsaktien von Apple gekauft hatte!!??
Plant HDC hier etwas von langer Hand?

gruss
talis

[talis]

Health Discovery Corporation's Private Equity Offering Oversubscribed
Thursday October 4, 1:20 pm ET

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation ("HDC") (OTCBB:HDVY - News) today announced that it has raised new equity capital exceeding the upper limit of its previously stated objective of $2.5 million. A number of institutions and individual accredited investors have purchased $2.555 million of the Company's common equity. In addition, $2.163 million in existing secured debt was converted into either common or preferred stock. As a result, HDC's equity base has increased by over $4.7 million.

"The success of this dual financing effort in a time of uncertain capital markets is really quite remarkable for a firm of our size," said Stephen D. Barnhill, M.D., HDC's Chairman and Chief Executive Officer. "I find it particularly gratifying that those who converted their debt gave up a security interest in our key assets in exchange for sharing in the possible growth of our equity. We now have the financial staying power to fully exploit many of our opportunities. During these past few months also, we dealt conclusively with a number of important matters that consumed so much of our time, energy and money, but did nothing to generate revenue. Not only are these issues now behind us, but with the addition of two outstanding business leaders to our Board of Directors, Dr. Richard Caruso and Jimmy Woodward, we are vastly better positioned to achieve our potential."

Daniel R. Furth, HDC's Executive Vice President, also noted: "Over the course of this financing, I think the potent combination of factual information and management's insights created a particularly compelling HDC story for the private placement participants. The success of this entire process reinforced our determination to increase the scope and quality of our communications for all of our shareholders, as well as the media, the investment community, and our prospective customers. And now with a stable financial base, we're far better situated to make good on that pledge."

[talis]

http://biz.yahoo.com/bw/071017/20071017005427.html?.v=1

Press Release Source: Health Discovery Corporation


Health Discovery Corporation Receives Notice of Allowance of U.S. Patent Application Covering Kernel Selection Methods for SVMs and Other Learning Machines
Wednesday October 17, 9:25 am ET
HDC's Portfolio Will Include 30 Issued U.S. and Foreign Patents Covering Uses of SVM and FGM Technology

[talis]

HDC zieht sich gerade zusammen wie eine Springfeder. Nur eine richtige news und hier kommt mächtig Bewegung rein. Bleibt nur zu hoffen, dass die news bald kommt und die Springfeder bis dahin keinen Rost ansetzt. Aber was red ich, ich bin sowieso überzeugt von dieser Aktie. Den Postern auf RB zufolge macht Clarient Fortschritte mit dem Gewebetest auf Prostatakrebs. HDC erwartet bis Jahresmitte 2008 erste Einnahmen aus dem Clarientdeal. Dann sind die Kurse von heute Geschichte.

[eri72]

noch immer auf der watch

[talis]

Antwort auf Beitrag Nr.: 32.264.759 von eri72 am 03.11.07 12:35:19

kannst Du gut englisch? und bist Du bereit für ein Telefonat mit Dan Furth?

[talis]

Der Quartalsbericht ist raus und die Kursentwicklung lässt zu wünschen übrig. Das Potential von HDC ist aber weiterhin immens. Zu Beginn des threads war HDC ein Investment, mit dem man alles verlieren konnte aber auf der anderen Seite auf mehr als nur auf eine Verzehnfachung spekulieren konnte. Zwischenzeitlich hat man den Gewebetest auf Prostatakrebs vermarktet, womit sich das Risiko in Grenzen hält. In anderen message-Boards wird Clarient zitiert, wonach man für das 1. Quartal 2008 damit rechnet, den Gewebetest auf Prostatakrebs fertiggestellt zu haben. Sollte dann der Test eingeführt werden, sollte der Kurs von HDC schnell auf 0,3 $ - 0,4 $ steigen. Damit hätte HDC eine dauerhafte finanzielle Basis, um die anderen Verhandlungen sicher zum Erfolg zu führen.

Das 10Q
http://www.sec.gov/Archives/edgar/data/1141788/0001188112070…

1.)Negotiations with a large European pharmaceutical company to develop a companion diagnostic test using our discovered biomarkers as surrogates in the last phase of a clinical trial for its new drug to treat BPH (enlarged prostate) remain delayed due to the prospect’s internal consolidation issues. Based on the prospect’s representations, we believe that discussions regarding this prospective opportunity will resume sometime in 2008.

2.)We have entered into a research agreement with a leading biotech company to develop an SVM-based diagnostic test to help interpret flow cell cytometry data for a particular medical condition. Our science team’s analysis of provided data demonstrates a successful proof of concept for presentation to our partner in the fourth quarter of 2007. If our partner accepts our conclusions, we hope to obtain similar work on diseases such as leukemia and lymphoma that are far more prevalent.

3.)We have advanced discussions with a large international healthcare company. Our objective is licensing and product development using SVMs in diagnostic radiology, including mammography, PET scans, CT scans, MRI and other radiological images. We own a number of SVM patents in this field that we believe are very important.

4.)We have also initiated dialogue with several other important industry players in the healthcare field, including a proposed project with one of the world’s largest pharmaceutical companies, a marketing arrangement with one of the world’s largest generic drug manufacturers, and other prospective partnership opportunities with additional companies and research institutions.

5.)In addition to traditional license and development agreements, we are expanding our approach to monetizing our intellectual property. In the first quarter of 2007, we formed an equity investment, SVM Capital, LLC, with Atlantic Alpha Strategies, LLC to apply our SVM pattern recognition tools to quantitative investment analysis. We believe that research efforts to date show promise in developing computer-based investment and hedging techniques. The specific goal is to substantially reduce investment risk while providing superior, but not necessarily outsized, returns for comparable asset classes. If SVM Capital can advance the predictive art sufficiently, the ultimate business objective is to create one or more funds that would appeal to conservative and risk-averse investors. We believe that there are many “quant funds” successfully using different mathematics-based techniques, including neural networks, to assist in the investment decision-making process by uncovering patterns that might otherwise be impossible or too time-consuming to discern. To the best of our knowledge, none use SVM-based models. In broad terms, if SVM Capital can replicate in this arena the consistent superiority SVMs have shown, for example, over neural networks in hundreds of medical field studies, it could achieve an advantaged and patent-protected position in quantitative-based investments in equities, debt instruments, currencies and commodities.

Gelänge HDC nur ein weiterer deal mit einer ähnlichen Bedeutung wie der mit Clarient, fände HDC auch mehr Beachtung unter den Investoren und Kurse um die 1 $ wären in Sichtweite.

[talis]

hopp hopp Dr. Barnhill, wo bleibt die news ?????

Wir haben gleich Weihnachten !!!!!

[talis]

http://www.provcogroup.com/index.php?option=com_content&task…

Richard E. Caruso Ph.D.



“By all means, become the Entrepreneur of the Enterprise of Your Own Life by Discovering, Understanding and Releasing the Uncommon Individual that resides within you.”

Richard E. Caruso, Ph.D.
Founder
The Uncommon Individual Foundation

RICHARD E. CARUSO, Ph.D., founded Integra LifeSciences Corporation in 1989. Dr. Caruso currently serves as the company’s Chairman. In August 1995, Integra became a publicly-held company listed on the National NASDAQ Market under the symbol “IART”. Integra Envisioned… And then Created a new branch of medicine now known as Regenerative Medicine where the body is enabled to re-create its own parts.

In 1998, Dr. Caruso recruited Stuart Essig from Goldman Sachs as Integra’s President and Chief Executive Officer. Currently, Integra has annual sales approaching $600,000,000 with approximately 2,000 associates.

In 1978, Dr. Caruso founded The Provco Group (“Provco”), a group or amalgamation of businesses or activities, which organizes and provides funding for a variety of entrepreneurs and complex business activities. In each transaction where Provco participates financially, it also participates in either selecting management or directly in management. Currently, Provco manages $500,000,000 in assets and concentrates in the following areas: manufacturers lease programs, venture financing, real estate, alternate energy, leveraged buyouts, reorganizations, personal property and investment strategies.

From 1969 to 1992, Dr. Caruso was a principal of LFC Financial Corp (LFC), located in Radnor, PA that originated approximately $3,000,000,000 of creative lease and project finance transactions. When he left LFC in 1992, he was a Director and held the position of Executive Vice President. Prior to joining LFC, Dr. Caruso was associated with Price Waterhouse & Co. in Philadelphia, PA where he practiced as a certified public accountant and auditor.

Dr. Caruso is also a founding shareholder of Interactive Investor International (www.iii.co.uk) (1996), once publicly-traded on NASDAQ and the London Stock Exchange (acquired by an Australian insurance group, of Advanced Voting Solutions, Inc. – 1999 (www.advancedvoting.com), a privately-held, touch screen voting company, and of First Sterling Bank which, after a series of mergers with Prime Bank, Summit Bank and Fleet Bank, is now part of Bank of America. Dr. Caruso also founded Tenly Enterprises in 1982, which acquired and operated Rustler Steak Houses before their sale to Sizzlers.

Dr. Caruso has more than 35 years of experience in entrepreneurial and finance type ventures. He has and continues to be actively involved in a variety of domestic and international business activities. He has a broad base of business experience and maintains an active involvement in the academic community in both the United States and Europe.

In 1992, Dartmouth Press published Dr. Caruso’s book entitled “Mentoring in the Business Environment”.

In 2000, Dr. Caruso was the recipient of the New Jersey Entrepreneurial Leadership Award in Biomaterial Science.

In 2006, Dr. Caruso was the award recipient for the prestigious Ernst & Young and Kauffman Foundation sponsored Greater Philadelphia areas Entrepreneur of the Year Award for his work with Integra LifeSciences Corporation and, subsequently, went on to Palm Springs, California to win both the National Award in the Health Sciences category as well as the Overall National Entrepreneur of the Year Award.

Dr. Caruso is also the Founder and Director of The Uncommon Individual Foundation, a non-profit foundation which encourages individuals to form and follow their dreams of personal success and, in effect, become the entrepreneurs of their personal lives (www.uif.org).

Dr. Caruso has served, or is serving, on the Boards of Susquehanna University, The Baum School of Art, the Business Performance Group of the London School of Economics, First Sterling Bank, Advanced Voting Solutions, Inc. and American Capital Mutual Funds, American Revolution Center and the Medici Archive Project. Dr. Caruso is also an advisor to Quaker BioVenture, a venture capital firm dedicated to investing in lifescience technology. He received a B.S. degree from Susquehanna University, M.S.B.A. degree from Bucknell University, and a Ph.D. degree from the London School of Economics, University of London (U.K.). Dr. Caruso resides in Villanova, PA.

[talis]

Antwort auf Beitrag Nr.: 33.103.164 von talis am 19.01.08 01:47:08

also Dr. Caruso, jetzt will ich aber so langsam was sehen.
Integra soll doch nicht der letzte Geniestreich gewesen sein.

[talis]

Antwort auf Beitrag Nr.: 33.104.642 von talis am 19.01.08 14:29:10

ein guter Wein braucht Zeit zum Reifen

[talis]

Antwort auf Beitrag Nr.: 33.408.777 von talis am 19.02.08 10:55:37

Menschen mit einer neuen Idee gelten so lange als Spinner, bis sich die Sache durchgesetzt hat.

Mark Twain

[talis]

Wer bei Raging Bull mitliest weiss, die Einführung des Prostatakrebstests steht kurz bevor. Man wartet auf die letzten Resultate, die jeden Tag eintreffen können. Innerhalb eines Monats kann dann der Test angeboten werden. Man kann bei dem Test auf sofortige Akzeptanz hoffen. Die vollständige Marktdurchdringung ist dann die nächste Schlacht, die geschlagen werden muss. Für eine Firma wie HDC wäre das ein enormer Schritt nach vorne.
Man kann warten bis die news über die Markteinführung des Krebstests tatsächlich veröffentlicht wird, dann aber unbedingt kaufen und drin bleiben.

HDC ist desweiteren in Verhandlungen mit sehr einflussreichen Entscheidungsträgern, woraus irgendwann weitere Lizenzeinnahmen resultieren können.

[alysant]

Hier brauchst eben Geduld, bis es anspringt. Eine positives Resultat und wir sehen eine Vervielfachung.

Laß Dich als quasi Alleinposter nicht beirren. Ich kenne das selber. Das hat auch den Vorteil des Wegfalls lästiger und fruchtloser Diskussionen.

by the way:

Müßte da nicht täglich wieder ein Quartalsergebnis kommen ? Wird zwar keine Überraschungen bringen, aber bleibt trotzdem eine aktuelle Information.

[talis]

Antwort auf Beitrag Nr.: 33.596.540 von alysant am 10.03.08 13:02:50

Ende März dürfte der Jahrebericht erscheinen, shareholderletter im Anschluss usw.

was mir zu fruchtlosen Diskussionen einfällt....!


Gesegnet seien jene, die nichts zu sagen haben und den Mund halten.
Oscar Wilde

[alysant]

Antwort auf Beitrag Nr.: 33.596.620 von talis am 10.03.08 13:12:13

oder

Wenn alle das Sagen haben, sagen am Schluß diejenigen nichts mehr, die was zu sagen hätten !

[alysant]

Ich empfehle das Studium des 6-Jahres-Charts und die finanzwirtschaftlichen Daten, z.B. bei yahoo.com.

Also, ich bekomme dabei ein beruhigendes Gefühl :

seriös in jeder Beziehung, vor allem wenn ich an den überwiegenden Schrott im Penny-Stock-Bereich denke, und umfassende, transparente Information der Aktionäre

P.S.:

talis, stell den Chart doch mal rein, ich bin hier - auch technisch - eine Niete

[talis]

Antwort auf Beitrag Nr.: 33.641.220 von alysant am 14.03.08 13:33:47

ich glaube wir brauchen Verstärkung!

gelernter Chartreinsteller bin ich eben auch nicht

[alysant]

Antwort auf Beitrag Nr.: 33.641.299 von talis am 14.03.08 13:38:05

wo bleiben die Graficker ?

[talis]

Antwort auf Beitrag Nr.: 33.641.559 von alysant am 14.03.08 13:57:14

test

[talis]

Antwort auf Beitrag Nr.: 33.641.945 von talis am 14.03.08 14:27:58

na also, was man mit einem Crashkurs alles erreichen kann

[talis]

Antwort auf Beitrag Nr.: 33.641.967 von talis am 14.03.08 14:29:15

den Chart schaun wir uns besser wie bisher bei

investorshub an

[alysant]

Antwort auf Beitrag Nr.: 33.642.163 von talis am 14.03.08 14:41:37

Ich gebe die Hoffnung nicht auf, daß sich noch ein Freiwilliger übers Wochenende findet.

Andernfalls zwinge ich einen meiner Freunde dazu.
==================


0.05 (Geld) vol. 27.000

[alysant]

3.000

[talis]

Antwort auf Beitrag Nr.: 33.649.490 von alysant am 15.03.08 11:09:57

am Wochenende war der thread gut frequentiert.

die Story lässt sich auf Dauer nicht verheimlichen

[alysant]

Antwort auf Beitrag Nr.: 33.661.433 von talis am 17.03.08 15:10:49

und ich habe nicht gedrückt !

(Versicherung an Eides Statt)

[cyba]

[talis]

HDC hat fast 2 Mio $ in der Kasse,
macht 0 Promotion
Phantasie wird vom Markt mit 0 bewertet
HDC hat 0 Schulden
Lizenzvertrag mit Clarient wird mit 0 bewertet

[alysant]

Antwort auf Beitrag Nr.: 33.662.260 von talis am 17.03.08 16:05:41

per 30.9.2007:

4.6 Mio. Eigenkapital bei 5.6 Mio. Bilanzsumme

=====================

Details bei yahoo.com / finance / HDVY

Bilanzmaterial und message board

=====================


per 31.12.2007 ist das EK natürlich niedriger w/ Forschungsaufwendungen

nicht auszudenken, wenn mal der Knoten platzt und Umsätze erzielt werden.

[talis]

http://www.forbes.com/2008/03/17/safeguard-scientific-clarie…

Clarient mit Schlagseite

[talis]

Antwort auf Beitrag Nr.: 33.669.132 von talis am 18.03.08 10:27:39

http://biz.yahoo.com/e/080321/clrt8-k.html

Clarient war kurz in der Krise. Nach einer sofortigen Cash Infusion von Safeguard aber wieder voll auf der Höhe.
Kein Wunder bei der Pipeline.

[talis]

Der Jahresbericht ist raus und es gibt Ermutigendes wie die ersten royalties von Bruker.
Das Potential ist weiterhin enorm.
Es geht aber um Einnahmen und so wartet man immer noch auf die Einführung des Prostatakrebstests, damit HDC endlich abhebt.

[talis]

Antwort auf Beitrag Nr.: 33.796.750 von talis am 03.04.08 11:00:37

einfach mal ein paar nackte Zahlen aus dem Jahresbericht

Year Ended December 31, 2007 Compared with Year Ended December 31, 2006

Revenue

For the year ended December 31, 2007, revenue was $57,905 compared with $203,889 in revenue for the year ended December 31, 2006. Revenue is recognized for licensing and development fees over the period earned. The decrease of revenue in 2007 was due largely to the fact that the contracts finalized in 2007 required recognition of the revenue generated be deferred and recognized over the contractual period rather than immediately recorded. As of December 31, 2007, the Company had deferred revenue of $516,424. This deferred revenue includes $291,424 of cash received but not yet recognized as revenue and $225,000 in accounts receivable. Deferred revenue was $101,111 at December 31, 2006.

immerhin hat man schon Einnahmen. Die fliessen einfach nur nicht gleich in die Bilanz.
Denkbar auch, dass die Ursache für die Einnahmen das Verheissungsvolle ist und nicht etwa der Prostatakrebstest

[talis]

nochwas aus dem Jahresbericht

In January 2007, SVM Capital, LLC was formed as a joint venture between HDC and Atlantic Alpha Strategies, LLC (“Atlantic Alpha”) to explore and exploit the potential applicability of our SVM technology to quantitative investment management techniques. Atlantic Alpha has over thirty years of experience in commodity and futures trading. SVM Capital has made significant progress since the formation of the joint venture. The SVM technology is now working well with dynamic time series for S&P data accumulated over the past fifty-eight years. The latest SVM-derived models generated by SVM Capital have successfully outperformed the static buy-and-hold model both in increased returns as well as in reduced risk. Once the stability of these models is confirmed, SVM Capital intends to apply the models to a wide range of financial asset classes such as interest rates, currencies, metals and petroleum products. The joint venture partners plan to apply the investment model either in a single fund or a fund of funds. SVM Capital will charge a management fee and a performance fee for managing client assets. Depending on the level of its success, this venture can be profitable given its reliance on cost effective use of computer technology and ready access to efficient trading platforms.

HDC braucht jetzt nur noch sein Investmentmodell auf den Kursverlauf auf HDC selbst anwenden und im nächsten Quartalsbericht veröffentlichen

[talis]

Antwort auf Beitrag Nr.: 33.844.714 von talis am 09.04.08 12:33:36

ähem... ich meinte natürlich das Ergebnis im nächsten Quartalsbericht veröffentlichen

quasi sowas wie eine Kristallkugel, der Wunschtraum eines jeden Börsianers.

[talis]

Antwort auf Beitrag Nr.: 33.846.729 von talis am 09.04.08 15:50:57

Im Jahresbericht kann man lesen

...the Company believes that it has sufficient capability to operate through the next twelve months.

Vielleicht kann hier der werte stille Mitleser mal einen Blick in den Jahresbericht werfen und eine Einschätzung abgeben, welche 12 Monate hiermit gemeint sind.

Vom 1.1.2008 bis 31.12. 2008 ?
Oder vom 1.4. 2008 bis 1.4.2009 ?

Im Falle von Verzögerungen bei den Entwicklungen könnte das entscheidend werden.

[alysant]

werde ich mal tun, aber intellektuell gibt das nur Sinn für 12 Monate ab Berichts-Veröffentlichung; so ist es vermutlich auch zu verstehen - Sicherheitsfaktor nach Jauch 90 %.

[talis]

Antwort auf Beitrag Nr.: 33.874.663 von alysant am 13.04.08 13:13:53

nun ich kenne jemand, den ich intelektuell für voll auf der Höhe halte.

Der hat sich aber für Jauchs 10%-Alternative entschieden

[alysant]

Antwort auf Beitrag Nr.: 33.874.797 von talis am 13.04.08 13:54:59

langer Rede kurzer Sinn:

Ich habe soeben der Company gemailt und gehe von einer Antwort bis Dienstag, 15.4., aus, die ich unverzüglich kundtun werde.

[alysant]

Antwort auf Beitrag Nr.: 33.874.971 von alysant am 13.04.08 15:01:33

Dan Furth - EVP hat schon geantwortet:

Formell beziehen sich die 12 Monate auf den Prüfungszeitraum 1.1. - 31.12.2008.

Er hat gleichzeitig bestätigt, daß die "Kohle" auch für die Periode 1.4.2008 - 31.3.2009 reicht.

weitere Anfragen sind willkommen:

"[e-mail]"

[talis]

auf RB ist jemand fündig geworden

http://www.epigenomics.com/en/Press_Releases/2008/datednews/…

man erinnere sich, es gibt eine Kooperationsvereinbarung zwischen

Epigenomics und HDC

[talis]

Antwort auf Beitrag Nr.: 33.886.048 von talis am 15.04.08 10:23:38

By: freefritz
15 Apr 2008, 04:58 AM EDT
Msg. 11374 of 11374
(This msg. is a reply to 11373 by RagingBullets.)
Jump to msg. #
This is good news and bad news

For me it looks as if Epigenomics develops a prostate cancer test based on the technology HDC has licensed to Epigenomics, we remember there is a cooperation from Sept 19, 2006.
Ironically this competes with the other biomarker discovery for diagnosis of prostate cancer, HDC has licensed to Clarient.

[talis]

Management believes that our research agreement with a leading biotech company to develop an SVM-based diagnostic test to help interpret flow cell cytometry data for a particular medical condition has resulted in a successful proof of concept. These findings were presented during the first quarter of 2008 and the due diligence process has accelerated to confirm our findings for that particular condition and determine other applications within flow cytometry.

Ich werd das Gefühl nicht los, der obige Ausschnitt aus dem Jahresreport, könnte für HDC sehr schnell zu Einnahmen führen.

[talis]

http://www.epigenomics.com/en/Press_Releases/2008/datednews/…

Epigenomics AG Successfully Validates Optimized Blood-Based Colorectal Cancer Assay in two Independent Clinical Studies
Date: Monday, 21.04.2008

Performance of Septin 9 assay optimized for clinical routine application confirmed as equivalent to earlier research assay – Blood test successfully run in more than 500 additional patient samples




Es gibt eine Lizenzvereinbarung zwischen Epigenomics und HDC.
Ich hoffe, HDCs Technologie ist hier beteiligt. Alles andere würde mich auch wundern. Ich bin gespannt, wann Epigenomics die ersten royalties zahlt

[talis]

83 $ haben heute Health Discovery um 10% steigen lassen.

Soll Herr Hopp doch mal in HDC investieren!

Sonst zieht er doch auch immer wie mit der Giesskanne durchs Land und kauft den gesamten deutschen Biotechschrott auf. Etwas weniger Lokalpatriotismus dafür mehr Weitsicht bei seinen Investments rate ich ihm. Dafür drück ich auch dem TSG Hoffenheim die Daumen, dass es noch was wird mit dem Durchmarsch in die 1. Liga

[talis]

On March 4, 2008, we formed two wholly owned subsidiaries, SVM Technology Inc., a Georgia corporation, and SVM Technology Inc., a Delaware corporation. We anticipate that we will use each of these subsidiaries to expand our business model by applying SVM technology outside of scientific discovery in the healthcare arena.

Zwei Unternehmen hat HDC gegründet. Vermutlich orientiert man sich mit dem Einen Richtung homelandsecurity und mit dem Anderen Richtung Softwarebranche.
Da in vielen Programmen patentgeschützte HDC-Technologie eingebaut ist, ohne dass deren Entwickler etwas davon ahnen, könnte man sich vorstellen, dass HDC das neugegründtete Unternehmen dazu benutzt, um irgendwann in ferner Zukunft gegen die grossen Softwarekonzerne vorzugehen. Zuerst muss aber über die biotechnologische Seite von HDC eine gesunde finanzielle Basis geschaffen werden.

[talis]

Biomarker sind im Kommen!


New Thomson Reuters Biomarkers Report Shines a Light on Revolutionary New Area of Drug Development
Tuesday April 29, 12:40 pm ET
- Biomarkers to Open the Door to Personalized Medicine and Represents a
Seismic Shift for the Pharma Industry


PHILADELPHIA and LONDON, April 29 /PRNewswire/ -- The Scientific business of Thomson Reuters today announced the launch of a new biomarkers report, "Establishing the Standards in Biomarker Research" which gives a detailed introduction to the world of biomarkers, an overview of the regulatory context surrounding them, and highlights ongoing biomarker research in some of the world's leading Pharma companies.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080424/NYTH069LOGO )

Thomson Reuters has chosen to highlight advances in biomarker research because of its capacity to change the way Pharma companies do business. Biomarkers which are blood-based tests, gene sequences or mutations, mRNA expression profiles or tissue proteins, provide unparalleled evidence of the state of an organism, or indicate normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention.

"Biomarkers seem destined to prove one of the major drivers of pharmaceutical research and drug development in the 21st century," said Jon Brett-Harris, EVP Pharmaceutical and Chemicals Markets, Thomson Reuters. "For example, the presence of a specific antibody in the blood might indicate a specific infection. Once an association between a biomarker and a disease is clearly established, the one can be used to signal the other, and to a high degree of certainty. As well, changes in the prevalence of a biomarker in the organism can immediately and reliably signpost a patient's response to treatment."

Some pharmaceutical companies are already advancing their research and harnessing the power of biomarkers, which can:



-- Be used to detect the predisposition for disease in a population,
screen for its presence, confirm its diagnosis, assess its severity,
predict its response to available therapies and measure its
clinical course
-- Be used as targets to discover new drugs
-- Be a decisive factor in determining whether or not to continue
research on an entity
-- Show early in the development phase whether an entity could lead to
side effects that should terminate further research
-- Help to make clinical trials more efficient
-- Reduce treatment overheads by optimizing dosages and measuring a
patient's response more quickly and accurately

It is believed that every drug process may have a number of biomarkers associated with it. Most scientists already use a core set of biomarkers, but this is insignificant when compared to the thousands of biomarkers that may exist and have yet to be discovered, documented or quantified. The new Thomson Reuters biomarker report suggests that the disease areas at the forefront of the drive to discover new biomarkers are: cancer, cardiology, neurology, and metabolic, autoimmune and inflammatory diseases.

However, although biomarkers represent the future of drug development, Thomson Reuters analysis has found broad differences in the Pharma industry's approach to them. Some innovators have important biomarker research projects progressing, while many others have yet to attempt any research at all.

In spite of this, biomarkers are clearly at the top of the agenda for regulatory authorities. The FDA has recognized that biomarkers are an area of supreme importance to pharmaceutical innovation and personalized medicine and is seeking to create a new framework for regulatory acceptance. Other agencies, including the EMEA, are engaging with same process. In Japan, the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Health, Labor and Welfare, have proposed biomarker development as a national project, and are actively promoting biomarker research.

To read the full report, "Establishing the Standards in Biomarker Research", please register online at: http://scientific.thomson.com/forms/biomarkers/" target="_blank" rel="nofollow ugc noopener">http://scientific.thomson.com/forms/biomarkers/

The Scientific business of Thomson Reuters provides information and knowledge to accelerate research, discovery and innovation. Its authoritative, accurate and timely information is essential for drug companies to discover new drugs and get them to market faster; researchers to find relevant papers and know what's newly published in their subject; and businesses to optimize their intellectual property and find competitive intelligence. We create the research platforms and services of the future that will power our customers toward business and personal success.

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. Thomson Reuters shares are listed on the New York Stock Exchange (NYSE: TRI - News); Toronto Stock Exchange (TSX: TRI - News); London Stock Exchange (LSE: TRIL - News); and Nasdaq (NASDAQ: TRIN - News). For more information, go to www.thomsonreuters.com.



CONTACTS
Eoin Bedford
PR Manager
Scientific
[phone]
[e-mail]

Web site: http://www.thomsonreuters.com
http://scientific.thomson.com/forms/biomarkers

[talis]

Health Discovery Corporation Announces Successful Clinical Trial Results for New Molecular Diagnostic Test for Prostate Cancer
Wednesday April 30, 4:16 pm ET
New Prostate Cancer Test Demonstrates Very High Accuracy Rate for Detecting Prostate Cancer

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (“HDC”) (OTCBB: HDVY - News) today announced the successful clinical trial results for HDC’s new molecular diagnostic test for prostate cancer licensed exclusively to Clarient (Nasdaq:CLRT - News), in which HDC will receive a 30 percent royalty based on reimbursements received by Clarient from third parties.

ADVERTISEMENT
The initial clinical validation study recently completed at Clarient from prostate tissues obtained in collaboration with MD Anderson Cancer Center demonstrated a very high success rate for identifying the presence of Grade 3 or higher prostate cancer cells (clinically significant cancer) in prostate cancer tissue. The new molecular diagnostic test achieved a Sensitivity of 100% meaning that the test correctly identified genomic evidence of prostate cancer cells in every tissue specimen known to be positive for prostate cancer. The test also demonstrated a very high success rate for correctly identifying those prostate specimens that did not have prostate cancer as being negative for prostate cancer and achieved a Specificity of 80% for identifying the non-cancer tissues, which included normal and benign prostatic hypertrophy (BPH) tissue, as not having genomic evidence of cancer.

In the United States alone there are over 1 million prostate cancer tissue biopsy procedures performed annually. Approximately 25% of these tissue biopsies are reported “positive” indicating the presence of prostate cancer. The other 75% of prostate cancer tissue biopsies are reported as “negative” for the presence of cancer. However, one-third of the men with prostate cancer tissue biopsies that are reported as “negative” for prostate cancer (roughly 25%) actually do have prostate cancer that was missed by the first biopsy (False Negative). These men actually have prostate cancer that was missed by the initial tissue biopsy for a variety of reasons. Health Discovery Corporation’s prostate cancer molecular diagnostic test is a genomics based test discovered using HDC’s patented SVM and SVM-RFE pattern recognition technology. This prostate cancer test is based on a unique combination of 4 genes that accurately identify the presence of Grade 3 or higher (clinically significant cancer) prostate cancer cells in prostate tissue.

HDC and Clarient will now move to phase two of the clinical trial process to increase the number of specimens tested in order to achieve the statistical significance necessary to validate these very successful initial results. Once the next phase of clinical testing is completed, The Companies will begin the commercialization process. Assuming the data continues to support these initial findings, it is possible that the product could be made available for clinical use by late Q3 of 2008 under the current CLIA regulations.

“We are thrilled with the results of this clinical trial and look forward to the commercial launch of this new prostate cancer test with Clarient,” stated Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “The success of this clinical trial also demonstrates that HDC, using our patented SVM and SVM-RFE technology, can develop new molecular diagnostic tests from conception of the idea through clinical discovery and validation of unique genomic signatures that can be commercialized as new molecular diagnostic tests. Our patent protected discovery method allows to us to develop molecular diagnostic tests that are free of outside intellectual property rights and thereby allows HDC to fully patent protect our discovery. We are currently duplicating this process to develop new molecular diagnostic tests in a variety of other cancers.”

Dr. Barnhill continued “We are looking forward to having HDC’s new prostate cancer test commercialized like similar molecular diagnostic tests based on unique gene expression profiles such as OncotypeDX from Genomic Health, Inc. (NasdaqGM:GHDX - News) and MammaPrint from Agendia.”

“The results of this clinical trial demonstrating genomic evidence of the presence of prostate cancer in prostate cancer tissue with 100% accuracy is a remarkable accomplishment,” stated Dr. Herbert Fritsche, Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas. “Health Discovery Corporation’s ability to develop state-of-the-art molecular diagnostic tests for cancer combined with Clarient’s ability to successfully commercialize these tests can provide a significant benefit to cancer patients and their physicians.”

Savannah-based Health Discovery Corporation (OTCBB: HDVY - News) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery(sm). The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct.


Contact:

Health Discovery Corporation
Daniel R. Furth, 912-443-1987
[e-mail]
www.healthdiscoverycorp.com

Source: Health Discovery Corporation

[alysant]

Antwort auf Beitrag Nr.: 34.008.177 von talis am 01.05.08 10:09:50

0.071 (plus 42 %) Vol. 1.4 Mio.

H/T

0.080
0.055


Hier fängt die show erst an !

[alysant]

0.066 vol. 2.8 Mio.

H/T

0.080
0.055

[sandrines]

Antwort auf Beitrag Nr.: 34.008.177 von talis am 01.05.08 10:09:50

Na ja, so wirklich viel hat´s leider nicht gebracht, obwohl sich die Meldung ganz ordentlich anhört. Hat sich aber gestern schon abgezeichnet, da haben zu viele entnervte abgeladen. Hier benötigt man, ähnlich wie bei Biph, den Faktor Geduld.

[alysant]

Das ist das Zauberwort:

G e d u l d

[talis]

Antwort auf Beitrag Nr.: 34.017.153 von sandrines am 02.05.08 16:33:44

man schaut zur Zeit streng auf die Einnahmen.
Aussichten werden an der Börse nicht mehr bezahlt, hab ich den Eindruck.

Wenn´s dann mal wirklich in der Kasse klingelt dürfte es nach oben gehen. Aber vermutlich werden die Investoren das erst glauben, wenn sie´s schwarz auf weiss im Quartalsbericht nachlesen können.

Schützenhilfe durch den Einstieg eines publikumswirksamen Investors könnte auch was bringen aber der Herr Hopp ist zur Zeit eher mit dem TSG Hoffenheim beschäftigt.

[sandrines]

Antwort auf Beitrag Nr.: 34.017.280 von talis am 02.05.08 16:46:23

TSG Hoffenheim kenn ich, aber wer ist Herr Hopp ??

[talis]

Antwort auf Beitrag Nr.: 34.017.353 von sandrines am 02.05.08 16:52:57

ich hätte erwartet, dass Du die Frage anders herum stellst.

Herr Hopp, vermögend geworden durch die Gründung eines Unternehmens namens SAP, tritt jetzt auf als der grösste Biotechinvestor Dtlands. Ausserdem sponsort er den Dorfclub TSG Hoffenheim in die 1. Liga.

[sandrines]

Lief vor 10 Minuten über meinen Ticker :



*vwd/BUSINESS WIRE: Health Discovery Corporation gibt die Ergebnisse der erfolgreich verlaufenen klinischen Studie für einen neuen molekularen Diagnosetest für
Prostatakrebs bekannt


MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN
DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
------------------------------------------------------------------------

SAVANNAH, Georgia, USA --(BUSINESS WIRE)--02.05.2008--

Neuer Test für Prostatakrebs zeigt eine extreme hohe Genauigkeit bei der
Erkennung von Prostatakrebs auf

Health Discovery Corporation ("HDC") (OTCBB: HDVY) gab heute die Ergebnisse der
erfolgreich verlaufenen klinischen Studie für HDCs neuen molekularen
Diagnosetest für Prostatakrebs an, der ausschliesslich an Clarient
(Nasdaq:CLRT) lizenziert wird und von dem HDC Lizenzgebühren in Höhe von 30%
der an Clarient von Dritten gezahlten Vergütungen erhält.

Die anfängliche, vor kurzem bei Clarient abgeschlossene klinische
Validierungsstudie, die mit in Zusammenarbeit mit dem MD Anderson Cancer Center
bezogenem Prostatagewebe durchgeführt wurde, zeigte eine sehr hohe Erfolgsrate
in der Erkennung von Prostatakrebszellen der Stufe 3 oder höher (klinisch
signifikanter Krebs) in Prostatakrebsgewebe. Der neue molekulare Diagnosetest
erzielte eine Sensitivität von 100%, was bedeutet, dass der Test die
genetische Evidenz von Prostatakrebszellen in jeglichen Gewebeproben, die
bekanntermassen positiv für Prostatakrebs testen, anzeigt. Der Test zeigte auch
eine extrem hohe Genauigkeit bei der Identifizierung von Prostatagewebeproben,
die keinen Prostatakrebs haben, bei denen der korrekterweise Test negativ ist.
Bei nicht-krebshaltigem Gewebe, einschliesslich normalem und gutartigem
Prostatahypertrophie-Gewebe (BPH), zeigte der Test bei der Erkennung, dass
dieses Gewebe keine genetisch evidenten Krebszellen enhält, eine Sensitivität
von 80%.

Alleine in den Vereinigten Staaten werden jährlich mehr als eine Million
Prostatakrebs-Gewebebiopsien durchgeführt. Etwa 25% dieser Gewebebiopsien sind
"positiv" und zeigen somit die Anwesenheit von Prostatakrebs an. Die restlichen
75% dieser Prostatakrebs-Gewebebiopsien sind "negativ". Ein Drittel der Männer
mit Prostatakrebs-Gewebebiopsien mit einem "negativen" Resultat (etwa 25%)
haben jedoch trotzdem Prostatakrebs, der in der ersten Biopsie nicht erkannt
wurde (falsch-negativ). Diese Männer haben Prostatakrebs, der in der
eingänglichen Biopsie aus unterschiedlichen Gründen nicht erkannt wurde. Der
molekulare Diagnosetest für Prostatakrebs von Health Discovery Corporation ist
ein Test auf Genom-Basis, der mit Hilfe von HDCs patentierter SVM und SVM-RFE
Mustererkennungs-Technologie entdeckt wurde. Dieser Test für Prostatakrebs baut
auf eine einzigartige Kombination von 4 Genen auf, die die Anwesenheit von
Prostatakrebszellen der Stufe 3 oder höher (klinisch signifikanter Krebs) in
Prostatagewebe exakt anzeigen.

HDC und Clarient werden nun die zweite Phase der klinischen Studien beginnen,
um die Anzahl der getesteten Gewebeproben zu erhöhen, um die zur Bestätigung
notwendige statistische Signifikanz dieser außerordentlich erfolgreichen
anfänglichen Ergebnisse zu erreichen. Nachdem die nächste Phase der klinischen
Tests abgeschlossen sein wird, werden die beiden Unternehmen mit der
Vermarktung beginnen. In der Annahme, dass die Daten diese anfänglichen Befunde
bestätigen werden, ist es möglich, dass das Produkt gegen Ende des dritten
Quartals 2008 entsprechend aktueller CLIA-Bestimmungen bereits zum
medizinischen Gebrauch zur Verfügung steht.

"Wir sind von den Ergebnissen dieser klinischen Studie begeistert und freuen
uns auf den kommerziellen Start dieses neuen Tests für Prostatakrebs mit
Clarient", sagte Dr. Stephen D. Barnhill, Chairman und CEO bei Health Discovery
Corporation. "Der Erfolg dieser klinischen Studie zeigt auch, dass HDC neue
molekulare Diagnosetests mit Hilfe unserer patentierten SVM- und
SVM-RFE-Technologie von der Idee bis zur klinischen Feststellung und
Bestätigung des einzigartigen genetischen Fingerabdrucks entwickeln kann, die
dann auch als neue molekulare Diagnosetests vermarktet werden können. Unsere
patentgeschützte Entdeckungsmethode gibt uns auch die Möglichkeit, molekulare
Diagnosetests zu entwickeln, die keinen Patenten dritter Parteien unterliegen
und die daher von HDC alleine patentiert werden können, um die Entdeckung zu
schützen. Momentan kopieren wir diesen Vorgang, um neue molekulare
Diagnosetests für eine Reihe anderer Krebsarten zu entwickeln."

Dr. Barnhill gab weiterhin an, dass "wir uns auf die Vermarktung von HDCs neuen
Test für Prostatakrebs, der, wie ähnliche andere molekulare Diagnosetests auch,
auf einzigartige genetische Expressionsmuster wie z.B. OncotypeDX von Genomic
Health Inc. (NasdaqGM:GHDX) und MammaPrint von Agendia aufbaut, freuen".

"Die Resultate dieser klinischen Studie zeigen eine genetische Evidenz von
Prostatakrebs in Prostatakrebsgewebe mit einer Genauigkeit von 100% an - das
ist eine außergewöhnliche Errungenschaft", sagte Dr. Herbert Fritsche,
Professor für Labormedizin und Leiter der Abteilung für Medizinchemie der
Universität Texas, MD Anderson Cancer Center in Houston, Texas. "Die Fähigkeit
von Health Discovery Corporation, modernste molekulare Diagnosetests für Krebs
zu entwickeln, gemeinsam mit Clarients Fähigkeit diese Tests erfolgreich zu
vermarkten, bietet Krebspatienten und deren behandelnden Ärzte einen
unwahrscheinlich bedeutsamen Vorteil."

Health Discovery Corporation (OTCBB: HDVY), mit Hauptsitz in Savannah, Georgia,
USA, hält im Bereich der Mustererkennungstechnologie eine einzigartige Position
inne. Durch die Anwendung dieser patentierten Technologie ist HDC ein
Unternehmen, das sich auf die Entdeckung von Biomarkern im biologischen Bereich
spezialisiert, die alle Aspekte der First-Phase Biomarker Discovery(sm) bieten.
Die SVM- und FGM-Mustererkennungstechnologien des Unternehmens haben ein
außerordentliches Anwendungspotential in anderen großen kommerziellen Märkten,
wie z.B. Radiologie, Finanzwesen, Internetsuche und Spam-Erkennung, innere
Sicherheit sowie andere Gebiete in denen die Analyse von großen Mengen
vielschichtiger Daten notwendig ist.

Diese Pressemitteilung enthält "zukunftsweisende Aussagen" im Sinne des
Abschnitts 27a des US-amerikanischen Wertpapiergesetzes (Securities Act of
1933) und Abschnitts 21E des US-amerikanischen Börsengesetzes (Securities
Exchange Act of 1934). Obwohl das Team der Geschäftsführung von HDC der Meinung
ist, das die in diesen zukunftsweisenden Aussagen ausgedrückten Erwartungen
begründet sind, können keine Zusicherungen hinsichtlich des Eintreffens solcher
Erwartungen gegeben werden.

Die Ausgangssprache, in der derOriginaltext veröffentlicht wird, ist die
offizielle und autorisierte Version. Übersetzungen werdenzur besseren
Verständigungmitgeliefert. Nur die Sprachversion, die im Original
veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen
mitder originalen Sprachversion der Veröffentlichung ab.

Kontakt:
Health Discovery Corporation
Daniel R. Furth, [phone]
[e-mail]
www.healthdiscoverycorp.com

[talis]

Antwort auf Beitrag Nr.: 34.017.774 von sandrines am 02.05.08 17:35:17

um eines festzustellen:

es handelt sich hier um einen Gewebetest.
Der eigentliche Knüller wird es, wenn es gelingt einen Bluttest daraus zu entwickeln

[sandrines]

Antwort auf Beitrag Nr.: 34.017.830 von talis am 02.05.08 17:40:46

Schon traurig, wenn man sich in Anbetracht der Fakten den Kursverlauf ansieht......

[alysant]

Your patience will finally be rewarded, very very (übe Englisch)

0.06 vol. 123.000

H/T

0.075
0.055


Wenns mal läuft, gibts Vervielfachungen.

[talis]

Antwort auf Beitrag Nr.: 34.017.996 von sandrines am 02.05.08 17:59:40

...nochmal die Pressemitteilung durchlesen...

wir haben 100% Sensitivität und 80% Spezifität
selbst wenn in der jetzt anstehenden klinischen Versuchsphase die Daten etwas schlechter werden (besser als 100% geht nicht) ist der Test auf jeden Fall immer noch vermarktungsfähig

...kaufen soviel, wie man kann...

[alysant]

Die Börse macht auch lfd. immer wieder Angebote:

0.055 Vol. 60.000

H/T

0.070
0.055

Man kann sich unschwer vorstellen, wie das Ding explodiert, wenn Kaufneigung aufkommt. Dazu wäre nur die Empfehlung eines Brokers erforderlich.

[talis]

http://biz.yahoo.com/bw/080506/20080506005671.html?.v=1


Press Release Source: Health Discovery Corporation and DCL Medical Laboratories LLC

Health Discovery Corporation and DCL Medical Laboratories to Develop a Computer Assisted Diagnostic Test for Cervical Cancer
Tuesday May 6, 9:15 am ET
Discovery Efforts to Develop a New Computer Assisted Imaging System to Improve the Sensitivity of Detecting Cervical Cancer

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (OTCBB: HDVY - News), a leader in support vector machine (SVM) based molecular diagnostics development, and DCL Medical Laboratories LLC, Indianapolis, IN, a full-service clinical reference laboratory focused on women’s health, today announced the signing of a Letter of Intent for the companies to jointly develop an SVM-based computer assisted diagnostic (CAD) test for the analysis of cervical cells. Cervical cancer is one of the most common cancers among women throughout the world with more than 11,000 primary diagnoses and over 3,700 cancer related deaths annually. While testing for human papilloma virus, the causative agent of cervical cancer, and the recent availability of the HPV vaccine have both contributed to increased awareness of the disease, screening for cervical cancer by the Pap test remains the principle mechanism for detection of the disease. Through the application of the advancing technology of pattern recognition, this new SVM-based system is intended to further improve the sensitivity of the Pap test and augment the recent improvements in computer guided screening that have already significantly improved detection rates. In addition, images and interpretative data from this new SVM-based system may now be transmitted electronically, thus allowing remote review and collaborative interpretation. Effective screening is vital to preventing cancer. Early detection using advanced screening technologies provides the best chance for effective, minimally invasive treatment before abnormal cell changes progress to advanced cancer.

“We are very excited to be working with DCL’s state-of-the-art clinical laboratory and their expert cytopathologists in the development of what could be the world’s first SVM-based computer assisted diagnostic (CAD) system available to improve the sensitivity of screening for cervical cancer,” said Stephen D. Barnhill, MD, Chairman and CEO of Health Discovery Corporation. “Using our patent protected SVM technology, we believe that our new screening system will further enhance current Pap systems in the detection of cellular abnormality. In addition, we believe that using currently available image capturing technology, our SVM-based image analysis could be made available for screening to physicians in clinical laboratory and hospital settings around the world via transmission and evaluation over the Internet.”

“DCL is pleased to partner with Health Discovery Corporation in the development of novel computer based imaging systems to improve the sensitivity for the detection of cervical cancer,” said Dr. Michael Hanbury, President and Chief Executive Officer of DCL. “This development opportunity extends DCL’s commitment to offering leading cytology services and education programs and further demonstrates DCL’s focus as a leading clinical laboratory specializing in women’s health. DCL provides an excellent development partner by leveraging DCL’s collective experience in cytopathology, clinical trials and product development, combined with an exceptional specimen library to facilitate the commercialization process. Partnering with HDC creates an opportunity for DCL to expand its participation in novel advancements in women’s health diagnostics. We believe this expanded relationship will substantially strengthen the position of both companies and deliver significant commercial results for DCL and Health Discovery Corporation.”

Financial terms of this Development Contract were not released.

About Health Discovery Corporation

Savannah-based Health Discovery Corporation (OTCBB: HDVY - News) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a leader in SVM-based molecular diagnostics development in genomics and proteomics, as well as, image analysis. The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.

About DCL Medical Laboratories LLC

DCL Medical Laboratories is a full-service regional reference laboratory offering a broad menu of tests and services including specialty testing capabilities in molecular diagnostics. DCL also provides anatomic and molecular pathology services in global clinical trials for both pharmaceutical and medical device companies in partnership with the world’s largest central laboratories and clinical research organizations. Following its recapitalization in late 2007, DCL has significantly expanded its testing capabilities and provides a unique collaborative development opportunity to expedite the development process for emerging diagnostic technologies. DCL is committed to being a preferred medical laboratory partner providing nationally recognized diagnostic services in women’s health. From its founding, DCL has maintained a personal approach to delivering innovative and consultative pathology services that empower clients and improve lives. DCL is a private company with principal equity holdings by Thompson Street Capital Partners in St. Louis.

This news release contains “forward-looking statements” within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the respective management teams of HDC and DCL believe that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct.

DCL and HDC do not assume any obligation to update any forward- looking statements or other information contained in this document.


Contact:

Health Discovery Corporation
Dan Furth, 912-443-1988
www.healthdiscoverycorp.com
or
DCL Medical Laboratories, LLC
Dr. Michael Hanbury, 317-874-1300

Source: Health Discovery Corporation and DCL Medical Laboratories LLC

[alysant]

0.06 vol. 263.000

H/T

0.06
0.056

[talis]

http://biz.yahoo.com/bw/080508/20080508005448.html?.v=1



Press Release Source: Health Discovery Corporation

Health Discovery Corporation Announces the Issuance of Two New U.S. Patents Covering Applications of Support Vector Machines (SVM's)
Thursday May 8, 9:15 am ET
HDC's Intellectual Property Portfolio Increases to 30 Issued U.S. and Foreign Patents Covering Both Medical and Non-Medical Applications

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (OTCBB: HDVY - News) today announced that the U.S. Patent and Trademark Office has issued two new patents to further expand HDC’s exclusive intellectual property holdings covering a variety of applications of SVMs to a wide range of technologies. The first patent, Patent No. 7,353,215, claims a method for analysis of any type of data that has a structure. One of the most familiar types of structured data is documents, making the patent claims highly relevant to commercial data mining applications, including Internet browsers and search engines.

Other commercial applications of this newly issued patent include document management and sorting, text comparison, plagiarism and forgery detection, handwriting recognition and signature verification, biometrics, and any number of other applications in the high technology arena. Other types of structured data covered by this patent include images and electromagnetic signals, such as wireless transmissions and spectra. Information extraction and pattern recognition capabilities within such structured data are widely being pursued by industries including communications, manufacturing, national defense, and oil exploration.

In molecular biology, DNA sequence matching is a critical operation. Since DNA databases contain huge volumes of structured data sequences, methods for efficient processing of DNA sequence matching are widely needed. In the area of proteomics, the widely used method for protein characterization involves comparison of tandem mass spectrometry data with libraries of identified spectra in an approach called “spectral matching.” These areas and more can benefit from the advancements provided by the method covered by this latest issued patent.

The second issued patent, Patent No. 7,318,051, covers additional feature selection techniques that can be used to successfully identify the most important pieces of information needed to solve complex pattern-recognition problems. HDC’s previously patented recursive feature elimination method (RFE-SVM) is a type of feature selection technique that has proven to be successful in a wide variety of applications. These feature selection methods are critical components often used as an important “pre-processing” step for the successful implementation of support vector machine (SVM) technology.

Development of feature selection techniques has become a widespread effort, driven by the increasing sizes of data records which have been made possible by ever-increasing data storage capacities. Recent advances in sensor technologies and machine learning techniques have made it possible to design recognition systems that are capable of performing tasks that could not have been performed in the past. Feature selection methods lay at the center of these advances, with applications for the Internet, as well as the pharmaco-medical industry, oil industry, industrial inspection and control systems, speech recognition, biotechnology, finance, targeted marketing, and many other emerging applications.

The inventors of these new HDC patents represent some of the world’s leading authorities on SVMs and learning machines. Bernhard Schoelkopf is currently a department director at the Max Planck Institute for Biological Cybernetics in Tübingen, Germany and co-author or co-editor of numerous books and published articles on pattern recognition and learning machines. Peter Bartlett, currently a professor in the Department of Electrical Engineering and Computer Sciences at U.C. Berkeley, Jason Weston, a researcher in machine learning at NEC Laboratories America, André Elisseeff, a researcher in the Zurich Research Lab of IBM, and Fernando Perez-Cruz, a fellow at the Electrical Engineering Department in Princeton University, are all widely published in the fields of pattern recognition, learning machines and bioinformatics.

“HDC’s patent inventors recognized the critical importance of developing specialized feature and kernel selection techniques to allow SVMs to be adapted for practical, real-world uses, well ahead of the entry of others into the SVM arena” stated Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “With the forward thinking of our world-renowned patent inventors, HDC has been able to assemble a patent portfolio that represents a ‘minefield’ within the overall field of SVM technology, obtaining exclusive rights to important improvements that others in the SVM field are certain to ‘step on’ in their efforts to optimize their own SVM usage. HDC continues to diligently identify and track those who may have already encountered their ‘mines’ as well as those whose relatively recent entry into the field could benefit from a license to use HDC’s patented improvements.”

With the issuance of these two new patents, Health Discovery Corporation now holds the exclusive rights to 30 issued U.S. and foreign patents covering uses of SVM and FGM (fractal genomics modeling) technology for discovery of knowledge from large data sets. Other issued patents cover methods and systems for pre-processing of data to enhance knowledge discovery using SVMs, analysis of data using multiple support vector machines and for multiple data sets, and providing SVM analysis services over the Internet. HDC’s pending U.S. and foreign patent applications cover numerous improvements to, and applications of, SVMs including computer-aided image analysis using SVMs, with particular application to diagnosis using medical images, methods of feature selection for enhanced SVM efficiency and biomarkers for colon cancer, prostate cancer, BPH and renal cancer discovered with these methods, and use of SVMs for analysis of spectral data, such as mass spectrometry data used for protein analysis.

About Health Discovery Corporation

Savannah-based Health Discovery Corporation is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of molecular diagnostic development. The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct.


Contact:

Health Discovery Corporation
Daniel R. Furth, 912-443-1987
[e-mail]
www.healthdiscoverycorp.com

[alysant]

0.06 vol. 166.000

H/T

0.065
0.06

[talis]

Antwort auf Beitrag Nr.: 34.056.520 von talis am 08.05.08 15:35:56

die letzte Patent-news sollte einigen zu denken geben, sagt sie doch, dass beispielsweise auch Suchmaschinen auf die Technologie von HDC angewiesen sind.


Können wir etwa mit royalties von Google rechnen?


Bisher gab es nur 2 Patentrechtsauseinandersetzungen und die hat HDC für sich entschieden ...
... bitte zurückblättern und siehe Ciphergen

[talis]

Nachtrag zur letzten Woche.

Der Quartalsbericht ist raus.

http://biz.yahoo.com/e/080515/hdvy.ob10-q.html

Es gibt aber nichts wirklich Neues seit den jüngsten News.
Ausser, dass wirklich genug Cash da ist, bis die Einnahmen aus der Vermarktung des Prostatakrebstest eintreffen. September soll es soweit sein.

[alysant]

0.071 vol. 137.000

H/T

0.071
0.06

wieder etwas Leben in der Bude

[talis]

Gut möglich, dass Clarient die zweite klinische Testphase nutzt, um aus dem Gewebetest einen Bluttest auf Prostatakrebs zu entwickeln.
Dann kann man PSA verdrängen.
Kaum auszudenken, was dann mit dem Kurs passiert.
Die PSA-Methode generiert weltweit einen Jahresumsatz von über 300 Mio $. Und HDC kassiert 30% royalties.

Zurückblättern und nachlesen, empfehle ich.

[alysant]

0.055 vol. 18.000

lustlose Konsolidierung, andererseits Gelegenheit zum Akkumulieren.

Im übrigen fällt mir nichts Neues ein. Ich würde es nur bedauern, wenn der thread hier einschläft, da talis zurzeit wegen Arbeitsstreß verhindert ist, aber sicher wieder eingreifen wird.

Im übrigen haben wir ja Geduld, da wir uns nicht im Optionsgeschäft befinden, wo meist die Zeit drängt.

[talis]

Antwort auf Beitrag Nr.: 34.280.866 von alysant am 11.06.08 13:03:22

alysant, da hast Du recht. Wir sind hier nicht im Optionsgeschäft.

Ich erwarte aber eine vergleichbare Hebelwirkung,
wenn erst mal im September die PR herausgegeben wird
über die Vermarktung des Prostatakrebstests.

[talis]

http://biz.yahoo.com/bw/080612/20080612005361.html?.v=1


Press Release Source: Health Discovery Corporation

SVM Technology Wins NSF-Sponsored Challenge at the World Congress for Computational Intelligence 2008
Thursday June 12, 9:15 am ET

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (OTCBB: HDVY - News), a leader in support vector machine (SVM) based molecular diagnostics development today announced that Yin Wen Chang, a student of Chih-Jen Lin from the National Taiwan University, distinguished herself in the first causality challenge organized for the World Congress on Computational Intelligence, WCCI 2008, which was held in Hong Kong, June 1-6, 2008.

The challenge, which is sponsored by the U.S. National Science Foundation, the European Network of Excellence Pascal, and Microsoft Corporation, attracted over 50 participants. Yin Wen Chang ranked first on two tasks of the challenge and second and third on the two others, using SVM both for feature selection and for classification.

The four tasks proposed to the competitors were derived from real data in genomics, pharmacology and econometrics. The goal of the challenge was to uncover causes of a given outcome in order to make predictions of the result of future actions. For example, find genes to cure disease, find risk factors to control epidemics. Uncovering causes superficially resembles the problem of feature selection. But most feature selection algorithms emanating from machine learning like RFE-SVM do not seek to model mechanisms: they do not attempt to uncover cause-effect relationships between feature and target.

“We did not expect non-causal feature selection methods to do so well on these tasks,” explained Dr. Isabelle Guyon, co-organizer of the challenge and a member of HDC’s Science Team. “Causal discovery methods did very well at unraveling causal structure, and on average, we observed good correlation between the fraction of causally relevant features selected and the predictive power of learning machines on the tasks of the challenge. Yet, non-causal feature selection methods like RFE-SVM find feature subsets containing complementary features with high predictive power and SVMs are insensitive to the presence of false positive, so this is a combination that’s very hard to beat.”

“Solving problems of causality in order to predict the results of future actions is a critical component of identifying the right drug at the right dose for the right patient and is the cornerstone for the successful implementation of personalized medicine,” stated Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “We are thrilled that once again SVM technology has proven to be superior to other mathematical algorithms in solving these very difficult and unique problems. We congratulate Yin Wen Chang for her great accomplishment using SVMs to win the NSF-Sponsored Challenge at the World Congress for Computational Intelligence 2008.”

Dr. Barnhill continued, “With 32 issued patents around SVM technology and the only issued patents in the world on RFE-SVM, Health Discovery Corporation is in a unique position to capitalize on the proven success of these techniques to create and commercialize new diagnostic tests and play a significant role in bringing the promises of personalized medicine to reality.”

The first causality challenge is supported by the National Science Foundation under Grant N0 ECCS-0725746. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation.

Savannah-based Health Discovery Corporation (OTCBB: HDVY - News) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a leader in SVM-based molecular diagnostics development in genomics and proteomics, as well as, image analysis. The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct.


Contact:

Health Discovery Corporation
Dr. Isabelle Guyon, 510-524-6211
www.healthdiscoverycorp.com

Source: Health Discovery Corporation

[talis]

Man nehme sich etwas Zeit, lese die Überschrift des untenstehenden Artikels, um sich selbst davon zu überzeugen, wie man hierzulande hinterm Mond lebt. Man kocht hier ungeniert das eigene Süppchen und ignoriert die Ergebnisse von Clarient und Health Discovery.



http://www.aerzteblatt.de/v4/news/news.asp?id=32688

Neue Nachweismethode für Prostatakrebs
Freitag, 13. Juni 2008

Heidelberg – Ein neues Verfahren entwickelt, um Tumoren in der Prostata zuverlässiger zu erkennen, haben Wissenschaftler am Deutschen Krebsforschungszentrum (DKFZ) gemeinsam mit Ärzten der Martini-Klinik am Universitätsklinikum Hamburg-Eppendorf. Sie publizierten ihre Ergebnisse in der Zeitschrift European Urology (doi: 10.1016/j.eururo.2008.04.105).

Prostatakrebs ist die häufigste Krebsart bei Männern. Besteht bei einem Patienten der Verdacht auf einen Prostatatumor, entnimmt der Arzt Biopsien und überprüft sie auf Krebszellen. Das Problem: Die Größe und die räumliche Lage des Tumors sind zunächst oft unbekannt.

Bei der Biopsie kann es deshalb vorkommen, dass die Biopsienadel die Wucherung verfehlt und der Arzt nur tumorfreies Gewebe entnimmt. In diesem Fall bleibt der Krebs unerkannt. „Das geschieht in etwa dreißig Prozent der Krankheitsfälle“, so Holger Sültmann von der Abteilung Molekulare Genomanalyse am DKFZ.

Die Arbeitsgruppe hat deshalb einen zuverlässigeren Test für Prostatakrebs entwickelt. Sie untersuchten, ob im Prostatagewebe von gesunden Männern eine andere Genaktivität herrscht als im tumorfreien Prostatagewebe von Krebspatienten. Dazu zogen sie Prostatabiopsien von 114 Männern heran.

Mithilfe der so genannten Microarray-Technologie fanden die Wissenschaftler fünf Gene, die bei Gesunden und Krebskranken deutlich unterschiedlich abgelesen werden. Es handelt sich um die Gene FOS, EGR1, MYC, TFRC und FOLH1. „Die Aktivität dieser Gene zeigt an, ob sich in der Prostata ein Tumor gebildet hat – und zwar unabhängig davon, ob die Gewebeprobe Tumorzellen enthält oder nicht“, schreiben die Forscher in ihrer Publikation.

Möglicherweise ließen sich Prostatatumoren mit solchen genetischen Tests wesentlich verlässlicher nachweisen als das bisher möglich war. Für sichere Aussagen sei es jedoch zu früh. „Mit unseren Partnern in Hamburg sind wir derzeit dabei, sie in weiteren Studien zu überprüfen“, meint Sültmann. © hil/aerzteblatt.de

[talis]

http://biz.yahoo.com/bw/080624/20080624005721.html?.v=1


Press Release Source: Health Discovery Corporation

Health Discovery Corporation Announces Successful Phase II Clinical Trial Results for New Gene-Based Molecular Diagnostic Test for Prostate Cancer
Tuesday June 24, 9:00 am ET
New Gene-Based Molecular Diagnostic Test for Prostate Cancer Should Be Commercially Available to Physicians in Q3 of 2008

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (“HDC”) (OTCBB: HDVY - News) today announced the successful phase II clinical trial results for HDC’s new gene-based molecular diagnostic test for prostate cancer licensed exclusively to Clarient (Nasdaq: CLRT - News), in which HDC will receive a 30 percent royalty on each test performed based on the per test reimbursement received by Clarient. In addition to the commercialization license HDC granted to Clarient, HDC retained the right to also commercialize this molecular diagnostic test for prostate cancer in one or more clinical laboratories that HDC elects to own and/or operate.

Results from both the Phase I and Phase II clinical validation studies now completed at Clarient with prostate tissues obtained from multiple sites, including those tested in collaboration with MD Anderson Cancer Center, demonstrated a very high success rate for identifying the presence of Grade 3 or higher prostate cancer cells (clinically significant cancer), as well as normal and BPH (benign prostatic hyperplasia) cells. Combining all of the patients from both Phase I and Phase II clinical trials, the new gene-based molecular diagnostic test achieved a Sensitivity of 91.3% for correctly identifying the presence of Grade 3 or higher prostate cancer cells, a Specificity of 100% for correctly identifying normal prostate cells and a Specificity of 90% for identifying BPH cells representing an overall test accuracy of 93.2%.

In the United States alone there are over 1 million prostate cancer tissue biopsy procedures performed annually. Approximately 25% of these tissue biopsies are reported “positive” indicating the presence of prostate cancer. The other 75% of prostate cancer tissue biopsies are reported as “negative” for the presence of cancer. However, one-third of the men with prostate cancer tissue biopsies that are reported as “negative” for prostate cancer (roughly 25%) actually do have prostate cancer that was missed by the first biopsy (False Negative). These men actually have prostate cancer that was missed by the initial tissue biopsy for a variety of reasons. Health Discovery Corporation’s prostate cancer molecular diagnostic test is a genomics based test discovered using HDC’s patented SVM and SVM-RFE pattern recognition technology. This prostate cancer test is based on a unique and patent protected combination of 4 genes that accurately identify the presence of Grade 3 or higher (clinically significant cancer) prostate cancer cells, as well as normal and BPH cells in prostate tissue.

“We are absolutely elated with the results of these additional Phase II clinical trial results and now look forward to having this new prostate cancer test commercially available and generating revenue for HDC in Q3 of 2008,” stated Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “The successful development, validation and commercialization of this new molecular diagnostic test for prostate cancer proves that HDC, by combining our patented SVM and SVM-RFE technology and our expert Scientific Team, has the ability to produce new molecular diagnostic tests which are the future of diagnostic medicine. Our patent protected discovery method allows us to develop molecular diagnostic tests that are free of outside intellectual property rights and thereby allows HDC to fully patent protect our molecular diagnostic gene signatures. Using the same expertise of our Scientific Team and the HDC patented technology, we are currently developing additional new molecular diagnostic tests in a variety of other cancers some of which we hope will be commercially available in Q4 of 2008.”

Dr. Barnhill continued, “We are looking forward to having HDC’s new gene-based prostate cancer test commercialized like similar molecular diagnostic tests based on unique gene expression profiles such as OncotypeDX from Genomic Health, Inc. (NasdaqGM: GHDX - News) and MammaPrint from Agendia.”

“The excellent results seen in both the Phase I and Phase II double blinded clinical trials validate the scientific accuracy and robustness of the HDC gene-based molecular diagnostic test for prostate cancer,” stated Dr. Herbert Fritsche, Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas. “Health Discovery Corporation’s proven ability to develop state-of-the-art molecular diagnostic tests for cancer brings the promise of personalized medicine to reality.”

Savannah-based Health Discovery Corporation (OTCBB: HDVY - News) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery(sm). The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct.


Contact:

Health Discovery Corporation
Stephen D. Barnhill, M.D., CEO, 912-443-1987
[e-mail]
www.healthdiscoverycorp.com

Source: Health Discovery Corporation

[talis]

Antwort auf Beitrag Nr.: 34.362.914 von talis am 24.06.08 15:24:00

bei genauer Durchsicht der Pressemitteilung fällt ein neues Detail auf

...In addition to the commercialization license HDC granted to Clarient, HDC retained the right to also commercialize this molecular diagnostic test for prostate cancer in one or more clinical laboratories that HDC elects to own and/or operate....

davon war bisher nicht die Rede, macht die ganze Sache aber noch aussichtsreicher als zuvor

[talis]

hier noch das Ganze auf deutsch

Wenn man für einen Prostatakrebstest nur 100 $ berechnen könnte, lässt sich leicht ausrechnen, wieviel bei HDC ankommt, bei 1 Mio Prostatabiopsien jährlich.





Die Health Discovery Corporation verkündet Ergebnisse ihrer erfolgreichen Phase-II-Studien zu neuem genbasierten molekularen Diagnosetest für Prostatakrebs
Leser des Artikels: 27

Die Health Discovery Corporation (,,HDC") (OTCBB: HDVY) gab heute die Ergebnisse der erfolgreichen Phase-II-Studie zu ihrem neuen genbasierten molekularen Diagnosetest für Prostatakrebs bekannt, an dem Clarient (Nasdaq: CLRT) eine exklusive Lizenz hält. Unter dieser Lizenz wird HDC Lizenzgebühren in Höhe von 30 Prozent für jeden durchgeführten Test basierend auf der von Clarient pro Test erzielten Vergütung erhalten. Neben der Vermarktungslizenz für Clarient behält sich HDC das Recht vor, den molekularen Diagnosetest für Prostatakrebs in einem oder mehreren klinischen Labors zu vermarkten, die sich im Besitz von HDC befinden und/oder von HDC betrieben werden.


Die Ergebnisse der jetzt bei Clarient abgeschlossenen klinischen Validierungsstudien der Phase I und II mit von mehreren Standorten stammendem Prostatagewebe, darunter das in Zusammenarbeit mit dem MD Anderson Cancer Center getestete Gewebe, demonstrierten eine hohe Erfolgsrate im Hinblick auf die Erkennung von Prostatakrebszellen der Stufe 3 oder höher (klinisch signifikanter Krebs) sowie normaler und gutartiger Prostatahyperplasie-Zellen. Die Sensitivität des neuen genbasierten molekularen Diagnosetests im Hinblick auf die korrekte Erkennung von Prostatakrebszellen der Stufe 3 oder höher lag für alle Patienten der klinischen Phase-I- und Phase-II-Studien zusammen bei 91,3 Prozent, die Spezifizität in Bezug auf die korrekte Erkennung normaler Prostatazellen bei 100 Prozent und hinsichtlich der Erkennung von gutartigen Prostatahyperplasie-Zellen bei 90 Prozent, woraus sich eine Testgenauigkeit von insgesamt 93,2 Prozent ergibt.

Allein in den USA werden jährlich über eine Mio. Prostatabiopsien vorgenommen. Ca. 25 Prozent von ihnen sind ,,positiv", d. h. in den Gewebeproben werden Prostatakrebszellen nachgewiesen. Die übrigen 75 Prozent der Biopsien sind ,,negativ" im Hinblick auf das Vorliegen von Krebs. Ein Drittel der Männer mit einer negativen Prostatabiopsie (ca. 25 Prozent) leidet jedoch trotz des negativen Ergebnisses an Prostatakrebs, was bei der ersten Biopsie jedoch nicht festgestellt wurde (falsch negativ). Bei ihnen liegt Prostatakrebs vor, der bei der ursprünglichen Gewebeprobe aus verschiedenen Gründen nicht nachgewiesen wurde. Der molekulare Diagnosetest für Prostatakrebs der Health Discovery Corporation ist ein genetisch basierter Test, der anhand der patentierten SVM- und SVM-RFE-Mustererkennungstechnologie von HDC entdeckt wurde. Dieser Prostatakrebstest beruht auf einer einzigartigen, patentgeschützten Kombination von vier Genen, die das Vorhandensein von Prostatakrebszellen der Stufe 3 oder höher (klinisch signifikanter Krebs) sowie normaler und gutartiger Prostatahyperplasie-Zellen akkurat nachweisen.

,,Wir sind überaus zufrieden mit diesen zusätzlichen Phase-II-Studienergebnissen und freuen uns darauf, unseren neuen Prostatakrebstest im dritten Quartal 2008 auf den Markt zu bringen und Umsätze für HDC zu generieren", erklärte Dr. med. Stephen D. Barnhill, Chairman und CEO der Health Discovery Corporation. ,,Die erfolgreiche Entwicklung, Validierung und Vermarktung dieses neuen molekularen Diagnosetests für Prostatakrebs zeigt, dass wir mit Hilfe unserer patentierten SVM- und SVM-RFE-Technologie und unseres fachkundigen Scientific Team in der Lage sind, neue molekulare Diagnosetests zu produzieren, die die Zukunft der diagnostischen Medizin darstellen. Unsere patentgeschützte Entdeckungsmethode ermöglicht es uns, molekulare Diagnosetests zu entwickeln, die keinen geistigen Eigentumsrechten Dritter unterliegen, und erlaubt es uns daher, unsere molekularen Gensignaturen vollständig zu patentieren. Auf der Grundlage des gleichen Know-how unseres Scientific Team und anhand der patentierten HDC-Technologie entwickeln wir derzeit weitere neuartige molekulare Diagnosetests für zahlreiche andere Krebsarten, von denen wir hoffen, dass sie im vierten Quartal 2008 auf dem Markt erhältlich sein werden."

Dr. Barnhill fuhr fort: ,,Wir freuen uns auf die Vermarktung unseres neuen genbasierten Prostatakrebstests, der wie ähnliche molekulare Diagnosetests, z. B. OncotypeDX von Genomic Health, Inc. (NasdaqGM: GHDX) und MammaPrint von Agendia, auf einem einzigartigen Genexpressionsprofil beruht."

,,Die hervorragenden Ergebnisse der doppelblinden klinischen Phase-I- und Phase-II-Studien validieren die wissenschaftliche Genauigkeit und Robustheit des genbasierten molekularen Diagnosetests für Prostatakrebs von HDC", führte Dr. Herbert Fritsche, Professor of Laboratory Medicine und Chief of the Clinical Chemistry Section der University of Texas, MD Anderson Cancer Center im texanischen Houston, aus.,,Die Health Discovery Corporation hat ihre Fähigkeit unter Beweis gestellt, innovative molekulare Diagnosetests für Krebs zu entwickeln und setzt so das Versprechen personalisierter Medizin in die Realität um."

Die Health Discovery Corporation (OTCBB: HDVY) mit Sitz in Savannah im US-Bundesstaat Georgia ist im Bereich der Mustererkennungstechnologie einzigartig positioniert. Das im biologischen Bereich tätige Unternehmen setzt seine patentgeschützte Technologie auf dem Gebiet der Entdeckung von Biomarkern ein und bietet alle Aspekte der First-Phase Biomarker Discovery(sm) an. Die SVM- und FGM-Mustererkennungstechnologien von HDC haben ein hohes Anwendungspotenzial in anderen umfangreichen kommerziellen Märkten, wie z. B. in den Bereichen Radiologie, Finanzwesen, Internetsuche und Spam, innere Sicherheit sowie auf anderen Gebieten, die die Analyse von großen Mengen komplexer Daten erfordern.

Diese Pressemitteilung enthält ,,zukunftsbezogene Aussagen" im Sinne von Absatz 27A des Securities Act aus dem Jahr 1933 und Absatz 21E des Securities Exchange Act aus dem Jahr 1934. Obwohl die Geschäftsführung von HDC der Ansicht ist, dass die in diesen zukunftsbezogenen Aussagen zum Ausdruck gebrachten Erwartungen begründet sind, kann sie nicht gewährleisten, dass diese Erwartungen eintreten werden.

Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.


Autor: © Business Wire

[talis]

Antwort auf Beitrag Nr.: 34.396.002 von talis am 28.06.08 10:09:00

Freunde!

Ist denn wirklich niemand beeindruckt von der obigen News ?

[talis]

Antwort auf Beitrag Nr.: 34.471.615 von talis am 09.07.08 16:26:21

ein paar sind beeindruckt

Kurs zieht an
bid/ask 0,75/0,8

[talis]

Antwort auf Beitrag Nr.: 34.553.045 von talis am 21.07.08 17:15:33

oops da hab ich mich wohl um eine Kommastelle vertan

jetzt auf jeden Fall

bid/ask
0,07/0,075

Volumen steigt

[talis]

Antwort auf Beitrag Nr.: 34.553.772 von talis am 21.07.08 18:37:31

Schlusskurs 0,08$, es sieht immer besser aus,

[talis]

http://biz.yahoo.com/bw/080724/20080724005763.html?.v=1

Press Release Source: Health Discovery Corporation

New Computer Assisted Diagnostic Tests for Ovarian Cancer, Cervical Cancer and Endometrial Cancer to Be Jointly Developed by Health Discovery Corporation and DCL Medical Laboratories
Thursday July 24, 10:43 am ET
Health Discovery Corporation and DCL Medical Laboratories Will Develop and Commercialize New Digital Pathology Diagnostics for Ovarian Cancer, Cervical Cancer and Endometrial Cancer

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (OTCBB: HDVY - News), a leader in support vector machine (SVM) based molecular diagnostics, and DCL Medical Laboratories, LLC, Indianapolis, IN, a full-service, clinical reference laboratory, today announced the signing of a Development and License Agreement for the collaborative development and commercialization of SVM-based computer assisted diagnostic (CAD) tests for the independent detection of ovarian, cervical and endometrial cancers. These new diagnostic tests will be performed on digital images to assist pathologists in providing more accurate diagnoses on biopsy and surgical specimens. HDC shall own the developed intellectual property and DCL shall have a sole use license relating to applications and new mathematical tools developed during the course of this Agreement. The companies will share future service revenues contemplated under the Agreement.

The target development areas of ovarian, endometrial and cervical cancer represent three of the most prevalent women’s health related cancers, each with significant mortality and morbidity. Through the advancing technology of pattern recognition, the new SVM-based diagnostic imaging systems are expected to improve the sensitivity of detection for endometrial and cervical cancers and significantly improve the specificity of ovarian cancer diagnosis. In addition, images and interpretative data from the new SVM-based systems will be designed for use in web based applications, thus allowing remote review, second opinions and collaborative pathologist interpretation. These new CAD-based digital pathology SVM-based algorithms could offer a faster, highly objective, and more accurate interpretation of cells to assist pathologists in making correct diagnoses for physicians and their patients.

“We are thrilled that DCL has decided to expand their SVM-based, digital pathology diagnostic development efforts in cervical cancer to now include ovarian and endometrial cancer,” said Stephen D. Barnhill, MD, Chairman and CEO of HDC. “Using our patent protected SVM technology, we believe these new digital pathology screening systems will further enhance current Pap systems in the detection of cellular abnormality, as well as improve the diagnostic interpretations related to ovarian and endometrial cancers. In addition, we believe that using currently available image capturing technology, our SVM-based image analysis could be made available to assist pathologists in clinical laboratories, hospitals, academic centers and medical/pharmaceutical industries provide an accurate objective diagnostic interpretation to physicians and their patients around the world via transmission and evaluation of these digital pathology images using telepathology techniques over the Internet.”

“DCL is pleased to expand our partnership with Health Discovery Corporation in the development of novel computer based imaging systems,” said Dr. Michael Hanbury, President and Chief Executive Officer of DCL. “This development opportunity extends DCL’s commitment to offer leading diagnostic pathology services and further demonstrates DCL’s commitment to providing remarkable contributions in women’s health. In recent months, DCL has transformed the company into a rapidly growing regional laboratory while forming strategic development partnerships with diagnostic companies. DCL’s collective experience in anatomic and clinical pathology testing services, clinical trial services, diagnostic product development and an extensive retrospective sample library focused in women’s health related cases have been strategically aligned to facilitate the commercialization of clinical diagnostic services. This partnership with HDC creates an excellent opportunity for both companies to explore novel advancements in diagnostic imaging, computer assisted diagnostics and remote pathology. We believe this expanded relationship will further the development of computer assisted image analysis and deliver significant commercial opportunities for DCL and Health Discovery Corporation.”

About Health Discovery Corporation

Savannah-based Health Discovery Corporation (OTCBB: HDVY) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a leader in SVM-based molecular diagnostic and prognostic test development in genomics and proteomics, as well as, digital image analysis in pathology and radiology. The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as oil exploration, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.

About DCL Medical Laboratories LLC

DCL Medical Laboratories is a full-service, regional reference laboratory offering a broad menu of services including specialty testing capabilities in molecular diagnostics. DCL also provides anatomic and molecular pathology services in global clinical trials for both pharmaceutical and medical device companies in partnership with the world’s largest central laboratories and clinical research organizations. Following its recapitalization in late 2007, DCL has significantly expanded its testing capabilities and provides a unique collaborative development opportunity to expedite the development process for emerging diagnostic technologies. Focused in women’s health, DCL provides over 25 years of experience in providing laboratory services and exceptional educational, assay development and clinical trial experience. DCL is committed to being a preferred medical laboratory partner providing nationally recognized diagnostic services in women’s health. From its founding, DCL has maintained a personal approach to delivering innovative and consultative pathology services that empower clients and improve lives. DCL is a private company with principal equity holdings by Thompson Street Capital Partners in St. Louis.

This news release contains “forward-looking statements” within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the respective management teams of HDC and DCL believe that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct.

DCL and HDC do not assume any obligation to update any forward-looking statements or other information contained in this document.


Contact:

Health Discovery Corporation
Stephen D. Barnhill, MD, CEO, 912-443-1987
[e-mail]
www.healthdiscoverycorp.com

Source: Health Discovery Corporation

[talis]

Dann wollen wir mal hoffen, dass Patent Profit International auch alles rausholt



Press Release Source: Health Discovery Corporation

Health Discovery Corporation Inks Agreement with Patent Profit International for Monetization of Patent Portfolio
Monday August 4, 10:40 am ET

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (OTCBB:HDVY - News), a leader in support vector machine (SVM) based molecular diagnostic and prognostic test development today announced the signing of an Agreement with Patent Profit International (PPI), a Silicon Valley-based patent brokerage firm, with the goal of exploiting the full monetization potential of HDC's extensive pioneering patent portfolio. Under the agreement, PPI will market HDC's patent portfolio, which includes exclusive rights to SVM techniques and applications that reach far beyond biomarker discovery and the Healthcare Field, to prospective buyers/licensees in a wide range of technologies, including, but not limited to, information technology such as Internet browsers and search engines, spam mail detection, oil exploration, homeland security, and the automotive industry.

As a requirement of any sale of the patent estate, HDC expects to retain a royalty-free, worldwide, exclusive license, with the right to grant sublicenses, in the entire field of healthcare. This strategic initiative would allow HDC to potentially generate significant revenue from its extensive and pioneering patent estate covering the field of SVM technology in non-medical applications while continuing uninterrupted its wide-ranging research, development, licensing and commercialization activities in broad-ranging diagnostic and prognostic areas such as prostate cancer, ovarian cancer, breast cancer, endometrial cancer, colon cancer, leukemia and other healthcare arenas. This is a strategy designed to transform HDC's underutilized patents into working financial assets to increase shareholder value.

PPI is one of a small number of successful patent brokerage firms that specialize in the sale of patent portfolios and has strong contacts in the high technology arena. Under the commission-based arrangement, PPI will utilize its contacts and market knowledge to identify companies to whom HDC's patent portfolio is relevant and position the portfolio to attract prospective buyers. PPI will then facilitate negotiations to obtain the best possible price and terms and with HDC's approval to close the deal.

The advances covered by the patents in the HDC portfolio represent work by several of the world's leading authorities in the field of SVMs and learning machines including Dr. Isabelle Guyon, one of the original SVM inventors at Bell Labs and a member of HDC's Scientific Advisory Board. A few of the other HDC inventors include Dr. Bernhard Schoelkopf, also a Member of HDC's Science Advisory Board and currently a department director at the Max Planck Institute for Biological Cybernetics in Tübingen, Germany and co-author or co-editor of numerous books and published articles on pattern recognition and learning machines. Dr. Nello Cristianini is a professor of artificial intelligence at the University of Bristol and co-author of two well-known books on machine learning. Dr. Peter Bartlett, currently a professor in the Department of Electrical Engineering and Computer Sciences at U.C. Berkeley, Dr. Jason Weston, a researcher in machine learning at NEC Laboratories America, Dr. André Elisseeff, a researcher in the Zurich Research Lab of IBM, and Dr. Fernando Perez-Cruz, a fellow in the Electrical Engineering Department at Princeton University. All of these HDC patent inventors are widely published in the fields of pattern recognition, learning machines and bioinformatics.

“Health Discovery Corporation's intellectual property portfolio, now includes 15 issued and 19 pending U.S. patents and 14 issued and 16 pending foreign patents, and has grown significantly as a valuable asset of the company,” stated Stephen D. Barnhill, M.D., Chairman and CEO of HDC. “A patent portfolio sale/license back with HDC retaining exclusive, world-wide, royalty free, rights to the patented technology in the entire field of healthcare could unlock the value of these intellectual property assets, provide substantial income to HDC and significantly reduce the cost of patent maintenance, prosecution, and litigation while allowing HDC full use, including sublicensing rights, of the patented technology in the entire field of healthcare; all of which clearly represents a win-win situation for HDC shareholders.”

"Today, intangible intellectual property assets are the largest and most valuable portion of the asset base for a majority of companies," stated Jeff Kalb of Patent Profit International. "Patent Profit International is very excited to be working with HDC to monetize the significant value of this very extensive pioneering portfolio of patents. This patent sale/license back strategy will allow HDC to potentially generate substantial income in the near term from the highest bidder for these unique and well protected patents which include the support vector machine (SVM), a technology which has become the subject of considerable interest to some of the largest companies in the world."

The sale of HDC's patent portfolio to a high tech company with extensive resources for establishing an aggressive licensing and enforcement program is a wining solution that could generate significant working capital for realizing HDC's primary mission and allowing HDC to devote its intellectual and financial resources to diagnostic and prognostic test development for personalized medicine and other medical applications of SVMs.

About Health Discovery Corporation

Savannah-based Health Discovery Corporation (OTCBB: HDVY - News) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a leader in SVM-based molecular diagnostic and prognostic test development in genomics and proteomics, as well as, digital image analysis in pathology and radiology. The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as oil exploration, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.

About Patent Profit International LLC

Based in Silicon Valley, California, Patent Profit International LLC helps companies realize revenues and profits from unused intellectual property through a detailed analysis of the IP for sale, explaining its value to purchasers which is possible through the development of long term business relationships with the leading IP buyers and companies around the world.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the respective management teams of HDC and PPI believe that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct. DCL and HDC do not assume any obligation to update any forward-looking statements or other information contained in this document.


Contact:

Health Discovery Corporation
Stephen D. Barnhill, MD, CEO, 912-443-1987
[e-mail]
www.healthdiscoverycorp.com
or
Patent Profit International, LLC
William J. Plut, Principal
[e-mail]

Source: Health Discovery Corporation

[talis]

Press Release Source: Clarient, Inc.

Clarient and Health Discovery Corporation Announce Results from Prostate Profile Clinical Validation Studies
Wednesday August 6, 4:14 pm ET
Double-Blind Study Renders 90% Sensitivity, 97% Specificity

ALISO VIEJO, Calif. & SAVANNAH, Ga.--(BUSINESS WIRE)--Clarient, Inc. (Nasdaq: CLRT - News), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, and Health Discovery Corporation (HDC) (OTCBB: HDVY) a leader in support vector machine (SVM) based molecular diagnostic and prognostic test development, today announced that the companies have completed the three-phased, double-blind clinical validation studies for their new gene-based molecular diagnostic test for prostate cancer.

Results from Phase I, Phase II and Phase III double-blinded clinical validation studies on prostate tissues obtained from multiple sites, including those tested in collaboration with MD Anderson Cancer Center and Clarient, demonstrated an excellent success rate for identifying the presence of Grade 3 or higher prostate cancer cells (clinically significant cancer), as well as normal and BPH (benign prostatic hyperplasia) cells. To date, 322 prostate tissues have been tested. The combined results of the recently completed double-blinded clinical validation studies, the new gene-based molecular diagnostic test achieved a Sensitivity of 90% for correctly identifying the presence of Grade 3 or higher prostate cancer cells, and a Specificity of 97% for correctly identifying non-cancer cells (normal and BPH), representing an overall test accuracy of 93%.

“We are very impressed with the results from these validation studies, and I applaud the development teams from both Clarient and HDC for their diligent efforts in bringing this new test through the validation phase significantly ahead of schedule,” stated Ron Andrews, Clarient’s Chief Executive Officer. “The early results from these studies confirm our belief that this powerful genomics-based test may provide physicians with useful information to ensure that men with prostate cancer get a more accurate diagnosis sooner and minimize the need for unnecessary biopsies.”

In the United States alone, there are over 1 million prostate cancer tissue biopsy procedures performed annually. Approximately 25% of these tissue biopsies are reported “positive” indicating the presence of prostate cancer. The other 75% of prostate cancer tissue biopsies are reported as “negative” for the presence of cancer. However, one-third of the men with initial prostate cancer tissue biopsies that are reported as “negative” for prostate cancer actually do have prostate cancer that was missed by the first biopsy (False Negative). Clarient believes this new genomics-based molecular diagnostic test may be able to detect molecular changes in the tissue adjacent to prostate cancer, assisting physicians in identifying which men in the “False Negative” group could have prostate cancer.

The Clarient Insight™ Dx Prostate Cancer Profile was discovered by HDC using their patented SVM and SVM-RFE pattern recognition technology, and is based on a unique and patent protected combination of four genes that are believed to accurately identify the presence of Grade 3 or higher (clinically significant cancer) prostate cancer cells, as well as normal and BPH cells in prostate tissue.

Dr. Herbert Fritsche, Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas, said, “The positive results seen in Phase I, Phase II, and Phase III double-blinded clinical studies appear to validate the scientific accuracy of this gene-based molecular diagnostic test for prostate cancer. Physicians who are diagnosing and treating prostate cancer patients should be greatly assisted by the additional information that this new prostate cancer test may add to their decision making process.”

Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation, stated, “We are very pleased with the final results of the double-blinded clinical trials and are looking forward to entering the commercialization phase of our prostate cancer test. The successful development and validation of this new molecular diagnostic test for prostate cancer proves that HDC, by combining its patented SVM and SVM-RFE technology with its expert Scientific Team, has the ability to produce new molecular diagnostic and prognostic tests that are contributing to the future of personalized medicine.”

The companies plan to immediately begin presenting papers for publication and presentations at upcoming meetings as they initiate the technical marketing phase of commercialization. The companies also believe that, once the required internal documentation is completed, the current validation studies will be adequate to establish the test as a Lab-Developed Test under current guidelines. Also, the companies intend to initiate a study utilizing urine samples to potentially expand the indication of this test to a screening application which could significantly expand the current market opportunity.

About Clarient

Clarient combines innovative diagnostic technologies with world class expertise to assess and characterize cancer. Clarient’s mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. The Company’s principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services available both onsite and over the web. The Company is also developing new, proprietary “companion” diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Clarient is a Safeguard Scientifics, Inc. partner company. www.clarientinc.com

About Health Discovery Corporation

Savannah-based Health Discovery Corporation (OTCBB: HDVY) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a leader in SVM-based molecular diagnostic and prognostic test development in genomics and proteomics, as well as, digital image analysis in pathology and radiology. The Company’s patent-protected discovery method allows us to develop molecular diagnostic and prognostic tests that are free of outside intellectual property rights and thereby allows HDC to fully patent protect in-house discovered molecular diagnostic gene signatures. The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as oil exploration, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.

About Safeguard

Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc. (NYSE: SFE - News) provides growth capital for entrepreneurial and innovative technology and life sciences companies. Safeguard targets technology companies in Software as a Service (SaaS) / Internet-based Businesses, Technology-Enabled Services and Vertical Software Solutions, and life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices and Specialty Pharmaceuticals with capital requirements between $5 and $50 million. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. www.safeguard.com

Forward-Looking Statements

The statements herein regarding Clarient, Inc. (the “Company”) contain forward-looking statements that involve risks and uncertainty. Future events and the Company’s actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to: the Company’s ability to market and fund continued development of this new genomics-based diagnostic test for prostate cancer, the Company’s ability to obtain third party payer reimbursement for this test, the efficacy of the test once introduced in the marketplace and the acceptance of this test by physicians and patients, failure to obtain any requisite regulatory clearances or approvals, the Company’s ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, and risks detailed from time to time in the Company’s SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to laboratory services, revenues and results of operations may not be indicative of future results for the reasons set forth above.

The company does not assume any obligation to update any forward-looking statements or other information contained in this document.


Contact:

Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
[e-mail]
or
Health Discovery Corporation
Stephen D. Barnhill, MD, CEO, 912-443-1987
[e-mail]
www.healthdiscoverycorp.com

Source: Clarient, Inc.

[talis]

das Ganze nochmal von HDC und auf deutsch



Neuer Prostatakrebstest ist nach erfolgreichem Abschluss der abschließenden klinischen Studien bereit zur Vermarktung


Die Health Discovery Corporation (,,HDC") (OTCBB: HDVY) hat heute bekannt gegeben, dass ihr neuer genbasierter molekularer Diagnosetest für Prostatakrebs seine doppelblinde klinische Phase-III-Studie erfolgreich abgeschlossen hat und jetzt zur Vermarktung an Ärzte für ihre Patienten bereit ist, bei denen ein Risiko für Prostatakrebs besteht. Der neue Prostatakrebstest wird im Clarient´s Clinical Laboratory in Aliso Viejo, Kalifornien durchgeführt werden. HDC wird für jeden durchgeführten Test eine Lizenzgebühr von 30 % erhalten.




Die Ergebnisse der jetzt abgeschlossenen klinischen Validierungsstudien der Phasen I, II und III mit von mehreren Standorten stammendem Prostatagewebe, darunter das in Zusammenarbeit mit dem MD Anderson Cancer Center getestete Gewebe, demonstrierten eine hohe Erfolgsrate im Hinblick auf die Erkennung von Prostatakrebszellen Grad 3 oder höher (klinisch signifikanter Krebs) sowie normaler und gutartiger Prostatahyperplasie-Zellen. Bis zum heutigen Tag wurden 322 Prostatagewebe getestet. Die kombinierten Ergebnisse der kürzlich abgeschlossenen doppelblinden klinischen Validierungsstudien demonstrierten, dass der neue genbasierte molekulare Diagnosetest für Prostatakrebs eine Empfindlichkeit von 90 % für die korrekte Erkennung von Prostatakrebszellen Grad 3 oder höher und eine Spezifität in Bezug auf die korrekte Erkennung normaler Prostatazellen und gutartiger Prostatahyperplasie-Zellen von 97 % erreichte, woraus sich eine Testgenauigkeit von insgesamt 93 % ergibt.

,,Wir sind überaus zufrieden mit diesen Endergebnissen der doppelblinden klinischen Studie und freuen uns darauf, unseren neuen Prostatakrebstest auf den Markt zu bringen", erklärte Dr. med. Stephen D. Barnhill, Vorsitzender und CEO der Health Discovery Corporation. ,,Die erfolgreiche Entwicklung, Validierung und Vermarktung dieses neuen molekularen Diagnosetests für Prostatakrebs beweist, dass HDC mit Hilfe unserer patentierten SVM- und SVM-RFE-Technologie und unseres fachkundigen wissenschaftlichen Teams in der Lage ist, neue molekulare Diagnosetests zu produzieren, die die Zukunft der personalisierten Medizin darstellen. Unsere Patent geschützte Entdeckungsmethode ermöglicht es uns, molekulare Diagnosetests zu entwickeln, die keinen geistigen Eigentumsrechten Dritter unterliegen, und erlaubt es uns daher, unsere molekularen Gensignaturen vollständig zu patentieren. Auf der Grundlage desselben Know-hows unseres wissenschaftlichen Teams und der patentierten HDC-Technologie entwickeln wir derzeit weitere neuartige molekulare Diagnosetests für zahlreiche andere Krebsarten, von denen wir hoffen, dass sie im vierten Quartal 2008 auf dem Markt erhältlich sein werden."

Dr. Barnhill fuhr fort: ,,Wir freuen uns auf die Vermarktung des neuen genbasierten Prostatakrebstests von HDC, der wie ähnliche molekulare Diagnosetests, z. B. OncotypeDX von Genomic Health, Inc. (NasdaqGM: GHDX) und MammaPrint von Agendia, auf einem einzigartigen Genexprimierungsprofil beruht."

Allein in den USA werden jährlich über 1 Million Prostatakrebsgewebebiopsien vorgenommen. Ca. 25 % davon sind ,,positiv", d. h. in den Gewebeproben werden Prostatakrebszellen nachgewiesen. Die übrigen 75 % der Prostatakrebsgewebebiopsien sind ,,negativ" im Hinblick auf das Vorliegen von Krebs. Ein Drittel der Männer, bei denen die erste Prostatakrebsgewebebiopsie ,,negativ" war (ca. 25 % der Männer, bei denen ein Risiko für Prostatakrebs besteht) haben aber dennoch Prostatakrebs, was bei der ersten Biopsie jedoch nicht festgestellt wurde (falsch-negativ). Bei diesen Männern liegt Prostatakrebs vor, der bei der ersten Gewebebiopsie aus verschiedenen Gründen nicht nachgewiesen wurde. Der molekulare Diagnosetest für Prostatakrebs der Health Discovery Corporation ist ein genetisch basierter Test, der bei den 75 % der Männer (allein in den USA sind das jährlich ca. 600.000 Männer) durchgeführt werden sollte, bei denen die erste Biopsie negativ war, um den Ärzten zu ermöglichen, diejenigen Männer zu identifizieren, deren Prostatakrebserkrankung bei der ersten Biopsie nicht festgestellt wurde.

,,Die hervorragenden Ergebnisse der doppelblinden klinischen Phase-I-, Phase-II- und Phase-III-Studien validieren die wissenschaftliche Genauigkeit und Robustheit des genbasierten molekularen Diagnosetests für Prostatakrebs von HDC", führte Dr. Herbert Fritsche, Professor für Labormedizin und Chief of the Clinical Chemistry Section der University of Texas am MD Anderson Cancer Center im texanischen Houston, aus. ,,Ärzte, die Prostatakrebs diagnostizieren und behandeln, werden durch die zusätzliche Information, die dieser neue Prostatakrebstest ihrem Entscheidungsfindungsprozess hinzufügt, eine große Hilfe erhalten."

In einer gestern herausgegebenen Pressemitteilung sagte Ron Andrews, CEO von Clarient: ,,Wir sind sehr beeindruckt von den Ergebnissen dieser Validierungsstudien, und ich applaudiere den Entwicklungsteams von Clarient und HDC für ihre engagierte Arbeit, die Validierungsphase für diesen neuen Test deutlich vor dem planmäßigen Abschlusstermin abzuschließen. Die frühen Ergebnisse aus diesen Studien bestätigen unsere Ansicht, dass dieser leistungsfähige Genomik basierte Test Ärzten nützliche Informationen bieten kann, um zu gewährleisten, dass Männer mit Prostatakrebs schneller eine akkuratere Diagnose erhalten und der Bedarf an unnötigen Biopsien minimiert wird."

HDC plant, gleich zu Beginn der Vermarktungsphase mit der Präsentation von Artikeln und Präsentationen auf kommenden Konferenzen zu beginnen. Auf Grund des Erfolgs der klinischen Studien zu diesem Prostatakrebstest plant das Unternehmen eine Studie unter Verwendung von Urinproben, um den Indikationsbereich dieses neuen Prostatakrebstests auf die Verwendung als Screening-Tool zu erweitern, was die derzeitigen Vermarktungschancen des Tests bedeutend verbessern könnte, da hierdurch alle Männer, bei denen ein Risiko für Prostatakrebs besteht, eingeschlossen würden.

Über die Health Discovery Corporation

Die Health Discovery Corporation (OTCBB: HDVY) mit Sitz in Savannah ist im Bereich der Mustererkennungstechnologie einzigartig positioniert. Durch die Anwendung ihrer patentgeschützten Technologie ist HDC ein Marktführer in der Entwicklung SVM-basierter molekulardiagnostischer und prognostischer Tests in der Genomik und Proteomik sowie in der Digitalbildanalyse in der Pathologie und Radiologie. SVM- und FGM-Mustererkennungstechnologien von HDC haben ein hohes Anwendungspotenzial in anderen umfangreichen kommerziellen Märkten, wie z. B. in den Bereichen Ölentdeckung, Finanzwesen, Internetsuche und Spam, innere Sicherheit sowie auf anderen Gebieten, welche die Analyse großer Mengen komplexer Daten erfordern. www.healthdiscoverycorp.com

Diese Pressemitteilung enthält ,,zukunftsbezogene Aussagen" im Sinne von Absatz 27A des Securities Act aus dem Jahr 1933 und von Absatz 21E des Securities Exchange Act aus dem Jahr 1934. Obwohl die Geschäftsführung von HDC der Ansicht ist, dass die in diesen zukunftsbezogenen Aussagen zum Ausdruck gebrachten Erwartungen begründet sind, kann sie nicht gewährleisten, dass sich diese Erwartungen erfüllen werden.

Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.



Autor: © Business Wire

[talis]

Es gibt wieder eine News zu melden

Press Release Source: Health Discovery Corporation

New Prostate Cancer Test to be Presented at Biomarker Discovery Europe 2008 Conference
Monday August 11, 9:14 am ET
Health Discovery Corporation's New Molecular Diagnostic Test for Prostate Cancer will be Presented at the Upcoming Biomarker Discovery Europe 2008 Conference in Dublin, Ireland on October 2-3

In Gänze hier:
http://biz.yahoo.com/bw/080811/20080811005413.html?.v=1

Man bereitet gerade den Productlaunch vor.
Das bedeutet Einnahmen. Dem Fundamentalisten sagt das was.

Wenn man´s charttechnisch betrachtet stehen wir vor einem lupenreinen Turnaround.

Es drängt sich auch ein philosophischer Standpunkt auf, der besagt, man macht sich zunutze mit dem IP in der Lage zu sein, aus grossen Datenmengen die signifikanten Daten herauszufiltern. Dabei setzt HDC den Schwerpunkt auf die Entdeckung von biomarkern. Um alles andere kümmert sich jetzt Patent Profit International.

[talis]

Press Release Source: Health Discovery Corporation

Health Discovery Corporation's Newest U.S. Patent Covers SVM-Based Analysis of Medical Images
Tuesday August 12, 9:10 am ET
Focus on Cytopathology Touches One of the Fastest Growing Areas of Diagnostic Testing

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (“HDC”) (OTCBB: HDVY - News) today announced that the United States Patent and Trademark Office has granted Patent No. 7,383,237 on HDC’s claims covering the use of Support Vector Machines (SVM’s) in computer-aided image analysis for analysis of digitized microscopic images of medical specimens. This new patent is a continuation of HDC’s Patent No. 6,996,549, which covers a broad range of uses of SVM’s for image analysis.

The claims of HDC’s newest patent focus on a method and computer system for analyzing medical images generated during microscopic evaluation of cytology specimens and tissue samples. Examples of commercial diagnostic and prognostic applications of the patented technology include circulating cell screening and cytopathology slide analysis, among others. Circulating tumor cells (CTCs) and/or circulating epithelial cells (CECs) in the blood of cancer patients have proven to be a strong, independent predictor of Overall Survival (OS) and Progression Free Survival (PFS). These cells can also be used for serial monitoring of patients for improved clinical management of metastatic cancer. Circulating cell analysis involves the generation of large numbers of microscopic “snapshots” of a sample chamber containing the patient’s blood. Currently, a small number of these snapshots are then selected for visual examination by a technologist or pathologist. However, SVM-aided image analysis using the patented method could permit automated and rapid analysis of all of the sample images, greatly increasing the sensitivity and accuracy of such tests.

Cancer screening using cervical cytology slides (“Pap Smear” testing) and pathological evaluation of biopsied tissue are important applications of the patented technology which are the subject of the recently-announced license, development and commercialization agreement between HDC and DCL Medical Laboratories, LLC, which includes a license under HDC’s newest patent. The patented SVM-based imaging method is expected to improve the sensitivity of detection for endometrial and cervical cancers and significantly improve the specificity of ovarian cancer diagnosis. The new CAD-based digital pathology SVM-based algorithms could offer a faster, highly objective, and more accurate interpretation of cells to assist pathologists in making correct diagnoses for physicians and their patients.

“This new patent goes to the heart of HDC’s vision of redefining the relationships between diagnostics and treatments for personalized medicine using our state-of-the-art SVM technology,” said Stephen D. Barnhill, MD, Chairman and CEO of HDC. “The U.S. cytology market was estimated to be approximately $2 billion in 2006 and continues to grow at a rapid pace. Our SVM-based image analysis provides a valuable tool for every facet of this market, assisting pathologists in clinical laboratories, hospitals, academic centers and medical/pharmaceutical industries by providing an accurate, objective diagnostic interpretation to physicians for their patients. We expect the technology to have enormous value as a ‘second opinion,’ so much so that insurers might even make the analysis a mandatory part of every cytopathology test.”

With the issuance of this new patent, Health Discovery Corporation now holds the exclusive rights to 31 issued U.S. and foreign patents covering uses of SVM and FGM (fractal genomics modeling) technology for discovery of knowledge from large data sets. Other patents issued to HDC cover methods and systems for pre-processing of data to enhance knowledge discovery using SVM’s, analysis of data using multiple support vector machines and for multiple data sets, and providing SVM analysis services over the Internet. HDC’s pending U.S. and foreign patent applications cover numerous improvements to, and applications of, SVM’s including computer-aided image analysis using SVM’s, methods of feature selection for enhanced SVM efficiency and biomarkers for colon cancer, prostate cancer, BPH and renal cancer discovered with these methods, and the use of SVM’s for analysis of spectral data, such as mass spectrometry data used for protein analysis.

About Health Discovery Corporation

Savannah-based Health Discovery Corporation (OTCBB: HDVY - News) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a leader in SVM-based molecular diagnostic and prognostic test development in genomics and proteomics, as well as, digital image analysis in pathology and radiology. The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as oil exploration, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required. www.healthdiscoverycorp.com.

This news release contains “forward-looking statements” within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the respective management teams of HDC and DCL believe that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct. DCL and HDC do not assume any obligation to update any forward-looking statements or other information contained in this document.


Contact:

Health Discovery Corporation
Stephen D. Barnhill, MD, CEO, 912-443-1987
[e-mail]
www.healthdiscoverycorp.com

Source: Health Discovery Corporation

[talis]

Clarient Inc. (NASD: CLRT) recently published their 2008 Corporate
presentation. http://www.clarientinc.com/Default.aspx?tabid=59
Below is the information released in this presentation concerning the
Prostate Cancer test in which HDC will receive a 30% royalty.


Initial indication for PSA +, Biopsy negative patients

Results of Clinical Validation Studies:
- All four genes exhibit moderate to abundant expression in prostate tissue
- HSPD1 and IMPDH2 appear to have similar expression levels (moderate)
- PDLIM5 and UAP1 appear to have similar expression levels (abundant)
- Small tissue biopsies provide sufficient RNA for analysis
- Study Results:
- 322 tissues analyzed; Positive, negative
- 90% sensitivity for correctly identifying the presence of Grade 3 or
higher prostate cancer cells
- 97% specificity for correctly identifying non-cancer cells (normal
and BPH)

Market Size:
€ ~ 1,000,000 prostate biopsies annually/600,000 negative after first biopsy
€ With a 97% specificity our test -men that do not specificity, can rule out
the 25 to 35% of need a second biopsy
- 150,000 biopsies saved @ ~$4,000/biopsy = $600M potential annual
savings to healthcare industry
€ Total Available Market: 600,000 samples x $750 per test = $ 450M Total
Market Opportunity

Next Steps:
€ Finalize our CLIA documentation-
€ Initialize our commercial launch process
- Begin submitting papers for publication
- Present data at upcoming industry conferences
- Prepare sales and marketing plan

[talis]

Antwort auf Beitrag Nr.: 34.772.415 von talis am 20.08.08 06:03:21

Rechnen wir doch mal nach,
von Clarient geschätztes Marktvolumen des Prostatakrebstest ist 450 Mio $

Sollte man 10% erreichen, bekommt Health Discovery über die royalties 13,5 Mio $. Das ist in etwa der jetztige Börsenwert von HDC.

[talis]

Zur Erfolgsgeschichte des Dr. Richard Caruso findet Ihr weiter vorne was im thread. Der Mann weiss genau, was er tut.



Press Release Source: Health Discovery Corporation

Smart Personalized Medicine, LLC, Founded by Dr. Richard Caruso, Signs Agreement with Health Discovery Corporation to Work to Develop New Breast Cancer Prognostic Test
Friday August 29, 9:20 am ET
Health Discovery Corporation to Receive a Fifteen Percent Equity Position in Smart Personalized Medicine, LLC and Will Receive Royalties Paid on a Per Test Basis from Breast Cancer Prognostic Tests Performed

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (“HDC”) (OTCBB: HDVY - News) today announced that it has signed a Licensing Agreement with Smart Personalized Medicine, LLC, founded by Dr. Richard Caruso, Chairman and Founder of Intergra Life Sciences (NasdaqGS:IART - News) to work to develop a superior breast cancer prognostic test using HDC’s support vector machine (SVM) technology in collaboration with MD Anderson Cancer Center.

Under the terms of the Agreement, HDC will receive a 15% equity position in Smart Personalized Medicine, LLC based on up to a $5 million initial investment from Smart Personalized Medicine, LLC investors. In addition, HDC will receive a per test royalty up to 7.5% based on Net Proceeds received from the sale of the new breast cancer prognostic test.

“Now that a formal License Agreement has been signed between Smart Personalized Medicine and HDC, we are ready to begin immediate development of what we believe could become a superior breast cancer prognostic test using HDC’s SVM technology,” stated Dr. Richard Caruso, CEO of Smart Personalized Medicine. “If our efforts prove successful, HDC shareholders can greatly benefit from this exciting development.”

“This is a tremendous opportunity for HDC to participate with Dr. Caruso as he pursues his goal to develop a superior breast cancer prognostic test to compete with other such tests like OncotypeDX provided by Genomic Health (NasdaqGM: GHDX - News),” stated Dr. Stephen Barnhill, Chairman and CEO of Health Discovery Corporation. “With Dr. Caruso’s successful track record as Chairman of the Board and Founder of Integra Life Sciences (NasdaqGS:IART - News) and honored as the National Ernst & Young Entrepreneur Of The Year in 2006, HDC shareholders should greatly benefit from his experience and determination as he sets his sights on using HDC’s SVM technology to develop a new and improved breast cancer prognostic test to predict the right treatment for the right patient at the right time – the essence of Personalized Medicine.”

About Health Discovery Corporation

Savannah-based Health Discovery Corporation (OTCBB: HDVY - News) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a leader in SVM-based molecular diagnostic and prognostic test development in genomics and proteomics, as well as, digital image analysis in pathology and radiology. The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as oil exploration, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.

www.healthdiscoverycorp.com.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct.


Contact:

Health Discovery Corporation
Stephen D. Barnhill, MD, CEO, 912-443-1987
[e-mail]
www.healthdiscoverycorp.com

Source: Health Discovery Corporation

[talis]

Schaut euch doch mal die Finanzierung vom letzten Jahr an.
Es gibt hier keine Convertibles!

HDC ist ein Megaschläfer.

Die Markteinführung des Prostatakrebstest steht kurz bevor.
Dann heisst es Aufwachen!

[talis]

jetzt ging der Kurs erst mal wieder runter auf 0,05 $

ich kann´s mir nur so erklären
Dr. Barnhill geht aufs Ganze
das gefällt mir an diesem Unternehmen

[alysant]

Mein beiläufiger Gesamteindruck des Ladens:

seriös

Damit hebt er sich schon mal von der Masse der penny stocks ab !

[alysant]

0.049 vol 152.000

H/T

0.050
0.041

mein Gefühl:

wieder Kaufkurse, nach der allgemeinen Vermögensvernichtung könnten exotische Werte, die nicht Betrug von Haus aus sind, durchaus wieder für den kleinen Geldbeutel interessant werden.

[talis]

Antwort auf Beitrag Nr.: 35.539.102 von alysant am 12.10.08 18:16:34

es gibt eine komplett neugestaltete homepage, mit eigenem message board

http://www.healthdiscoverycorp.com/

ausserdem nochmal eine Pressemitteilung, die darauf hindeutet, dass alles nach Plan läuft.
Das macht nicht den Eindruck als wäre HDC gegen die Wand gefahren.

[talis]

Health Discovery hat sich Personalisierte Medizin auf die Fahnen geschrieben und sollte Barack Obama die Wahl gewinnen, könnte Fantasie in HDC kommen.

http://www.personalizedmedicinecoalition.org/sciencepolicy/p…

[alysant]

Antwort auf Beitrag Nr.: 35.593.280 von talis am 16.10.08 16:51:13

Obama gewinnt mit großem Vorsprung:

Fahrt frei für Phantasie

[talis]

http://biz.yahoo.com/pz/081106/154018.html

Health Discovery Corporation: Four Genes Comprising the New Molecular Diagnostic Signature for Prostate Cancer Successfully Identified in Urine
Thursday November 6, 9:40 am ET
These Promising Results Could Lead to a New Urine Based, Non-Invasive Screening Test for Prostate Cancer

SAVANNAH, Ga., Nov. 6, 2008 (GLOBE NEWSWIRE) -- Health Discovery Corporation (``HDC'') (OTC BB:HDVY.OB - News) today announced that the RT-PCR assay for the four genes comprising HDC's recently commercialized gene-based molecular diagnostic test for prostate cancer, which is currently available at Clarient Inc.'s (NasdaqCM:CLRT - News) Clinical Laboratory, can be successfully used in urine samples for gene testing.

The study, completed in collaboration with MD Anderson Cancer Center, demonstrated that the gene expression of all four genes comprising the molecular signature for clinically significant prostate cancer could be detected in urine samples spiked with as few as 50 prostate cancer cells.

These are the same genes in HDC's recently commercialized molecular diagnostic test for prostate cancer. Results from Phase I, Phase II and Phase III double-blinded clinical validation studies completed with prostate tissues obtained from multiple sites, including those tested in collaboration with MD Anderson Cancer Center demonstrated a very high success rate for identifying the presence of Grade 3 or higher prostate cancer cells (clinically significant cancer), as well as, normal and BPH (benign prostatic hyperplasia) cells. To date, 322 prostate tissues have been tested. The combined results of the recently completed double-blinded clinical validation studies demonstrated that the new gene-based molecular diagnostic test for prostate cancer achieved a Sensitivity of 90% for correctly identifying the presence of Grade 3 or higher prostate cancer cells, and a Specificity of 97% for correctly identifying non-cancer cells (normal and BPH), representing an overall test accuracy of 93%.

``We are very pleased that the results of our clinical trial demonstrated that the four genes comprising HDC's recently commercialized molecular diagnostic test for prostate cancer could indeed be successfully identified in urine,'' stated Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. ``Based on these initial findings, we intend to immediately begin clinical testing to confirm these successful findings in a larger clinical trial. If the results of the larger clinical trial confirm these initial findings in urine, we believe that this could lead to the rapid development of a more accurate screening test for prostate cancer to compete in the PSA market where more than 45 million PSA tests are performed annually worldwide.''

Dr. Barnhill continued, ``In addition to HDC's recently commercialized molecular diagnostic test for prostate tissue biopsies, this would be HDC's second molecular diagnostic test for prostate cancer which could be used for screening all patients at risk for prostate cancer.''

The molecular diagnostics market is the fastest-growing segment of the in vitro diagnostics industry. In little more than a decade, the clinical market for molecular diagnostic products has increased from less than $50 million to over $1 billion. The worldwide in vitro serum cancer diagnostic market is US$800 million and growing at a rate of 7% per year. Therefore, the prospect of identifying novel markers for early detection of various cancer types will have a significant impact on the diagnostic market. Prostate cancer is the second leading cause of cancer mortality among men in the United States behind lung cancer. According to the American Cancer Society, 232,000 new cases of prostate cancer will be diagnosed in the U.S. and an estimated 30,350 deaths will occur from this disease. Furthermore, more than 350,000 patients worldwide are diagnosed with prostate cancer every year.

PSA sales represent about 40% of all annual cancer serum biomarker revenues with an estimated $320 million in sales. However, it is estimated that PSA levels can generate as many as 75% false positives, resulting in an estimated 750,000 unnecessary prostate biopsies being performed in the U.S. each year. Therefore, identifying new and improved diagnostics for prostate cancer is imperative.

Thomas A. Stamey, MD, Founding Chairman of the Stanford University Urology Department stated, ``We need to recognize that PSA is no longer a marker for prostate cancer.'' Dr. Stamey continued, ``We urgently need to find a new marker for prostate cancer, and that marker must be proportional to how much cancer you have.''

``The excellent results seen in this initial study to identify the presence of the gene expression of the four genes comprising the molecular diagnostic test for prostate cancer in urine validate the robustness of these genes,'' stated Dr. Herbert Fritsche, Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas. ``If these initial promising results are validated in a larger clinical study, these findings could lead to a non-invasive screening test for clinically significant prostate cancer.''

About Health Discovery Corporation

Savannah-based Health Discovery Corporation (OTC BB:HDVY.OB - News) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a leader in SVM-based molecular diagnostic and prognostic test development in genomics and proteomics, as well as, digital image analysis in pathology and radiology. The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as oil exploration, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required. http://www.healthdiscoverycorp.com

The Health Discovery Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5506

This news release contains ``forward-looking statements'' within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct.


Contact:

Health Discovery Corporation
Stephen D. Barnhill, MD, CEO
912-443-1987
[e-mail]
www.healthdiscoverycorp.com

Source: Health Discovery Corporation

[talis]

da steht jemand
im bid bei

0,055 $

und lässt sich nicht vertreiben

[talis]

der Test ist am Markt, wurde auch Zeit



http://finance.yahoo.com/news/Clarient-Launches-Gene-bw-1404…



Clarient Launches Gene Expression Test for Prostate Cancer
Gene Profile Discovered By Health Discovery Corporation Will Provide Molecular Confirmation of Gleason Grade 3 and 4 Cancer Cells in Prostate Biopsies

* Tuesday January 13, 2009, 6:00 am EST

* Yahoo! Buzz
* Print

Related:

* Clarient, Inc.
* , Health Discovery Corp.
* , Safeguard Scientifics, Inc.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Clarient, Inc. (Nasdaq: CLRT - News), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, today announced the commercial launch of its new gene expression test for prostate cancer. This new test will be available through Clarient’s PATHSiTETM virtual reporting tool and accessible to the company’s entire pathology network
Related Quotes
Symbol Price Change
CLRT 1.56 +0.03
Chart for Clarient, Inc.
HDVY.OB 0.05 +0.02
Chart for HEALTH DISCOVERY CP
SFE 0.69 -0.02
Chart for SAFEGUARD SCIENTIFIC
{"s" : "clrt,hdvy.ob,sfe","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Clarient’s new test is based on a unique and patent protected combination of four genes that have been shown to accurately identify the presence of Grade 3 or higher (clinically significant cancer) prostate cancer cells in prostate tissue. The association of these four genes with prostate cancer was discovered by Health Discovery Corporation (OTCBB: HDVY - News) using their patented SVM and SVM-RFE pattern recognition technology.

“Clarient is proud to be a leader in offering the latest in cancer diagnostic testing, allowing patients to avoid unnecessary toxicities and treatment delays, while lowering the overall cost of therapy,” stated Ron Andrews, Clarient's Chief Executive Officer. “The solid results from our clinical validation study confirm our belief that this powerful genomics-based test may assist physicians in the tissue diagnosis of prostate cancer. Working with Health Discovery Corporation, we have now completed the scientific paper documenting our validation results and have submitted our work to a respected international medical journal for peer review and publication which will be paramount to our marketing efforts.”

Today, the two companies also announced that in order to insure market uptake of the new prostate cancer test, they will transition to a non-exclusive agreement to allow for licensing to additional laboratories. Under the amended agreement, Clarient will retain the exclusive rights for a prognostic test which may be developed in the future in conjunction with Health Discovery Corporation.

Commenting on the amended agreement, Andrews stated, “To drive the utility of new clinical laboratory tests to a standard-of-care position requires significant marketing efforts and resources. Both Health Discovery Corporation and Clarient believe that opening up the playing field for this new prostate cancer test will encourage market uptake helping to achieve the standard-of-care objective.”

Andrews concluded, “Clarient is focused on delivering high-value content for cancer management through the community pathologist. Clarient has a solid track record of success marketing non-exclusive tests as evidenced by our recent success with KRAS. Clarient continues to study additional markers that may influence a cancer pathway, and looks forward to introducing new tests that will help our client base further deliver the promise of personalized medicine.”

“We are excited to announce that Clarient is now formally launching HDC’s molecular diagnostic test for prostate cancer,” stated Stephen D. Barnhill, MD, Chairman and CEO of Health Discovery Corporation. “In order to achieve a more rapid market uptake, we look forward to having additional clinical laboratories join Clarient in promoting and performing this new prostate cancer test in the near future.”

According to Dr. Barnhill, “Prostate cancer biopsies are not easy to interpret. When a biopsy is labeled atypical, which happens in about 5 percent of biopsies at most institutions, it means that a pathologist sees something that could be cancer, but isn’t sure that it’s definitely cancer. The other end of this vexing spectrum is that physicians seem just as likely to over-diagnose cancer. There are many mimickers of prostate cancer under the microscope, and people not as familiar with prostate biopsies as specialists in urologic pathology can diagnose cancer when it’s not actually present.”

In a recently published document, physicians at Johns Hopkins Medical Center reported that in a six month period they looked at 3,000 patients’ prostate cancer biopsies, almost 700 of which were sent at the request of either the patient or the urologist. Overall, the expert uropathologists at Johns Hopkins changed the diagnosis about 35 percent of the time, and these were not cases in which the pathologist appeared to have difficulty diagnosing the case.

Dr. Barnhill continued, “The high sensitivity and specificity demonstrated in the validation results of our new prostate cancer test suggest that this new molecular diagnostic could assist physicians in more accurately identifying the presence of prostate cancer in patients with both positive and negative biopsies.”

Prostate Profile Clinical Validation Studies Results

The final results from the combined clinical validation studies were previously announced in August 2008. The studies were performed on prostate tissues obtained from multiple sites, including those tested in collaboration with a prestigious cancer center and Clarient demonstrated the ability to accurately identify the presence of Grade 3 or higher prostate cancer cells (clinically significant cancer). 71 out of a total of 322 prostate tissues tested, were validated at Clarient, and the results provide evidence of the gene set’s ability to help confirm the presence of high grade prostate cancer at a molecular level. The Prostate Gene Expression Profile uses expression values from four genes variably expressed in cancer cells as inputs to a mathematical classifier. In the clinical validation study, the new gene-based molecular diagnostic test achieved a sensitivity of 90% for correctly identifying the presence of Grade 3 or higher prostate cancer, and a specificity of 97% for correctly identifying non-cancer tissue (normal and BPH), representing an overall test accuracy of 93%.

In the United States alone, there are over 1 million prostate cancer tissue biopsy procedures performed annually. Approximately 25% of these tissue biopsies are reported "positive", indicating the presence of prostate cancer. The other 75% of prostate cancer tissue biopsies are reported as "negative" for the presence of cancer. However, one-third of the men with initial prostate cancer tissue biopsies that are reported as "negative" for prostate cancer actually do have prostate cancer that was missed by the first biopsy (False Negative).

About Clarient

Clarient combines innovative technologies with world class expertise to assess and characterize cancer. Clarient’s mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company’s principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics partner company. www.clarientinc.com

About Health Discovery Corporation

Savannah-based Health Discovery Corporation (OTCBB: HDVY - News) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a leader in SVM-based molecular diagnostic and prognostic test development in genomics and proteomics, as well as, digital image analysis in pathology and radiology. The Company's patent-protected discovery method allows us to develop molecular diagnostic and prognostic tests that are free of outside intellectual property rights and thereby allows HDC to fully patent protect in-house discovered molecular diagnostic gene signatures. The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as oil exploration, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required. www.healthdiscoverycorp.com

About Safeguard Scientifics

Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc. (NYSE: SFE - News) provides growth capital for entrepreneurial and innovative technology and life sciences companies. Safeguard targets technology companies in Software as a Service (SaaS) / Internet-based Businesses, Technology-Enabled Services and Vertical Software Solutions, and life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices and Specialty Pharmaceuticals with capital requirements between $5 and $50 million. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. www.safeguard.com

Forward-Looking Statements

The statements herein regarding Clarient, Inc. (the “Company”) contain forward-looking statements that involve risks and uncertainty. Future events and the Company’s actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to: the Company’s ability to market and fund continued development of this new genomics-based diagnostic test for prostate cancer, the Company’s ability to obtain third party payer reimbursement for this test, the efficacy of the test once introduced in the marketplace and the acceptance of this test by physicians and patients, failure to obtain any requisite regulatory clearances or approvals, the Company’s ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, and risks detailed from time to time in the Company’s SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to laboratory services, revenues and results of operations may not be indicative of future results for the reasons set forth above.

The company does not assume any obligation to update any forward-looking statements or other information contained in this document.

Contact:

Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
[e-mail]
or
Health Discovery Corporation
Stephen D. Barnhill, M.D.
[e-mail]

[talis]

Urologen jetzt mal hergehört, vor allem die, die Privatpatienten betreuen. Es gibt einen neuen Prostatakrebstest für 250$. Ergänzend zum PSA Test.

Details wie folgt.


http://www.clarientinc.com/Default.aspx?tabid=403


Prostate Gene Expression Profile



Methodology
Real-time RT-PCR

Specimen Requirements
Formalin-fixed, paraffin-embedded tissue


Highlights

* Sensitivity of 90% for correctly identifying the presence of grade 3 or higher prostate cancer
* Specificity of 97% for correctly identifying normal tissue (normal and BPH)
* Overall test accuracy of 93%


Indications for Use
Assist in the confirmation of grade 3 or higher prostate cancer in the tissue biopsy


Clinical Indications
Perform on prostate biopsies to aid the pathologist in the molecular confirmation of prostate cancer


Clinical Significance
Prostate cancer is a deadly disease. There are an estimated 200,000 new cases and 25,000 deaths from prostate cancer each year in the US alone.1 While most men diagnosed with prostate cancer will not die as a result of this disease, Gleason grades 3 and 4 cancer cells (graded on a scale of 1 to 5) which are identified at biopsy are generally recognized as aggressive cancers that require treatment. Through this discovery approach, we have identified a diagnostic molecular signature consisting of only four genes, and have designed a practical, cost effective RT-PCR assay which is highly accurate for detecting the presence of grade 3 or 4 cancer cells in prostate biopsy tissue.2

Clarient’s Prostate Gene Expression test has been shown to identify prostate cancer at a molecular level. After microscopic review of prostate biopsies, the Prostate Gene Expression test uses a number of common cancer genes to assess the underlying molecular profile of the tissue. The result from this test can further confirm the microscopic evaluation of the biopsy.

Turnaround Time
5-7 days

References

1. NCI (2007 National Cancer Institute statistics)
2. Guyon, I., Fritsche, H., Choppa, P. et. al; A Four-Gene Signature For Prostate Cancer Cells: UAP1, PDLIM5, IMPDH2, and HSPD1 (2008); Submitted for publication

[talis]

zwei sehr gute News

http://finance.yahoo.com/news/Health-Discovery-Corporation-b…


Health Discovery Corporation Licenses New Prostate Cancer Test to Abbott

* Thursday February 5, 2009, 5:52 pm EST

Related:

* Abbott Laboratories
* , Health Discovery Corp.

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (OTCBB: HDVY - News) today announced that it has entered into an agreement with Abbott (NYSE: ABT - News) to commercialize HDC’s new molecular diagnostics gene-based tests for clinically significant prostate cancer. Abbott has acquired co-exclusive clinical laboratory rights and exclusive in vitro diagnostic rights for commercialization of HDC’s tissue-based prostate cancer test as well as HDC’s urine-based prostate cancer test.
Related Quotes
“We are very pleased to partner with Abbott on commercialization of these exciting new molecular diagnostic tests for prostate cancer,” said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “Abbott is an innovative leader in the fast paced, high growth medical technology space serving customers around the world.”


http://finance.yahoo.com/news/Health-Discovery-Corporation-b…

Health Discovery Corporation Licenses Biomarkers for Noninvasive Urine-Based Prostate Cancer Test to Quest Diagnostics

* Thursday February 5, 2009, 5:51 pm EST

Related:

* Quest Diagnostics Inc.
* , Health Discovery Corp.

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (OTCBB:HDVY - News), a molecular diagnostics company, today announced that it has licensed rights to develop a new urine-based test for clinically significant prostate cancer to Quest Diagnostics Incorporated (NYSE: DGX - News), the world’s leading provider of diagnostic testing, information and services. Under the terms of the agreement, HDC will receive payments, royalties and additional undisclosed financial considerations.
“We are pleased to work with Quest Diagnostics on the development of an exciting new noninvasive test for clinically significant prostate cancer,” stated Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “Quest Diagnostics performs testing for more than half a million patients each day, serving approximately half of the physicians and hospitals in the United States. It is an ideal clinical laboratory to use our markers for developing a test as an aid in detecting prostate cancer."

Prostate cancer is the second leading cause of cancer mortality among men in the United States behind lung cancer. According to the American Cancer Society, 232,000 new cases of prostate cancer will be diagnosed in the U.S. and an estimated 30,350 deaths will occur from this disease. Furthermore, more than 350,000 patients worldwide are diagnosed with prostate cancer every year. More than 45 million PSA blood tests are currently performed annually worldwide.


Das Ganze gibt es auch als filing

http://biz.yahoo.com/e/090205/hdvy.ob8-k.html

[alysant]

0.09 vol. 400.000

H/T

0.10
0.08

[talis]

Antwort auf Beitrag Nr.: 36.528.868 von alysant am 06.02.09 16:19:31

alysant,

im Vergleich zu den toten Pferden, die bei WO geritten werden bis sie zum Schimmel werden ist das hier doch eine ganz andere Spezies.

Nicht wahr?

[alysant]

Antwort auf Beitrag Nr.: 36.535.135 von talis am 07.02.09 22:48:13

wohl wahr

[Bachalor]

[talis]

von der Idee
zum Patent
über die Entwicklung
zum Produkt
und letztendlich zur Markteinführung

Wer an der OTC glaubt Ihr bekommt das sonst noch hin?

[talis]

...andächtiges Lauschen...

[alysant]

Antwort auf Beitrag Nr.: 36.603.525 von talis am 18.02.09 15:24:49

eher vergleichbar mit der Stille an Weihnachten kurz vor der Bescherung

[talis]

Antwort auf Beitrag Nr.: 36.603.610 von alysant am 18.02.09 15:32:03

vielleicht sollten wir doch besser bei der Fachsprache bleiben.

Wenn Du das nämlich so sagst, versteht das sogar der Brötchenbumser.

Nicht das der aus Versehen noch was richtig macht

[talis]

was die Verwendung eines moeglichen Gewinns angeht

lass ich mich gerne von den Berufskollegen des kürzlich erschienenen Fuchs auf Deutschlands Boersensender Nr. 1 beraten

hab auch keine Lust als der reichste Mann auf dem Friedhof in die Geschichte einzugehen

[Fortschritt]

" target="_blank" rel="nofollow ugc noopener">http://finance.yahoo.com/news/Health-Discovery-Corporation-bw-183094673.html?x=0&.v=1

[Stayc]

Die Rakete ist geatartet - Kann nur up gehen! Bei den News

[Pennystockchampion]

Handel 25% über Pari, erstaunlich...

Penny

[talis]

http://finance.yahoo.com/news/Health-Discovery-Corporation-b…

die Sache nimmt Gestalt an

[talis]

enjoy the ride

[Fortschritt]

Es kommt was ganz grosses auf uns zu

[gweschl]

...das teil wird in den nächsten tagen laufen....sollte man noch schnell einsteigen.

[talis]

Wenn man die Ergebnisse mit denen von Epigenomics vergleicht ist leicht ersichtlich, dass HDVY den besseren Test auf Darmkrebs entwickelt.


http://finance.yahoo.com/news/Health-Discovery-Corporation-b…

Health Discovery Corporation Inks Deal for Final Validation of a New Molecular Diagnostic Test for Colon Cancer


SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (OTCBB: HDVY) announced today that the Company has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to provide clinical specimens to be utilized to complete the final validation of HDC's molecular diagnostic test for colon cancer. This test demonstrated a 93% Sensitivity and a 93% Specificity in a previous validation study.

Today’s announcement is in addition to last week’s press release announcing a new collaboration with the Pancreas, Biliary and Liver Surgery Center of New York related to the discovery of a new molecular diagnostic test for pancreatic cancer.

There are an estimated 1.2 million new cases of colorectal cancer worldwide and approximately 637,000 deaths from the disease.

“We are very excited about the results of our previous validation study and look forward to achieving the same success in this final validation," said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “If we are successful in finding the molecular signature in blood as we were in tissue, HDC will have both a tissue-based colon cancer test to be used on biopsy specimens as well as a blood test which can be used as a screening test for colon cancer,” said Dr. Barnhill.

Under the terms of the agreement, the Pancreas, Biliary and Liver Surgery Center of New York will provide specimens from their collected specimen banks, as well as blood and tissue specimens on all new patients along with all associated clinical and outcomes data.

Health Discovery Corporation owns all of the intellectual property and commercialization rights to this molecular diagnostic test for colon cancer and HDC intends to partner with a large clinical laboratory for development, marketing and commercialization of this new colon cancer test.

In developing this new molecular diagnostic test for colon cancer, Health Discovery Corporation employed the same discovery process that led to the urine-based prostate cancer test that is licensed for development and commercialization to Quest Diagnostics (NYSE: DGX - News) and Abbott (NYSE: ABT - News) on a royalty-based, world-wide co-exclusive basis.

About Health Discovery Corporation

Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com.

[talis]

http://finance.yahoo.com/news/OVA1-Blood-Test-Now-Available-…



..und das mit einer Technologie von HDVY

[talis]

http://finance.yahoo.com/news/Health-Discovery-Corporation-b…

Health Discovery Corporation and Smart Personalized Medicine Form Agreement for Developing Laboratory Tests for Breast Cancer Therapy Selection with Quest Diagnostics

Eine weitere Kooperationvereinbarung zwischen Quest und Health Discovery zur Entwicklung eines Brustkrebstests wurde gestern gemeldet.

Ich bewerte dies als Bestätigung dafür, dass der Prostatakrebstest auf gutem Weg ist, sonst hätte Quest sich ja wohl kaum darauf eingelassen, die Zusammenarbeit zu intensivieren.

[talis]

Health Discovery Corporation Appoints Maher Albitar M.D., Former Medical Director of Hematology and Oncology and Chief of Research and Development at Quest Diagnostics, Chief Medical Officer

http://finance.yahoo.com/news/Health-Discovery-Corporation-b…

Der ehemalige Forschungsleiter von Quest Diagnostics wird Chief Medical Officer von Health Discovery. So einen Wechsel von einem Unternehmen mit einer Marktkapitalisierung von 10 Mrd. zu einem Unternehmen mit einem Börsenwert von 33 Mio sieht man auch nicht alle Tage. Auch dies sagt mir, das würde nicht passiert sein, wenn der urinbasierte Prostatakrebstest sich als Flop erweist.

[talis]

http://biz.yahoo.com/e/100802/hdvy.ob8-k.html

Entry into a Material Definitive Agreement


Item 1.01 Entry Into a Material Definitive Agreement.

As previously disclosed, the Company has received numerous letters from the lead purchaser (the "Investor") in the Company's 2007 private placement ("2007 Private Placement"), claiming, among other things, (a) that rights to receive up to 146,664,375 additional shares of the Company's common stock for no additional consideration have been triggered by certain actions of the Company, (b) breaches of its contractual rights to approve certain issuances of options and warrants, (c) breaches of other covenants made by the Company in the 2007 Private Placement, (d) the Company had violated its SEC disclosure obligations, and (e) various breaches by the members of the Board of Directors of their fiduciary duties.

The Company denied the Investor's claims and allegations. However, due to the expense, distraction and uncertainty of potential litigation regarding the claims, the Company negotiated a settlement with the Investor, effective July 27, 2010. Pursuant to the settlement agreement, the Company agreed, among other things, to (a) pay $145,625 to cover certain expenses of the Investor, (b) credit $1,134,375 to cover the aggregate exercise price of warrants to purchase 6,875,000 shares of the Company's common stock held by the Investor, (c) issue to the Investor a new two year warrant to purchase an additional 6,875,000 shares of common stock at an exercise price of $0.17 per share, and (d) file a registration statement covering the resale of the shares of common stock underlying the new warrant. In exchange, the Investor agreed, among other things, to (a) release the Company and certain related persons from all claims through the date of the settlement (including the claims relating to the 2007 Private Placement), (b) waive all future rights under the 2007 Private Placement agreements, and (c) standstill from certain actions related to the Company and its equity securities for a period of five years from the date of settlement. Neither the Company nor the Investor admitted liability or wrongdoing in connection with the settlement.

The Company expects to recognize a charge of approximately $1.9 million related to the settlement, including approximately $598,000 in non-cash charges related to the issuance of the new warrant.



Der Streit mit einem der Private Placement Investoren aus dem Jahr 2007 wurde
nun mit einem Vergleich beigelegt.
Der Markt kommentiert das mit einem Gähnen

[talis]

unbedingt lesen!!

Health Discovery Corporation 2010 Shareholder Letter


http://finance.yahoo.com/news/Health-Discovery-Corporation-b…

[talis]

http://finance.yahoo.com/news/Health-Discovery-Corporation-b…

Health Discovery Corporation Awarded a $244,479.25 Qualifying Therapeutic Discovery Project (QTDP) Grant Under the Patient Protection and Affordable Care Act of 2010
businesswire

*
Share
*
retweet
* Email
* Print

*
Companies:
o Health Discovery Corp.


Press Release Source: Health Discovery Corporation On Tuesday November 2, 2010, 2:26 pm EDT

SAVANNAH, Ga.--(BUSINESS WIRE)-- Health Discovery Corporation (OTCBB:HDVY.ob - News) is pleased to announce that it has been awarded $244,479.25 by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of the company's SVM and RFE-SVM technology. The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in new therapies, to treat areas of unmet medical need, or to prevent, detect, or treat chronic or acute diseases and conditions, or to reduce long-term health care costs in the United States, or to significantly advance the goal of curing cancer

“Our patented and award-winning technology is creating innovative molecular diagnostic tests, such as our urine-based 4-gene biomarker discovery for clinically significant prostate cancer,” said Stephen D. Barnhill, M.D., Chairman and CEO, Health Discovery Corporation. “HDC's new 4-gene prostate cancer test has been shown to have a 90% Sensitivity (for finding clinically significant, grade 3 or higher prostate cancer cells) and a 97% Specificity (for finding non-cancerous cells) and was published (August 2009) in the peer-reviewed publication, UroToday International,” said Dr. Barnhill.

Health Discovery Corporation's new urine-based 4-gene prostate cancer test is licensed on a per test royalty, worldwide co-exclusive basis to Quest Diagnostics Incorporated (NYSEGX - News) and Abbott (NYSE:ABT - News).

“In addition, we are using our patented technology to develop a new molecular test for breast cancer under a world-wide exclusive licensing and development agreement with Quest Diagnostics Incorporated (NYSEGX - News) and Smart Personalized Medicine, LLC.

“We are also working with Dr. Avram Cooperman and his team at the Pancreas, Biliary and Liver Surgery Center of New York at Beth Israel Medical Center and other locations, to develop new molecular diagnostic tests for the early detection of pancreatic cancer, as well as to complete validation of our molecular diagnostic test for colon cancer.

“Other products in our pipeline include new test development for interpreting Pap Smears for cervical cancer, automated interpretation of digital cytogenetics, flow cytometry, and circulating tumor cells for micrometastasis, as well as, an iPhone App for determining the risk of melanoma using our SVM technology on submitted images. We are also developing platforms to allow for the integration of clinical, pathological and radiological data to advance the goal of personalized medicine, among other activities,” said Dr. Barnhill.

"This federal grant is terrific news for cancer patients and for the future of personalized medicine,” said Kimberly Egan, Partner and Co-Chair, Health Care Sector, DLA Piper, LLP, Washington, DC, who represents Health Discovery Corporation on FDA and other regulatory matters.

“The grant allows Health Discovery Corporation to continue to develop its innovative molecular diagnostic tests for prostate and breast cancer, which will lead, we believe, to new therapies for these and other devastating forms of cancer," said Attorney Egan.

Earlier this year, Health Discovery Corporation was awarded the prestigious MICO Award for our intellectual property portfolio. The word “mico” is Latin for “to shine.” Unbeknownst to the Health Discovery Corporation, San Francisco, Calif.-based MDB Capital Group, LLC, spent millions of dollars and hours creating PatentVest, a proprietary intellectual property analytical tool. MDB Capital rigorously analyzed the intellectual property portfolios of 1,600 publicly-traded, small cap companies to determine which ones had the most valuable and disruptive technology. Health Discovery Corporation was honored to be chosen by MDB Capital as the recipient of their MICO Award.

Health Discovery Corporation has 81 U.S. and foreign patents, including 47 issued and 34 pending patents, in the state-of-the-art pattern recognition technology known as Support Vector Machines, Recursive Feature Elimination and Fractal Genomics Modeling, and the discoveries made from these technologies. In addition, our technology is used in the discovery of knowledge from large and/or complex data sets.

About Health Discovery Corporation

Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com.

[talis]

aus dem Quartalsbericht

Research and development fees were $325,403 for the nine months ended September 30, 2010, and $18,494 for the same period in 2009. This increase relates primarily to the costs associated with completion of the Abbott validation study of the urine-based molecular diagnostic test for prostate cancer performed at a major U.S. academic cancer center.

Ich finde, man hat damit ein sehr ernstes Lebenszeichen von sich gegeben

[talis]

der Jahresbericht 2010 ist da.

die für mich wichtigste Aussage ist das

"
Quest Diagnostics has now completed the urine prostate cancer test clinical trial described in our Licensing and Development Agreement with them. In addition, Quest has completed all clinical laboratory genomic testing on the clinical trial specimens. The clinical trial has now been un-blinded and the patient information has been supplied to Quest. Quest is now in the process of fully analyzing the data and validating the results.
"
Eigentlich dürfte es jetzt nicht mehr lange dauern

[talis]

http://finance.yahoo.com/news/Veteran-Wall-Street-prnews-216…

Veteran Wall Street Securities Analyst Reports on Health Discovery Corporation


Companies:
Health Discovery Corp.

Related Quotes
Symbol Price Change
HDVY.OB 0.13 0.0050
Chart for HEALTH DISCOVERY CP
Press Release Source: Health Discovery Corporation On Wednesday April 20, 2011, 9:30 am EDT

SAVANNAH, Ga., April 20, 2011 /PRNewswire/ -- "We are in the midst of a revolutionary change in diagnostic medicine that targets early detection of major health issues such as cancer. It is based upon mathematical algorithms that can accurately identify between healthy and diseased human tissue," said Howard Stillman, a veteran Wall Street Securities Analyst in a report about Health Discovery Corporation.

Health Discovery Corporation (OTC Bulletin Board:HDVY.ob - News), located in Savannah, GA., has pioneered in the field of Molecular Diagnostics for over 10 years and has been awarded 49 patents with an additional 39 patents pending for its established technology utilizing Support Vector Machines.

Reflecting its accomplishments to date, as mentioned in its recently released Annual Report, Health Discover Corporation has completed its testing and has received payments on two major joint ventures with Abbott Labs and Quest Diagnostics. The successful results have been announced on their urine test for prostate cancer where it demonstrated 97-99 % effectiveness in diagnosing cancer cells as well as normal body tissues. This compares with the PSA blood test for prostate cancer, which has only 70-80% accuracy.

"It looks like the Company is primed for significant operating growth when the aforementioned medical companies launch their worldwide commercial programs following their successful validation of the results of the preliminary tests. It has taken a longer period of time than first predicted to get to this stage of the process, but now with the tests completed, one can expect a quicker resolution of the introduction of the product to the market," Mr. Stillman reported.

The techniques' applied mathematical formulas combined with artificial intelligence sources to identify the chromosomes and the cells genetic makeup to determine if disease is present and which specific targets to treat. Moreover, the test can disclose by testing the blood if the cancer has spread through the body. These studies provide early detection which can lead to an improved opportunity for doctors to treat and cure disease in its early stages when greater success can be achieved. It can also enhance the use of existing drugs and advance the development of new medicines that can effectively cure the disease. In summary, early detection, optimal therapy, reduced drug reaction and lower health costs are possible in this new world of Personalized Medicine.

New agreements have also been established with the Anderson Cancer Center in Texas and Beth Israel hospital in New York, among others, and the tests are in progress for diagnosing cancers of the breast (subsequent contract with Quest), pancreas, colon melanoma and leukemia with current and future partners. The Company's current sources of revenue include license fees, milestone payments, service programs and royalties. The Company is at a stage when its potential can be realized as an important participant in the $50 billion annual medical diagnostic market growth, Stillman concludes.

[talis]

und hier die Richtigstellung obige news stammt garnicht von HDC

Health Discovery Corporation Not Source for Recent Press Release
businesswire



Companies:
Health Discovery Corp.

Related Quotes
Symbol Price Change
HDVY.OB 0.1150 -0.0031
Chart for HEALTH DISCOVERY CP
Press Release Source: Health Discovery Corporation On Friday April 22, 2011, 5:55 pm EDT

SAVANNAH, Ga.--(BUSINESS WIRE)-- A press release disseminated by PRNewswire on or about April 20, 2011 reporting comments made by securities analyst Howard Stillman regarding Health Discovery Corporation (OTCBB:HDVY.ob - News) (HDC) incorrectly stated that HDC was the source of the press release. HDC was not the source of the press release and was not involved in the preparation of Mr. Stillman’s report.

Information regarding HDC is available on our website, www.healthdiscoverycorp.com. In addition, the Company files annual and quarterly reports with the Securities and Exchange Commission. Those reports are available at www.sec.gov.

[talis]

noch etwas zur Analystenkonferenz von Quest Diagnoxtics vor 1 Monat

auf die Frage wie wichtig der 4-Gen-Test ist
gab es die Antwort

"solange der Test noch in der Entwicklong ist, wollen wir das nicht kommentieren. Wir sind aber über den Verlauf sehr erfreut und sobald ein Stadium erreicht ist, bei dem es etwas mitzuteilen gibt, werden wir das sicherlich tun"

Ich denke in den nächsten Wochen werden wir etwas hören.
Bei einer Markteinführung des urinbasierten Prostatakrebstests kann sich der Kurs leicht verzehnfachen mit weiterem Potenzial nach oben.

[talis]

das iPhone App für Melanome ist nun da

http://appshopper.com/healthcare-fitness/melapp

[talis]

Antwort auf Beitrag Nr.: 41.745.914 von talis am 05.07.11 20:49:11

World’s First SVM-Based Image Analysis iPhone App for Melanoma Risk Assessment, MelApp, Launched by Health Discovery Corporation

http://finance.yahoo.com/news/Worlds-First-SVMBased-Image-bw…

[talis]

na also, läuft doch gut an

Early Rapid Worldwide Success of iPhone MelApp Reported by Health Discovery Corporation

Website Rankings Illustrate Consumer Desire for Melanoma Risk Assessment on a Global Level

[talis]

Antwort auf Beitrag Nr.: 41.778.295 von talis am 12.07.11 19:49:45

http://finance.yahoo.com/news/Early-Rapid-Worldwide-Success-…

oops hab den link vergessen

[talis]

sieht so aus als würde Intel
hier den Kürzeren ziehen

Health Discovery Corporation Announces Progress in its Efforts to Cancel Intel Patent Claiming the RFE-SVM Method

http://finance.yahoo.com/news/Health-Discovery-Corporation-b…

[talis]

HDC konnte in der vergangenen Woche eine interessante Personalie vermelden- Ein ehemaliger Quest Mitarbeiter wechselt zu HDC. Er scheint genau zu wissen, welches Potential in HDC steckt.


http://finance.yahoo.com/news/Health-Discovery-Corporation-b…

Health Discovery Corporation Appoints John Hadden Senior Vice President of National and International Business Development

Former Quest Diagnostics Vice President, Sales, Central Region Joins HDC Leadership Team, Is Responsible for Sales Leadership and Licensing the Company's Products and Developing Strategic Alliances

Business WirePress Release: Health Discovery Corporation – Tue, Nov 8, 2011 12:11 PM EST


SAVANNAH, Ga.--(BUSINESS WIRE)-- Health Discovery Corporation (OTCBB:HDVY.ob - News) today announced the appointment of John R. Hadden to the position of Senior Vice President of National and International Business Development. An industry veteran with more than 26 years experience, Hadden brings to Health Discovery Corporation (HDC) a record of innovation and successes in the laboratory and healthcare fields. In his new role, Hadden is tasked with sales leadership and licensing of the Company’s products and technologies to clinical labs and medical diagnostics testing companies world-wide. He is also responsible for developing strategic alliances with these and other partners.

Most recently with Quest Diagnostics (NYSEGX - News), one of the largest commercial clinical laboratories in the world, Mr. Hadden oversaw a variety of wide-ranging assignments that included new product introductions, sales leadership, strategic alliances, and mergers and acquisitions. A former “Best of Quest” award winner, Mr. Hadden excelled at Quest for nearly eight years.

Prior to Quest Diagnostics, Mr. Hadden was Senior Vice President of Business Development at American Medical Laboratories, Inc. which was acquired by Quest Diagnostics in a transaction valued at $500 million. In addition, Mr. Hadden was Senior Vice President of National Business Development with LabOne, Inc. which was acquired by Quest Diagnostics in a transaction valued at $934 million. He also served as Associate Vice President for Laboratory Corporation of America (LabCorp).

“Throughout an impressive career with global, national and regional commercial clinical laboratories, John has accomplished a striking track record of success in all areas, from new product launches and sales leadership to mergers and acquisitions,” notes Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “We are thrilled to have his expertise to catapult the commercialization of Health Discovery’s products and technologies and to create strategic alliances driving the future of the Company.”

“I am honored to join Health Discovery Corporation and its distinguished team of world-renowned leaders and innovators at this very exciting time in the Company's development and commercialization cycle,” stated John Hadden, Senior Vice President for National and International Business Development. “I look forward to working closely with Dr. Barnhill to help bring commercial success to the tremendous pipeline of products, as well as developing strategic relationships to advance the goals of the Company.”

Mr. Hadden’s compensation, among other things, will include both monthly compensation as well as an equity component. The equity component is composed of one million warrants issuable upon the closing of a merger with or purchase of a CLIA Certified laboratory approved by The Board of Directors. An additional equity award of one million warrants will be issuable when the company’s stock price reaches $0.75 per share.

A native of Tampa, Florida, Mr. Hadden is an avid public and motivational speaker that has addressed crowds as a national spokesperson for March of Dimes, where he serves as Communications Chair; graduation speaker at Saint Petersburg College; and a repeat keynote speaker for Future Business Leaders of America, to name a few. Hadden holds a Bachelor’s of Science in Business Administration.

Health Discovery Corporation holds 50 issued patents and 40 pending patents related to its SVM and SVM-RFE development tools. For more information about its products, joint ventures and latest news, visit www.healthdiscoverycorp.com.

[gerdass]

http://ih.advfn.com/p.php?pid=staticchart&s=NB%5EHDVY&p=0&t=…

[talis]

http://finance.yahoo.com/news/Health-Discovery-Corporation-b…

Health Discovery Corporation Enters into Worldwide Licensing Agreement with NeoGenomics

License is for Hematopoietic and Solid Tumor Cancers



SAVANNAH, Ga.--(BUSINESS WIRE)-- Health Discovery Corporation (OTCBB: HDVY.OB - News), a molecular diagnostics leader in the use of patent protected advanced mathematical techniques for personalized medicine, has entered into an exclusive worldwide licensing agreement with NeoGenomics, Inc. (OTCBB: NGNM.OB - News) for laboratory developed tests (LDT’s) in the Field of hematopoietic and solid tumor cancers excluding breast cancer, which was previously licensed to Quest Diagnostics (NYSEGX - News) and Smart Personalized Medicine and excluding cancer of the retina which was previously committed to Retinalyze, LLC. HDC retains all rights to in-vitro diagnostic (IVD) test kit development in cancer. In addition, HDC’s pre-existing licenses remain in effect.

Under the terms of the Agreement, NeoGenomics paid $1 million in cash and issued 1,360,000 (one million three hundred and sixty thousand) shares of NeoGenomics common stock to HDC in upfront licensing fees. In addition, NeoGenomics will make milestone payments, in cash or stock, based on sublicensing revenue and revenue generated from products and services developed as a result of the Agreement. Milestone payments will be in increments of $500,000 for every $2 million in revenue recognized by NeoGenomics up to a total of $5 million in total milestone payments. After $20 million in cumulative revenue has been recognized, NeoGenomics will pay a royalty of 6.5% on product sales and will share profits from sub-licensing arrangements. In addition, NeoGenomics will pay a royalty of 50% of the revenue recognized from any sub-licensing arrangements for the Cytogenetics Interpretation System and the Flow Cytometry System.

NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company’s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Tampa, FL, and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, urologists and other clinicians, and hospitals throughout the United States.

“This License Agreement with NeoGenomics with their high complexity CLIA certified clinical laboratory represents a tremendous opportunity to complete the LDT development and commercialization of HDC’s cancer related products including tests for prostate cancer, pancreatic cancer, and colon cancer, as well as, the cytogenetics and flow cytometry interpretation software,” stated Stephen D. Barnhill, M.D., Chairman and Chief Executive Officer of Health Discovery Corporation. Dr. Barnhill added, “As a requirement of this Licensing Agreement, we are very excited that Dr. Maher Albitar will be the Chief Medical Officer and Director of Research and Development at NeoGenomics and will personally direct the final development and commercialization of these cancer products at NeoGenomics.”

Dr. Barnhill continued, “Under the terms of the License Agreement, NeoGenomics has agreed to use its best efforts to complete the development of these tests and have a first commercial use of products in the next 12 months, subject to extensions if required.”

Herbert A. Fritsche, Ph.D., Chief Science Officer at Health Discovery Corporation and recently retired Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center, stated, “Now that we have our cancer products poised for final development and commercialization in the NeoGenomics CLIA certified clinical laboratory under the direction of Dr. Maher Albitar, we can now focus our attention to finalization and commercialization of our Retinalyze product for macular degeneration, as well as, move into product development for non-cancer diseases such as Alzheimer’s, dementias, cardiac diseases and others. We will also be moving forward on using our SVM pattern recognition tools for radiologic interpretation techniques.”

[talis]

http://finance.yahoo.com/news/Health-Discovery-Corporation-b…

Health Discovery Corporation and Doctors Optimal Formula Launching Retinalyze Analytics for Detection of Macular Degeneration

Retinalyze Analytics is Scheduled for Introductory Product Launch at upcoming National Optometric Convention on Feb 17th 2012
Business WirePress Release: Health Discovery Corporation – Fri, Feb 10, 2012 8:30 AM EST

Email
Print

Companies:

Health Discovery Corp.

RELATED QUOTES
Symbol Price Change
HDVY.OB 0.091 +0.0079

SAVANNAH, Ga.--(BUSINESS WIRE)--

Health Discovery Corporation (OTCBB: HDVY.OB - News), a molecular diagnostics leader in the use of patent protected advanced mathematical techniques and pattern recognition technology (SVM) for personalized medicine, and Doctors Optimal Formula LLC, a physician exclusive anti-aging, health and wellness company are launching Retinalyze Analytics, to assist Ophthalmologists and Optometrists with the Detection of Macular Degeneration, at the upcoming Heart of America Convention geared for primary eye care practitioners this February 17th and 18th 2012. With thousands in attendance expected, this meeting will provide an excellent opportunity to launch our ground-breaking vision saving technology.

Retinalyze Analytics will initially be used for age-related macular degeneration (“AMD”), a progressive eye disease affecting more than 15 million Americans, with over 200,000 new cases diagnosed each year. AMD is the leading cause of blindness in adults 55 years and older which can result in severe visual loss because it affects the macula portion of the eye, where the sharpest central vision occurs.

Coinciding with the upcoming launch, the website www.retinalyze.com will be unveiled. This website will provide an extensive health care library relating to eye diseases. Additionally, we will offer a Macular Degeneration Risk Assessment tool that will help evaluate the patient’s risk factors for developing macular degeneration. It will also provide very useful information on how best to prevent, minimize and/or treat their eye disease. Patients will be able to learn more about their eye disease, as well as, Retinalyze Analytics can also search for Retinalyze Providers in their area.

“With Doctors Optimal Formula’s current extensive physician network of over 7,000 eye doctors, we expect thousands of Ophthalmologists and Optometrists to begin utilizing Retinalyze Analytics within the first few months after this initial launch,” states Howard Loff, MD, a renowned Oculo-Plastic Surgeon and CEO of Doctors Optimal Formula.

“For the first time we’re able to objectively quantify eye disease and very precisely monitor for even the most subtle of changes that even the Human Eye can’t see,” exclaims Dr. Sunil Malkani, a Vitreo-Retinal specialist. “Moreover, we’re incredibly excited about the applications this affords not only with Macular Degeneration but also with other retinal diseases including cancerous eye lesions. The earlier we can diagnose these diseases, the better we can treat and ultimately save vision or even lives.”

“We are very excited that with thousands of attendees scheduled for this optometric convention, this will provide an ideal platform to launch our ground-breaking vision-saving technology,” exclaims Howard Loff, MD. “With a sensitivity of greater than 95% accuracy in assisting with the diagnosis of AMD, Retinalyze has the ability to create a new standard of care for eye diseases and in the very near future could be used by the vast majority of eye doctors. The initial pricing structure will include a continuing monthly participation fee of $25 per doctor and a $15 per patient fee for each Retinalyze scan. I not only see this as being a primary tool used by the more than 60,000 eye doctors here in the US but also by those around the world.”

Dr. Stephen Barnhill, Chairman and CEO of Health Discovery Corp, stated, “We are very proud of the work of Health Discovery Corporation’s SVM image analysis expert Dr. Hong Zhang and his use of HDC’s patented Support Vector Machine Technology in the development of Retinalyze Analytics.” Dr. Barnhill continued, “As a 50% joint venture owner in Retinalyze, LLC, HDC could recognize significant revenue in the very near term as a result of the potential success of Retinalyze Analytics in the Ophthalmic arena.”

Physicians interested in learning about Retinalyze Analytics’ referral and reimbursement program may contact Howard Loff, MD at [e-mail].

To contact Health Discovery Corp, please send inquiries to [e-mail].

About Doctors Optimal Formula LLC

Having been founded by medical doctors, Doctors Optimal Formula prides itself on providing the best, scientifically formulated nutritional supplements and anti-aging skin care available today! Focusing on maintaining and improving the health and well-being of our customers, Doctors Optimal Formula has become vertically integrated to encompass all aspects of healthcare, such as Vision Care Plans, Prescription Pharmacy Plans and a physician provider network of over 10,000 physicians. For more information, visit www.DoctorsOptimalFormula.com.

About Health Discovery Corporation

Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.

All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.

Contact:
Health Discovery Corporation
Colleen Murphy, 404-214-0722, ext. 109
[e-mail]

[talis]

Is Health Discovery Corporation Finally on the Verge of a Turnaround?

http://finance.yahoo.com/news/health-discovery-corporation-f…

[talis]

Wer sich hier informieren will liest sich am Besten den Jahresbericht und die Pressemitteilungen diesen Jahres durch.

Hervorzuheben wäre meiner Meinung Retinalyze Analytics, von dem man ausgeht, dass bis Jan 2013 eine Rate von minimal 110000 scans pro Monat erreicht werden. Das entspräche hochgerechnet Einnahmen für HDC von 7 Mio $ jährlich

Das Chance/Risiko-Verhältnis ist ausgesprochen gut.

[talis]

der Quartalsbericht ist raus

für mich das Wichtigste, folgende Passage...

As of May 2012, Retinalize, LLC began realizing revenue.

In May 2012 Retinalize, LLC was nearing completion of development and validation of the second product using fundoscopic images of retinal vessels to assist our optometrist and ophthalmologist customers in the detection of Alzheimer's Disease. We expect a 2nd Quarter 2012 launch of this Alzheimer's disease detection product. This product is expected to generate revenue at or near the same price per test as our first product for macular degeneration.

[talis]

die Meinung von Bill Quirk zur Situation. Wurde zuerst auf Raging Bull gepostet. (Raging Bull funktioniert gerade nicht)
Bill Quirk hält 10% aller HDC-Aktien

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…

Good morning all. This note from Bill Quirk came across my desk and I don't think that he would mind if I share it here. I happen to agree with him on this:
"All,
Following the 10Q release, concern has been raised about HDC's near-term liquidity that I think is unfounded. The fear is HDC would start selling its NeoGenomics shares in July to fund operations, but since NGNM trades only about 35,000 or so shares a day, HDC couldn't sell enough shares fast enough without depressing NGNM's stock price and thus get less. It's in NeoGenomics' interest that selling by HDC not hurt its stock price since they hope for a NASDAQ listing and need a higher stock price. Presumably NGNM itself could buy some or all of the stock or arrange for another party to do so in a private transaction. Abbott Labs already owns 3.5 million NGNM shares. Alternatively, HDC could elect to not sell NGNM stock but rather use it as collateral for a working capital loan (necessarily guaranteed by a third party who would not do so without access to HDC inside information) to fund operations until operating cash flow is (hopefully) generated from Retinalyze or other sources. In my view, HDC won't sell NGNM on the open market because they won't have to and they may not sell it at all or at least not any time soon. Bottom line, in my view HDC has little if any liquidity issues in the near term."
Bill Quirk

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…

Follow-Up Note from Bill Quirk 20-May-12 07:31 pm
From chazzy58 on the Raging Bull Board:
"You're welcome guys! Hey, this follow up from Bill Quirk just in:"
"FWIW, I'm increasingly optimistic about HDC's prospects, at long last. I think the Retinalyze JV has a legitimate potential to mushroom with the existing macular degeneration app and accelerate with more apps. I recently learned that retinal analysis can also give early indications of otherwise asymptomatic diseases like Alzheimers and diabetes. Who knew? The good thing is that its ops require little if any HDC involvement, so 50% of all of Retinalyze's net revenue flows through to HDC's bottom line (nice margin …). The NeoGenomics cancer partnership in January was a huge coup for NGNM for true chump change. HDC had to take it because it was the life-saver needed at the time. But if NGNM actually accomplishes what they plan on this year (and beyond), because they have the ability to physically create and market diagnostic tests that HDC never had and never would, this could be a tremendous royalty generator (at 100% profit margin ...) for HDC in 2013 and beyond. And if the Patent Office ever comes back from its siesta and rules conclusively for HDC', the Intel situation could develop very positively."
Bill Quirk

[talis]

http://finance.yahoo.com/news/health-discovery-corporation-i…

das Überraschende an dieser Pressemitteilung ist, dass man im 3.Quartal profitabel geworden ist

Health Discovery Corporation Issues Corporate Update
Business WirePress Release: Health Discovery Corporation – Tue, Oct 23, 2012 9:00 AM EDT




RELATED QUOTES
Symbol Price Change
HDVY 0.07 0.00

SAVANNAH, Ga.--(BUSINESS WIRE)--

Health Discovery Corporation (HDVY) announced today that Stephen D. Barnhill, M.D. has resigned as CEO of the Company to accept a new opportunity. Dr. Barnhill, at the request of the Board of Directors, has agreed to continue as a Consultant and Interim CEO until a suitable replacement CEO is hired and fully educated on the technology and product pipeline thereby ensuring a smooth executive transition.

“The Board of Directors wishes to thank Dr. Barnhill for his numerous contributions to the company and the integral role he has played in the company's growth and successes from founding the Company through leading the Company to a profitable 3rd Quarter of 2012,” states Dr. Joe McKenzie, Lead Director, “We wish him all the best and look forward to his continued leadership as we search for an experienced senior executive to continue to drive HDC’s growth strategy.”

“Dr. Barnhill is a scientific visionary having brought together the fields of medicine and mathematics in a way that has and will continue to benefit patients worldwide. He is considered an international expert in this new area of medicine and it is a great pleasure to work with him on cutting edge scientific discovery,” states Dr. Herbert Fritsche, Chief Science Officer at HDC and retired Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center, “As an inventor of approximately 36 of the patents owned by HDC, Dr. Barnhill’s contribution to the science driving our technology is remarkable and unprecedented.”

“Starting a public biotech company from its inception and taking it to profitability is no easy task and I could not have achieved this goal without the incredible scientific staff, including Dr. Herb Fritsche and mathematics staff including Dr’s Hong Zhang and Isabelle Guyon, at HDC that have joined together and dedicated themselves to the goal of helping patients through scientific discovery,” states Stephen D. Barnhill, MD, Chairman and CEO of HDC. “The Company is now on a solid path with cash, no long-term debt, products on the market and a pipeline in development, a valuable patent portfolio, and an incredible team in place to continue this success. I look forward to working with the Company to find a new CEO and spending time educating that person on the technology and product pipeline to ensure a smooth transition of executive management.”

Dr. Barnhill continued, “I would like to thank the shareholders of the Company for supporting our efforts in the past and for their continued support in the future.”

In addition to the announcement of Dr. Barnhill’s departure, HDC is providing the following current update on the progress at the Company.

First Time Profitability: The Company expects to announce its first profitable quarter in the upcoming Form 10-Q. In addition, the Company has no long-term debt.

NeoGenomics (NGNM),: The Company signed a Worldwide Licensing Agreement with NeoGenomics on January 6, 2012 for Laboratory Developed Test (LDT) rights for hematopoietic and solid tumor cancers. Under the terms of the Agreement, NeoGenomics paid $1 million in cash and issued 1,360,000 (one million three hundred and sixty thousand) shares of NeoGenomics common stock to HDC valued at $1.43 per share (then valued at $1,945,000.00) in upfront licensing fees. Since that time, the NeoGenomics stock price has increased closing at $2.80 per share on Friday, October 22, 2012. On August 13, 2012, HDC sold 409,000 shares of the NeoGenomics stock and received proceeds, net of fees, in the amount of $891,363.00. The Company still retains ownership of 951,000 shares of NeoGenomics stock which is freely tradable and valued at $2,662,800.00 based on the October 22 closing price.

In addition, NeoGenomics will make milestone payments, in cash or stock, based on sublicensing revenue and revenue generated from products and services developed as a result of the Agreement. Milestone payments will be in increments of $500,000 for every $2 million in revenue recognized by NeoGenomics up to a total of $5 million in total milestone payments. After $20 million in cumulative revenue has been recognized, NeoGenomics will pay a royalty of 6.5% on product sales and will share profits from sub-licensing arrangements. In addition, NeoGenomics will pay a royalty of 50% of the revenue recognized from any sub-licensing arrangements for the Cytogenetics Interpretation System and the Flow Cytometry System.

Retinalyze, LLC: Retinalyze, LLC is a 50/50 joint venture between Health Discovery Corporation and Doctors Optimal Formula, LLC formed October 18, 2011 to develop SVM based analysis tools for diagnosing diseases such as macular degeneration using fundoscopic images of the eye.

On February 17, 2012, the Company announced the commercial launch of Retinalytics SVMTM, to assist Ophthalmologists and Optometrists in the Detection of Macular Degeneration. While the first Retinalytics SVMTM product released focuses on age-related macular degeneration (“AMD”), the Company continues to develop a second Retinalytics SVMTM product using fundoscopic images of retinal vessels to assist eye care professionals in the detection of Alzheimer’s disease and diabetic retinopathy.

At the end of the 3rd Quarter, 2012 there have been 753 Doctors signed up to use the service and 1700 scans were sent for analysis during the 3rd Quarter for a total of 2,274 scans analyzed to date. Revenue numbers and further detail will be provided in the upcoming 10Q.

SVM Capital: SVM Capital, LLC (“SVM Capital”) is a joint venture between Atlantic Alpha Strategies, LLC (“AA”), a Savannah, Georgia based Registered Investment Advisor (RIA) and Health Discovery Corporation, Inc. (OTCBB: HDVY and “HDC”), a Savannah, Georgia based molecular diagnostics company that uses patent protected SVM technology for personalized medicine. The purpose in forming the joint venture was to apply the advanced mathematical pattern recognition techniques as demonstrated by HDC's SVM technology and intellectual property (“IP”) assets and leverage their capabilities for the first time in the financial markets.

As part of the joint venture agreement, SVM Capital acquired the exclusive and perpetual right to apply HDC’s patent protected SVM technologies to all financial markets world-wide. Since executing their joint venture agreement in 2007, SVM Capital has developed and live traded a series of fully automated trading models based on an initial ETF strategy, the first investment program developed as a result of the joint venture. The results of this ETF program are audited and available for review. A second trading program, using a long/short large cap hedging strategy began live trading in July 2012 and a third and fourth program, currently in development and based on a small cap and mid cap strategy respectively, have yet to begin live trading.

SVM Capital desires to rapidly grow the joint venture and is now evaluating potential joint venture partnerships, IP licensing opportunities and/or various strategic alternatives, including mergers and acquisitions as a means to realize this objective. SVM Capital is actively targeting a combination of individual traders, investment analysts, hedge funds and brokerage firms in addition to research organizations, financial data providers, and financial technology providers as potential clients and/or partners.

Smart Personalized Medicine, LLC: Health Discovery Corporation owns an equity position in and has signed a Licensing Agreement with Smart Personalized Medicine, LLC, founded by Dr. Richard Caruso, Chairman and Founder of Intergra Life Sciences (IART) to work to develop a novel breast cancer prognostic test using HDC’s support vector machine (SVM) technology in collaboration with MD Anderson Cancer Center. Smart Personalized Medicine, LLC and HDC recently terminated their development agreement with Quest Diagnostics and plan to identify a new partner to complete the development of this breast cancer test.

MelApp: MelApp is the world’s first SVM-based iPhone App for assessing the risk of melanoma. MelApp uses highly sophisticated patent protected state-of-the-art mathematical algorithms and image based pattern recognition technology to analyze the uploaded image and give an indication if a mole is low, moderate, or high risk of being a melanoma. In all cases, MelApp refers the App user to a physician for an appropriate medical evaluation. It is an educational tool never to be used as a substitute for a physician diagnosis.

There have been approximately 11,500 MelApp downloads purchased to date. In addition to the revenue generated from the App itself, the Company hopes to generate additional revenue from physician subscriptions for potential patient referrals and advertising for sun care and protection product companies as soon as there is sufficient critical mass in the ordering patterns.

Patent Portfolio: The Company now holds the exclusive rights to 57 issued U.S. and foreign patents covering uses of SVM and FGM technology for discovery of knowledge from large data sets. The Company also has 23 pending U.S. and foreign patent applications covering uses of the SVM technology as well as biomarkers and diagnostic methods that have been discovered using the SVM technology.

Intel: Regarding Intel’s Patent No. 7,685,077 entitled “Recursive Feature Eliminating Method Based on a Support Vector Machine,” the Company has received notification from the United States Patent and Trademark Office that it intends to issue a re-examination certificate to Intel Corporation. During the re-examination, the Patent Office agreed that all elements of the HDC patented SVM-RFE method are present in the Intel claims. A fundamental principle of patent law is that the addition of one or more elements to a patented claim does not avoid infringement. In this case, Intel merely added a standard computer operation to the Company’s SVM-RFE method. Furthermore, possession of a patent on series of steps does not avoid infringement of a patent covering a subset of those steps.

The matter has now moved to the interference issue. An interference is an administrative proceeding within the Patent Office through which a determination is made of who is entitled to a patent when two parties make claims to the same invention. Under current U.S. Patent Law, the first person to invent an invention is entitled to a patent. An interference is commonly provoked by submitting a new continuation application with claims that were copied from an issued patent or published application. If the owner of the continuation application can show that they are entitled to an earlier priority date than the issued patent, then the party with the issued patent must provide persuasive evidence that they actually invented the claimed subject matter before the earlier priority date of the other party. In this case, the HDC’s earliest application describing SVM-RFE was filed in March 2000. Intel’s application for SVM-RFE was filed in August 2005.

The patent examiner who is examining the Company’s continuation application has agreed that the claims of the application are identical to those of the Intel patent and that they are, therefore interfering. As a result, the Company is confident that it will prevail and be declared the sole owner of the SVM-RFE method when its claims are compared side-by-side with Intel’s claims.

University Licensing Program: The Company continues to implement the University Licensing Program for it Intellectual Property Portfolio. Further detail will be provided in the upcoming 10-Q.

[talis]

http://www.healthdiscoverycorp.com/4-22-14_Update.php


im nächsten posting folgt die Übersetzung


April 22, 2014

Dear Fellow Owners of Health Discovery Corporation,

Recently you received information about SVM Capital LLC's ("SVMC") success in achieving a risk-adjusted tie for first place in an audited investment contest featuring quantitative techniques in which SVMC used its proprietary SVM-based algorithm. We believe this could have implications for both SVMC and Health Discovery Corporation ("HDC" or the "Company"). This development also makes for an opportune time to share our views as to where we think HDC and our "flagship" technology, the Support Vector Machine ("SVM"), fits into today's data-based technology landscape.

The world is full of impressive machines like Google glass, iPhones, robots and Boeing 767s that we can see, touch, drive, fly, work and play with. But there's another noteworthy machine, intangible and invisible, that exists only in the world of zeroes and ones but is very impressive in its own right. This is the SVM, an algorithmic invention in the field of machine learning that, in the right hands, can find computer-based solutions to problems when other mathematical or analytical efforts may fail. One of its special features is that it operates in multi-dimensional space. That is to say it can marshal many different approaches (often called kernels) to analyze and deal with limitless variables contained in huge amounts of data. The SVM, a supervised machine learning technique, is particularly useful in detecting patterns and isolating key variables in dense data thickets.

The SVM was invented by Vladimir Vapnik (who won the Humboldt Prize) and refined into more practical application by Isabelle Guyon. Both Mathematicians have provided significant contributions to HDC. In fact, it was Dr. Guyon's work for HDC that led to the discovery of genes associated with prostate cancer and a diagnostic test that HDC's commercial partner is expected to launch this summer. HDC invented some of the earliest SVM's, which are part of our 80 patents. In addition, HDC has the first patent related to SVM-RFE (recursive feature elimination) in the world. In brief, HDC has had broad experience in using SVM's in its efforts to work with partners to build commercial products.

One of the hottest topics in the hi-tech world today is "big data", a very broad term that covers a lot of waterfront. Why? Some 94% of all the world's data has been created in the past two years and continued zettabyte data flows will present incredible opportunities for many, particularly those who can analyze it. The March-April 2014 issue of Harvard magazine has an illuminating article entitled, "Why Big Data Is a Big Deal". It is well worth reading in order to get a sophisticated and comprehensive perspective. Summarizing and paraphrasing, here's why:

There is a big data revolution but it's not the quantity of data that's revolutionary; rather it's that now something can be done with it. The revolution lies in improved statistical and computational methods, not in the exponential growth of computer capacity and storage. The doubling of computer power every 18 months (Moore's law) is nothing compared to the "big algorithm" - a set of rules that can be used to solve a problem a thousand times faster than conventional computational methods could.

Easier said than done because so much data is "tangled" and multi-dimensional, that it cannot simply be unraveled by standard mathematical techniques like neural networks, Bayesian models, etc. In math jargon, when epistemic density is great, the SVM's high dimensionality can often unravel the complexity and yield a meaningful solution. At a recent conference on machine learning, an IBM expert said its approach to big data was to "cast a very wide net." But after SVM Capital LLC's architect, Mark Moore, spoke, he acknowledged to Mark that HDC's "tangled", multi-dimensional description was much more accurate and that while IBM's "big net" approach has clear benefits, it also has notable limitations.

It is not sufficient simply for work-a-day mathematicians who also "do" SVMs to try to address difficult problems for they, like musicians, brain surgeons and quarterbacks, are distributed on their own bell curve. HDC has virtuoso-level talent that can attack a problem directly and, just as importantly, train and supervise other mathematicians in SVM techniques that have already worked well for us. It is also impossible for any mathematician to solve a data problem without the intimate involvement of domain experts in their field, and this is precisely the road HDC has traveled with its partners over the years.

One of those partners is SVMC which has created an investment algorithm that in 17 months of live trading (with internal capital) has not only outperformed the S&P 500 but simultaneously reduced portfolio risk to levels below that index. This could not have been achieved without the SVM. SVMC's initial goal is to start a hedge fund investing in large and mid-cap U.S. stocks and this recent development with BattleFin suggests this is within reach. Longer term, SVMC's goal is to create comparably derived algorithms for other well-established stock markets as well as for currencies and commodities since there are similar factors influencing prices in all financial markets.

It took SVMC, 45% owned by HDC, six years to create this algorithm but that's not because the experts were slow learners. Rather, one of the Gordian Knot issues that had to be solved was using a tool (SVM) designed to deal with static data like genes and adapting it to dynamic data like stock market prices. This was not a trivial challenge and the solution required deep knowledge, imagination and a lot of patience. The end result though has been worth it. Notably, SVMC invests as distinct from "trading" as the portfolio is rebalanced only quarterly. Because of the design of the algorithm, the portfolio is hugely scalable without increasing investment complexity: the decisions required to manage $5 billion are the same as for $5 million, the only difference is that investment positions are proportionately larger.

SVMC is a "quant" fund with modest human intervention but portfolio decisions are based on rank ordering new fundamental data from Zack's on a quarterly basis. One thing that differentiates SVMC from other hedge funds is what it doesn't do.

* it doesn't "bet" on anything or use risky leverage

* it doesn't "trade" at warp speed, hourly, daily, weekly or monthly

* it doesn't chase interest rates or currencies or market trends

* it doesn't do debt or financial exotica or illiquid instruments

* it doesn't do international or pick investment sectors

* it doesn't do "sentiment" or "momentum" or "psychology"

HDC was originally founded to develop diagnostic tests, principally for cancer, by combining its mathematical SVM expertise with the intimate knowledge of "domain experts" such as M.D. Anderson Cancer Center, Quest Diagnostics, Abbott Labs, Genzyme and others. Essentially, we envisioned the "marriage of math and medicine" to create a vehicle to help develop what has come to be known as personalized medicine. More recently, IBM Medical was started with the same objective in mind.

In 2012, HDC licensed many of its patents for medical diagnostics to NeoGenomics, with whom HDC envisions a productive and profitable future. The first test is NeoSCORE™, a highly accurate blood and urine prostate cancer test that has the potential to supplement or compete with or, in time, even replace the PSA test. In addition, HDC is working diligently with NeoGenomics on Cytogenetics and Flow Cytometry projects that use the SVM to help domain experts analyze complex images.

It is almost a truism to point out that any identifiable technology today may be just an integral part of a larger paradigm tomorrow. Why? Because technologies tend to converge. For example, first there was the automobile, a technological wonder at the time and next came autos and electronics together, and now we have autos, electronics, ergonomics, new propulsion systems and computer informatics all bundled up. While experience, intuition and judgment will continue to be essential to solving problems, future decision-makers will necessarily rely more and more heavily on analytics to help with that. And this is where an ability to interpret new tsunamis of data that inundate us daily will be invaluable in simply sorting it all out, first into information and then into actionable intelligence. And in the right hands with the right domain experts, the SVM can do that exceedingly well. Almost regardless of the field or technology, HDC believes that sophisticated mathematical analytics will be a thread common to advances in all of them. There are many data-based market opportunities ripe for exploitation including medical diagnostics, genomics, proteomics, digital imaging, bioinformatics, stock market analysis, internet search and security, credit card fraud detection, health data analysis and many others.

We hope this broad-brush treatment gives you, the owners of HDC, a good idea of what your Company is and does and what we're capable of and aspire to in the many fields of "big data".

With kind regards,
The HDC Team

[talis]

die übersetzung des obigen postings
ohne Gewähr für die Richtigkeit der Übersetzung


Aktionärsbrief von HDC

April 22, 2014

Vor Kurzem bekamen Sie die Meldung über den Erfolg von SVM Capital LLC's ("SVMC"), einen risikoberichtigten ersten Platz erreicht zu haben. In einem auditierten Investment-Wettbewerb, der quantitative Investmenttechniken zum Thema hatten, brachte SVCM seine patentrechtlich geschützten SVM-basierten Algorithmen zur Anwendung. Wir glauben dies könnte sowohl für SVCM als auch für Health Discovery Corporation ("HDC" or the "Company") Auswirkungen haben. Diese Entwicklung bietet eine günstige Gelegenheit, unsere Sichtweise darzulegen wie HDC und unsere Flaggschifftechnologie die Support Vector Machine in die heutige Landschaft der datenbasierten Technologie passt.

Die Welt ist voller beeindruckender Maschinen wie die Googlebrille, iPhones, Roboter und die Boeing 767, die wir sehen, berühren, fahren, fliegen und damit arbeiten und spielen können. Aber es gibt noch eine andere bemerkenswerte Maschine, unberührbar und unsichtbar, die nur in der Welt von Nullen und Einsern existiert aber als eigenständige Einheit sehr beeindruckend ist. Dies ist die Support Vector Maschine, eine algorothmische Erfindung auf dem Gebiet des Maschinenlernens, die in den richtigen Händen, computerbasierte Lösungen für Probleme finden können, wenn andere mathematische oder analytische Ansätze versagen. Eines ihrer besonderen Wesenszüge ist, dass es im multidimensionalem Raum agiert. D.h es kann viele verschiedene Näherungen (oft auch Kernel genannt) ordnen, um mit unbegrenzten Variablen umzugehen und zu analysieren, die in sehr, sehr grossen Datenmengen enthalten sind. Die SVM, eine kontrollierende maschinenlernende Technik, ist insbesondere nützlich bei der Mustererkennung und dem Isolieren von Schlüsselvariablen im dichten Datendickicht.

Die SVM wurde erfunden von Vladimir Vapnik (Gewinner des Humboldt-Preises) und verfeinert für praktischere Anwendung von Isabelle Guyon. Beide Mathematiker haben erhebliche Beiträge für HDC geleistet. In der Tat war es Dr. Guyons Arbeit die zur Entdeckung der Gene geführt haben, die mit Prostatakrebs in Verbindung stehen, und dem dazugehörenden diagnostischen Test, den HDCs Partner voraussichtlich ab diesen Sommer kommerziell an den Markt bringen wird. HDC erfand einige der frühesten SVMs, die Teil unserer 80 Patente sind. Darüberhinaus hat HDC das erste Patent bezüglich SVM-RFE (recursive feature elimination) in der Welt. In wenigen Worten: HDC hat breite Erfahrung bei der Nutzung von SVMs bei seinen Anstrengungen, mit Partnern zu kooperieren, um kommerzielle Produkte zu erstellen.

Eines der heissesten Themen in der heuigen Hochtechnologiewelt ist „Grosse Datenmengen“, ein sehr weitläufiger Ausdruck, der die Sicht versperrt. Warum? Ungefähr 94% der Daten auf der ganzen Welt sind in den vergangenen 2 Jahren erzeugt worden und fortschreitende zettabyte Datenflüsse stellen für viele unglaubliche Gelegenheiten dar, insbesondere für die, die sie analysieren können. In der März-April Ausgabe des Harvard Magazins gibt es einen erhellenden Artikel mit dem Titel „Warum sind Grosse Datenmengen eine ganz Grosse Sache“ Er ist wirklich lesenswert um eine durchdachte und umfassende Perspektive zu bekommen. Zusammengefasst und hervorgehoben ist hier Warum:

Es gibt eine grosse Datenrevolution aber es ist nicht die Quantität der Daten was revolutionär ist; es ist eher, dass jetzt etwas damit getan werden kann. Die Revolution liegt in den verbesserten statistischen und computerbetreffenden Methoden, nicht in dem exponentiellen Wachstum der Computerkapazitäten und Speicherung. Die Verdopplung der Computerleistungsfähigkeit alle 18 Monate (Moores Gesetz) ist nichts im Vergleich zu dem „Grossen Algorithmus“ - ein Satz von Gesetzen, der genutzt werden kann, um ein Problem tausendmal schneller zu lösen, als konventionelle Computermethoden das könnten.

Leichter gesagt als getan, weil so viele Daten sind „verworren“ und multi-dimensional, dass sie nicht so einfach enträtselt werden können durch Standard- mathematische Techniken wie Neuronale Netzwerke, Bayesian Modelle, usw.. Im Mathejargon, wenn die erkenntnistheoretische Dichte gross ist, kann die hohe Dimensionalität oft die Komplexität enträtseln und eine sinnvolle Lösung erbringen. Bei einer kürzlichen Konferenz über Maschinenlernen sagte ein IBM-Experte, dass ihre Methode sich den GROSSEN DATENMENGEN zu nähern, wäre „ein grosses weites Netz zu werfen“. Aber nachdem der SVM Capital LLC Architekt, Mark Moore, gesprochen hatte, anerkannte er gegenüber Mark, dass HDCs verworrene multidemensionale Beschreibung akkurater ist, und dass während IBMs „Grosses Netz“-Methode klare Vorteile hat, hat es auch beträchtliche Grenzen.

Es ist nicht ausreichend für einen Mathematiker, der sich mal eben so mit SVM s beschäftigt, zu versuchen sich mit schwierigen Problemen zu befassen, denn sie, wie Musiker, Hirnchirugen und quarterbacks sind auf ihrer eigenen Gauss`schen Glockenkurve verteilt. HDC hat virtuose Talente, die ein Problem direkt angehen können, und genauso wichtig, andere Mahematiker in SVM Techniken zu trainieren und anleiten zu können, die dann auch bereits gut für uns gearbeitet haben. Es ist auch unmöglich für irgendeinen Mathematiker ein Datenproblem ohne den engen Kontakt mit Domänenexperten (Fachgebietsexperten) auf ihrem Gebiet lösen zu können. Und dies ist genau der Weg, den HDC mit seinen Partnern über die Jahre eingeschlagen hat.

Einer dieser Partner ist SVMC, die einen Investmentalgorithmus kreiert hat, das in 17 Monaten des live-Handels (mit internem Kapital) nicht nur besser abgeschnitten hat als der S&P 500 sondern auch gleichzeitig das Portfoliorisiko gesenkt hat, das unterhalb von diesem Index liegt. Dies hätte nicht ohne SVM erreicht werden können. SVMCs anfängliches Ziel wäre es, einen Hedgefond zu initiieren für large- und mid-cap Aktien und diese kürzliche Entwicklung mit BattleFin legt den Schluss nahe, dass dies in Reichweite ist. Langfristig ist das Ziel von SVMC die Kreierung von vergleichsweise abgeleiteten Algorithmen für andere etablierte Aktienmärkte und auch für Währungen und Rohstoffe, da es ähnliche Faktoren gibt, die die Preisbildung in allen Finanzmärkten beeinflussen.

SVMC, zu 45% im Besitz von HDC, benötigte 6 Jahre um diesen Algorithmus zu kreieren, nicht weil die Experten nur langsam lernten, eher, weil zunächst ein Gordischer Knoten gelöst werden musste, weil das Tool (SVM) konzipiert dafür war, mit statischen Daten wie Genen umzugehen, dazu angepasst werden musste, mit dynamischen Daten wie Aktienkursen umzugehen.

Dies war keine triviale Herausforderung und die Lösung erforderte vertiefte Kenntnisse, Vorstellungsvermögen und sehr viel Geduld. Das Endresultat ist es jedoch wert gewesen. SVCM investiert anders als beim „Trading“, da das Portfolio nur einmal im Quartal umgeschichtet wird. Wegen der Konzeption des Algorithmus ist das Portfolio enorm skalierbar ohne die Komplexität des Investments zu vergrössern. Die Entscheidungen 5 Milliarden zu managen sind die gleichen wie bei 5 Millionen. Der einzige Unterschied ist, dass die Investmentpositionen proportional grösser sind.

SVMC ist ein „Quant“-Fonds mit geringen menschlichen Eingriffen. Die Portfolioentscheidungen basieren auf Rangordnung neuer fundamentaler Daten überliefert von Zack im vierteljährlichen Takt. Eines was SVMC von anderen Hedgefonds unterscheidet ist, was es nicht tut.
Es „wettet“ nicht auf irgendwas oder benutzt riskante Hebelprodukte
Es „tradet“ nicht mit Hochgeschwindigkeit, stündlich, täglich, wöchentlich oder monatlich
Es jagt nicht Zinssätzen oder Währungen oder Merkttrends hinterher
Es befasst sich nicht mit Schulden oder exotischen Finanzen oder illiquiden Instrumenten
Es befasst sich nicht mit Internationalem oder dem Heraussuchen von Investmentsektoren
Es befasst sich nicht mit „Sentiment“ oder „Momentum“ oder „Psychologie“

HDC wurde ursprünglich gegründet, um diagnostische Methoden hauptsächlich für Krebs zu entwickeln, indem es ihre mathematische SVM Experise mit den vertieften Wissen von „Domänenexperten“wie dem M.D. Anderson Cancer Center, Quest Diagnostics, Abbott Labs, Genzyme und Anderen kombinierte. Im Wesentlichen standen wir der „Heirat von Mathematik und Medizin“ gegenüber, um Vehikel zu kreieren, um dabei der Entwicklung zu helfen, was als Personalisierte Medizin bekannt wurde. Vor Kurzem ging IBM Medical mit der gleichen Zielsetzung an den Start.

Im Jahr 2012 lizensierte HDC viele seiner Patente für medizinische Diagnostik an Neogenomics, mit der HDC eine produktive und profitable Zukunft bevorsteht. Der erste Test ist NeoSCORE, ein hochakkurater Blut- und Urinprostatakrebstest, der das Potential zur Ergänzung des PSA-Tests hat, oder das Potential hat, mit ihm in Wettbewerb zu treten oder, beizeiten sogar den PSA-Test zu ersetzen. Darüberhinaus arbeitet HDC mit Neogenomics an Cytogenetics und Flow Cytometry-Projekten, die SVM anwenden, um Domänenexperten bei der Analyse komplexer Abbildungen zu helfen

Es ist fast schon eine Binsenweisheit, dass jede identifizierbare Technologie von heute einfach ein integraler Bestandteil eines grösseren Paradigmas von morgen sein könnte. Warum? Weil Technologien zum Konvergieren neigen. Z.B. erst gab es das Automobil, ein technologisches Wunder zu der Zeit und als nächstes kamen Autos und Elektronik zusammen, und nun haben wir Autos, Elektronik, Ergonomie, neue Antriebssysteme und Computerinformatik, alle gebündelt. Während Erfahrung, Intuition und Beurteilungsvermögen weiterhin wesentlich für die Lösung von Problemen sein wird, werden sich künftige Entscheidungsträger notwendigerweise immer mehr auf die Analytik verlassen müssen. Und dies ist wo eine Fähigkeit zur Intepretation neuer Tsunamis von Daten, die uns täglich überfluten, unerlässlich sein wird, um einfach alles sortiert zu bekommen; erst in Information und dann in handlungsfähige Intelligenz. Und in den richtigen Händen mit den richtigen Domänenexperten, kann die SVM dies sehr, sehr gut. Beinahe ungeachtet des Gebiets oder Technologie glaubt HDC, dass alle den roten Faden in Form ausgekügelter mathematischer Analytik zur Erzielung des Fortschritts gemeinsam haben werden. Es gibt viele datenbasierte Marktchancen, die reif für die Nutzbarmachung sind, wie medizinische Diagnostik, Genomics, Proteomics, digitale Bildgebung, Bioinformatik, Aktienmarktanalyse, Internetsuche und-Sicherheit, Detektion von Kreditkartenbetrug, Gesundheitsdatenanalytik und viele andere.

Wir hoffen, diese Betrachtung im breiten Aufwasch gibt Ihnen, den Eigentümern von HDC eine gute Vorstellung darüber, was Ihre Firma tut und wozu wir fähig sind und was wir auf den vielen Gebieten der „Grossen Datenmengen“ anstreben .

Mit freundlichen Grüssen
Ihr HDC-Team

[talis]

Vor fast 2 Monaten gab es diese winzige Mitteilung

http://biz.yahoo.com/e/150617/hdvy8-k.html

mit dem Hinweis hierauf

http://www.grailpartners.com/news/2015/6/16/svm-capital-join…

Dies ist wohl der Grund, weswegen der Kurs sich ein wenig gefestigt hat

[talis]

http://www.healthdiscoverycorp.com/2015Update.php


Shareholder Update - August 25, 2015




Dear Fellow Owners of Health Discovery Corporation,

In light of some recent developments, your leadership team believes that a brief update regarding Health Discovery Corporation’s (“HDC” or the “Company”) current financial circumstances and outlook is now warranted.

Recently it became clear to us that, despite our best efforts and those of NeoGenomics, initial commercialization and recurring revenues from the three diagnostic tests on which we have been collaborating would be further delayed. Therefore we sought to raise more money to “lengthen our runway” and we were successful. HDC believes there is sufficient cash and NeoGenomics stock to finance operations until at least the end of 2016, and likely well into 2017 if we are able to sustain our very low monthly expenditures. HDC sold both Series C preferred stock and common stock at $0.03 per share which is above the $0.01 - $0.02 recent price range. The buyers are current shareholders who also received warrants to buy more stock at the same price. Additionally, the Company was able to negotiate a significant reduction in our outstanding accounts payables and clear the accounts payables it had carried for some time.

Both HDC and NeoGenomics are exploring opportunities to commercialize the NeoLAB prostate cancer test, flow cytometry software (“Flow”) and cytogenetic interpretation software (“Cyto”). Initial discussions regarding Flow and Cyto are encouraging and we plan further outreach. As NeoGenomics has indicated, while NeoLAB still requires additional sample collection and analysis, the findings to date continue to confirm the initial highly accurate results. An additional encouraging note is Medicare’s approval of reimbursement for new prostate cancer tests recently launched. NeoGenomics stated that it expects to launch NeoLAB commercially next spring but we are hopeful that it will be sooner.

There has been great progress since SVM Capital, LLC became a member of Manifold Partners to create Manifold Vector (“MV”). In the recent stock market swoon, this portfolio has outperformed the S&P 500 by a wide margin. If, as it appears likely, Manifold Partners’ intense marketing efforts start to bear fruit, SVM Capital, LLC and HDC may begin to enjoy modest but recurring revenues. Far more important though would be recognition by institutional investors that MV's unique SVM-based algorithmic suite may be able to achieve consistently superior returns under any market conditions, and with very low risk and very high liquidity. There are thousands of hedge funds around, each touting its own “unique approach” in an effort to differentiate itself and attract assets. We think that SVM Capital, LLC made an inspired decision to join with Manifold Partners; and what we have learned so for only reinforces our expectation that Manifold Vector will indeed be able to demonstrate its value to major investors.

Considering the very tenuous business and financial condition your Company was in two years ago, we believe HDC has made tremendous strides towards investor credibility and financial viability. Management has dealt effectively with most of HDC’s legacy problems and distractions and has been focused on developing a sustainable business enterprise dedicated to delivering commercially successful products. This has been accomplished because we believe that, for the first time in its history, HDC has a leadership team that cares more about HDC’s success than their personal interests. We remain excited about what has been accomplished to transform your Company and are looking forward to what HDC will achieve in the future.

Thank you for your continued patience and support.

With kind regards,

The HDC Team



Forward-Looking Statements
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies, medical devices, or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings. All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.
© 2015 Health Discovery Corporation Stock Symbol: HDVY.OB

[talis]

würde mich sehr wundern, wenn dieses Jahr nicht das Jahr
von Health Discovery wird